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ABSTRACT

THE IMMOBILIZATION OF TICAGRELOR ON IMPLANT MATERIALS
AND
CORROSION AND BIOLFOULING INHIBITON BY NOVEL LAYERED POLYMER
THIN FILMS FOR MARINE APPLICATION

By
Tell Lovelace
December 2021

Dissertation supervised by Professor Ellen S. Gawalt, Ph.D.
Percutaneous coronary interventions are a widely used cardiovascular surgery which is
typically accompanied by the insertion of a vascular stent. After the procedure patients are put on
dual anti-platelet therapy (DAPT) to prevent stent thrombosis, a common complication to this
procedure in which platelets aggregate in the blood vessel on the inserted stent. Systemic
deactivation of platelets in patients via oral DAPT results in patients becoming bleeding risks in
future medical procedures, necessitating the development of a localized delivery system for antiplatelet medications from the surface of the stent. A novel anti-thrombogenic vascular stent coating
has been prepared by covalent linking of Ticagrelor onto the surface of low carbon stainless steel
grade 316L (SS316L) and Cobalt Chromium L605 (CoCr). The surface of stents were
functionalized with an amine terminated self-assembled monolayer (SAM). The functionalized
surface was modified via the Mitsunobu reaction, forming a covalent secondary amine linkage
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between the molecules in the monolayer and Ticagrelor. Surface characterization by diffuse
reflectance infrared spectroscopy confirmed the presence of TIC on the surface. Atomic force
microscopy and contact angle goniometry established significant chemical changes to the surface
post-reaction, consistent with surface immobilization. Following analytical characterization,
protection against thrombus formation was evaluated using platelet rich plasma and scanning
electron microscopy, an ELISA assay, and flow cytometry. Platelets did not adhere to the modified
substrates and platelet inhibition was localized to the surface so that platelet activation was not
inhibited in a systemic manner.
Pitting corrosion and biofouling in marine settings is one of the most costly forms of
environmental damage in the world, with an estimated $654 billion dollars spent in the United
States on corrosion repair in 2019. The estimated cost of corrosion worldwide is estimated to be
3.1% of the global GDP each year. Metals are also vulnerable to biofouling by barnacles and
mollusks which results in increased drag on ships and the need for regular ship cleaning, which
greatly increases shipping costs over the initial cost of corrosion damage. To provide a corrosionresistant surface on SS316L, polymer films of styrene, styrene-co-(poly-oligo[ethylene glycol]
methyl ether methacrylate, and styrene-co-(poly-oligo[ethylene glycol] methyl ether methacrylateco-styrene were formed on SS316L using surface-initiated atom transfer radical polymerization
(SI-ATRP). DRIFT spectroscopy and contact angle goniometry have been employed to confirm
the polymerization of the polymer films on the surface. Both techniques successfully demonstrate
successful modifications, with distinct changes in both the IR spectra and in the observed
hydrophobicity/hydrophilicity of the surface after each modification. Cyclic voltammetry was
employed to characterize the corrosion resistance of the polymer films and was performed in a
3.5% NaCl solution, representative of the saline content in marine settings. Polymer films of
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styrene, styrene-co-(poly-oligo[ethylene glycol] methyl ether methacrylate, and styrene-co-(polyoligo[ethylene glycol] methyl ether methacrylate-co-styrene exhibited fractional coverages of
0.86, 0.83, and 0.82. As a first level cytotoxicity and biofouling inhibition test, NIH 3T3 fibroblasts
were grown on the bare and modified surfaces and then evaluated at 1, 3, and 5 days with a
LIVE/DEAD assay. Cells proliferated rapidly on bare, HUPA, and Sty surfaces but cell adhesion
was eliminated on Sty-PEG surfaces.
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Chapter 1 – Introduction to Thrombosis and Vascular Stents
1.1 Introduction to Percutaneous Coronary Intervention
Coronary heart disease (CHD) kills an average of 660,000 Americans a year, accounting
for 25% of mortalities annually.1 The main cause of CHD is atherosclerosis, the build-up of plaque
in the arteries.1-2 Patients suffering from atherosclerosis experience acute coronary syndrome due
to the occlusion of their blood vessels and are at an increased risk for myocardial infarctions, or
heart attacks, which in many cases can be fatal.1-6 A percutaneous coronary intervention (PCI) is
a conventionally used, minimally invasive procedure to combat this undesirable accumulation of
plaque in blood vessels by reopening narrowed arteries.4-6 During this interventional treatment, a
catheter is inserted into the patient and guided to the site of the blockage. Once at the site of the
obstruction, a small balloon is inflated and compresses the atherosclerotic plaque against the walls
of the lumen (Figure 1).8-10 A common complication with this procedure is restenosis, the renarrowing of the blood vessel, usually due to plaque prolapse, vessel recoil, and/or constrictive
remodeling of the endothelial lining of the lumen.6, 11 This occurs in 25-45% of PCI patients postintervention unless a vascular stent is inserted during the PCI.4-6 This is accomplished by crimping
a stent over the inserted catheter prior to the procedure, which is then expanded when the balloon
catheter is inflated. Once expanded, the stent is permanently set in place to provide continuing
mechanical support to the walls of the blood vessel to prevent restenosis post-PCI.2-3, 12-13 Due to
the frequency of restenosis, the use of a vascular stent has become the standard when performing
PCI procedures and over 1.5 million metallic vascular stents are implanted in CHD patients each
year.14 Unfortunately, the implantation of a foreign body coupled with mechanical disruption to
the endothelial membrane also provokes a wound response from the body, resulting in two
common complications during stent implantation: neointimal hyperplasia (NH) and thrombotic
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clot formation.15 NH is considered a form of restenosis due to it resulting in a decrease in total
lumen of the blood vessel itself, while thrombotic clots are platelet aggregates formed on the stent
or wound site clogging the lumen similarly to an atherosclerotic plaque.

1.2 Neointimal Hyperplasia
NH refers to undesirable remodeling of the endothelial membrane via an exaggerated
inflammation

response,

referred

to

as

the

‘response-to-injury’ model introduced by Ross et
al. in 1976.16 This response is characterized by the
deposition of excess extracellular matrix (ECM)
from activated smooth muscle cells (SMC). These
SMCs proliferate in an uncontrolled manner,
migrating inwards and obstructing the blood vessel

Figure 1.1: Depiction of atherosclerosis and restenosis

lumen, while being bound together by surplus caused by neointimal hyperplasia

ECM.17 It is commonly accepted that damage to the endothelial wall is linked to the pathogenesis
of NH and a failure to complete re-endothelialization of the wound site likely to act as a trigger for
an uncontrolled wound response.7, 16 However, not all repopulated endothelium appears to be
functional and variable rates of reported re-endothelialization calls into question the exact timeframe in which inflammation will occur due to a lack of SMC coverage.7, 18 In any case, the
development of NH warrants remedial action in clinical settings to combat the complication and
avoid loss of lumen diameter post-PCI procedure.
Due to the likelihood of this complication, drug-eluting stents (DES) have been developed
and used in preference of bare metal stents (BMS) to combat the incidence of NH.7 DES operate
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by the release of antiproliferative drugs, such as rapamycin and paclitaxel (PAT), from polymeric
scaffolds formed on a BMS to inhibit restenosis via the constrictive remodeling mechanism of
NH.13, 19-21 Regrettably, the inhibition of neointimal hyperplasia appears to be inversely related to
the occurrence of stent thrombosis (ST). Restricting proliferation of SMCs to mitigate NH results
in a delayed wound response, which has been linked to the exacerbation of late- and very late-ST
incident rates.22-24 Characteristics and time-frames related to early, late, and very late stent
thrombosis are discussed in detail in Section 1.4.

1.3 Types of Stents
Early balloon angioplasty procedures had limited efficacy due to the prominence of
restenosis or sudden vessel collapse due to coronary dissections, arterial recoil, and/or intimal
tissue generation. To improve restenosis rates, expandable metallic scaffolds known as vascular
stents were developed to provide continued mechanical support to blood vessels following
percutaneous interventions. The introduction of vascular stents greatly improved interventional
angioplasty procedures, but neointimal hyperplasia rates remained high, affecting 20-30% of
patients. As a response to this prevalent complication, DES were developed to locally deliver antiproliferative medications at the stent site to inhibit the exaggerated wound response. DES have
made significant overall improvement to NH rates from small but constant advances in to stent
technology. Despite this, recent studies have implicated the delayed wound healing from antiproliferative medications as a cause for increased rates of ST.7
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1.3.1 Bare Metal Stents
BMS were the first devices developed for the purposes of coronary stenting. The
mechanical support to the lumen of a blood vessel provided by these devices successfully
decreased the occurrence of vascular recoil and coronary dissection but were not capable of
inhibiting restenosis caused by NH. Although BMS have been made obsolete by the introduction
of DES, they remain an important technology to consider because most DES are produced from a
BMS scaffold. To produce DES, a bare stent is surface modified to produce a more biocompatible
surface for use during a PCI.
Outside of modifying the stent surface, only minimization of the length and thickness of
stent struts and the length of the stent itself has been shown to be a reliable method for inhibiting
restenosis rates in BMS.7, 25-26 A comparative study of stent strut sizes found that reducing stent
struts thickness from 140 microns to 50 microns, decreased both angiographic and clinical
restenosis rates by ~40%.27 In addition, the recent development of biodegradable stent coatings
will necessitate an evaluation of the properties of underlying BMS from both surface interactive
and mechanical stability perspectives.28-29 As such, BMS technology has improved in parallel to
innovations in surface modification to provide superior scaffolds with lower surface area but
equivilant mechanical support for use in DES production.
Defining ideal mechanical qualities is a key step towards the selection of materials for stent
production. In a general sense, the ideal stent material would be biocompatible, fully corrosion
resistant, non-thrombogenic, and wear resistant.26, 30-31 The use of a material with a high elastic
modulus and high ductility is more capable of withstanding deformation and reduces recoil rates
after expansion during a PCI procedure.32-33 Similarly, a low yield strength material allows for
improvements to the ease of crimping the stent onto the balloon catheter and allows expansion
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within reasonable balloon pressures for a vascular catheter. Conversely, high tensile strength is
also desirable to maximize radial strength while minimizing strut volume to provide overall lower
surface area which leads to improved flexibility, deliverability, and access to smaller blood
vessels.31 Another important material characteristic for stents outside of mechanical property
influence is density. Radiopacity is improved in materials with higher density and most stents are
imaged using either X-Ray or MRI technology making this an important consideration.32-33
Unfortunately, the material characteristics needed to achieve ideal stent qualities are contradictory
because the ideal stent is ductile enough to be expanded by the catheter but have high enough
tensile strength to resist deformation after expansion.
Table 1.1: Comparison of the Mechanical Qualities of SS316L and CoCr L60531
Material Characteristic

SS316L

CoCr L605

Yield Strength at 0.2% Offset (MPa)

366

629

Stress at 30% strain (MPa)

655

1089

Ultimate tensile strength (MPa)

675

1147

Spring back after 30% strain

0.34

0.45

Ductile loading (MPa/% strain)

9.63

15.35

Elongation (%)

43

46

The first stents were produced from stainless steels and saw reasonable success, despite
poor radiopacity and incompatibility with magnetic resonance imaging.34 Stainless Steel 316L
(SS316L) was formerly the standard reference material for stent applications as the American
College of Cardiology (ACC) had recommended its use in both BMS and DES prior to the shift to
cobalt-chromium alloys.10, 12-13, 23 SS316L is frequently used as an implant material for its low
cost, corrosion resistance, and favorable strength to weight ratio.35-37 Much like other materials
used as implants, the untreated surface of SS316L is susceptible to neointimal growth and
thrombotic clot formation due to the foreign body response.3, 23, 38-40
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Cobalt alloys present universally superior mechanical qualities to SS316L demonstrating
increases in density (and thus radiopacity), Young’s Modulus, strength, and greater variance
between ultimate tensile strength and yield strength while maintaining similar ductility to SS316L.
Of the non-proprietary CoCr alloys, L605 has the highest values for the desired properties which
is why it is most commonly used today for stents.31 By 2016, the shift from stainless steels to CoCr
as the standard material for stent production was nearly complete for its undeniable improvement
of thinner stent struts.30 Prior to this transition, a study was conducted to compare the mechanical
properties of L605 and SS316L which succinctly demonstrates the logic behind this wide-spread
change in stent manufacturing. SS316L and CoCr stents were drawn-out to a 30% strain which is
a typical of a stent expansion during a PCI. Once expanded, the stents were unloaded and reloaded
until failure to determine acute recoil. Acute recoil is described as the elastic modulus and stress
at 30% strain. L605 was demonstrated to have higher recoil rates when compared to SS316L this
comes as no surprise given the superior strength of the CoCr alloy. It was also shown that L605
achieves significantly superior strengthening after expansion due to strain hardening at 15 MPa/%
strain, whereas the SS316L only has a strengthening of 9.6 MPa/% strain. Based on the vast
improvements in mechanical properties, the shift to CoCr was made.

1.3.2 Drug Eluting Stents
DES are simply BMS that have been modified so that drugs may be eluted from the surface
to provide targeted delivery to the wound site, usually from a textured surface or polymeric
coating.13, 23 DES were first developed in response to high rates of NH by delivering drugs which
inhibit the growth and spread of endothelial cells.15. Polymers are typically employed to entrap the
delivered drug and slow the rate of release as the drug elutes from the porous coating.25, 41
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1.3.2.1 Polymer Drug Eluting Stents
The first generation of DES were drug-loaded polymers coated on a metallic surface. The two
main products representing the first generation of stent devices were the Taxus stent which was
coated with non-biodegradable poly(styrene-co-isobutylene-co-styrene) loaded with PAT and the
Cypher stent which was coated in a blend of nonbiodegradable poly(ethylene-co-vinyl acetate) and
poly(n-butyl methacrylate) loaded with sirolimus.7, 42 These stents were superior to BMS when
inhibiting neointimal hyperplasia and restenosis but were linked to late ST.7 The increase in late
ST observed using these stents is due to the diminished re-endothelialization in the blood vessel
caused by the delivery of the anti-proliferative drug. BMS exhibit complete re-endothelialization
within 6-7 months while in DES this process was incomplete up to 40 months post-procedure.7, 43
Additionally, these DES demonstrated a lack of biocompatibility due to persistent local and
downstream inflammatory responses caused by the polymer scaffold after the elution period had
ended.23, 42, 44
The second generation of DES exhibited greater control of drug release and utilized CoCr
stents with thinner struts to minimize surface area for potential thrombosis and reduced rates of
luminal loss from restenosis events.24,

45

However, the continued use of nonbiodegradable

polymers such as phosphorylcholine and poly(vinylidene fluoride-co-hexafluoropropylene), lead
to inflammatory responses triggering late ST in an acute manner in some patients.7, 42 Despite this,
improvements in design resulted in second-generation stents achieving superior reendothelialization and reduced rates of thrombosis compared to their first-generation
counterparts.20,

46

A sirolimus derivative, everolimus, which has been shown to lead to less

myocardial infarctions and thrombosis events is largely responsible for these improvements.24, 4749

Regardless of these advances, further improvements may be implemented by developing
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coatings which eliminate the need for DAPT and improve long-term safety without increasing risk
of late ST.7, 11, 28, 46
The current paradigm for polymer DES (PDES) coatings utilizes fully biodegradable
polymers in an attempt to improve biocompatibility by reducing local hypersensitivity,
inflammatory response, and delayed strut endothelization. However, these suffer from reduced
strength and elasticity.29 It should be noted that there are an exceptionally large number of different
stent devices currently in production. There are an equivalent number of studies done to
demonstrate their capability, most of which only compare two stents with no particular stent being
used as a common baseline for such determinations.19, 47, 50-54 Furthermore, recent studies of very
late ST and neoatherosclerosis formation call into question the safety of modern stenting options
when observing stent complications in extended timeframes beyond 2 or more years.28, 51-52, 55 As
such, meta-analyses comparing clinical trial results offer the most objective perspective towards
the efficacy of modern biodegradable stent technology. Several of these recent studies have shown
that biodegradable stents have equivalent safety and efficacy profiles which only prove noninferiority to second-generation durable DES options.51-52, 56-57

1.3.2.2 Non-polymer Drug Eluting Stents
Due to the failure to definitively address issues with inflammation, neoatherosclerosis, and
ST in PDES, interest has developed in the production of non-polymer DES (NPDES). Dipping the
stent in a solution of the drug and allowing a coating to form by evaporation of the intended drug
for delivery is the most basic method of functionalizing the stent. Chemical stability and desorption
rates of surfaces with crystallized drugs are favorable when compared to amorphous drug coatings.
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Crystallized drug coatings are typically produced using either a microdrop spray system patented
by MINVASYS and direct surface crystallization induced by temperature control.58-60
This method suffers from poor loading, rapid elution, and drug loss during implantation, often
completely desorbing from the surface prior to expansion at the site of a blockage.42 The dipping
methodology has only been shown to be viable within NPDES utilizing PAT such as in the Taxus,
V-flex plus, and Achieve production stent families, due to it’s propensity for forming of hydrogen
bonds to the oxide layer of a metallic stent surface.21, 61 Despite this hydrogen bonding quality,
even these stents were shown to be inferior to PDES in long-term prevention of restenosis and
thrombosis due to rapid release of drug from the surface.21
Porous stents were produced to improve these deficiencies by generating physical reservoirs
on the surface in the form of grooves, channels, or holes to entrap delivered pharmaceuticals.
Surface pores of µm size can be produced using sandblasting, mechanical modification, or coating
with hydroxyapatite to create longer diffusion distances and retard release of the drug from the
surface.62-65 Since the system for loading drugs is so simple in these systems, that being a simple
spray or soak application, they allow the use of single or multiple drugs at once. 63, 66-67 The dualdrug eluting Yukon stent provides a rare example of a simultaneously anti-restinotic and antithrombotic coating when impregnated with both sirolimus and probucol.68 Unfortunately, in vivo
testing using a porcine model has found drug levels to be extremely low or undetectable using
porous stents after only 24 hours elapsed from the PCI procedure.69 Janus and Optima-jet stents
attempt to resolve this issue by coating abluminal reservoirs with a patented anti-thrombogenic
Carbofilm™.70 Fifty-percent of the impregnated drug has been shown to be released over the
course of 1 month and allowed reduction of DAPT from 6 to 2 months. 71-72 However, this method
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was never widely applied in a clinical setting and incidence rates of late ST, very late ST, and
neoatherosclerosis remain in question with no further studies having been performed since 2013.

1.3.2.3 Non-polymer drug eluting stents utilizing self-assembled monolayers
Self-assembled monolayers (SAMs) are nanomolecular coatings of 1 to 10 nm in thickness
formed from long-chain hydrocarbons which incorporate an acidic head-group for covalent
attachment to the oxide layer of metal surfaces.36, 73 Often, a chemically active tail-group is also
present on the terminal end of the molecule which provides surface functionality after film
formation by supporting the immobilization of biologically active compounds via chemical
reactions or intermolecular interactions. SAMs may be deposited on substrates surfaces via several
methods including aerosol spray, solution immersion, or by dipping substrates in solution.74
Several works in the literature have established the feasibility of delivering therapeutic drugs from
the surface of metal coronary stents using SAMs to act as effective local drug delivery platforms.61,
75-76

It should be noted that none of these studies exploit the potential for covalent linkage of

therapeutic agents to SAM surfaces, instead seeking to improve the elution rates of NPDES by
intermolecular interaction. Despite this, these studies demonstrate the potential for the use of
SAMs in the role of improving coronary stent technology and thus warrant additional research into
the topic.
Thiols are often a popular choice of headgroups in the literature for SAMs on gold but are
considered an inferior headgroup to the use of phosphonic acids on metal oxide layers such as
those found on stent devices made from SS316L. Despite the the poor interaction of alkylthiol
SAMs with SS316L, they have been shown to demonstrate stability in PBS for up to 21 days and
even longer under oxidative conditions.77 This justified further study of localized drug delivery

10

from hydroxyl terminated alkanethiol SAMs produced using 11-mercapto-1-undecanol. Ibuprofen
was used as a model drug and was linked to the functional SAMs using Novozume-435 as a
biocatalyst.75 Thus it was shown that SS316L could be modified utilizing SAMs as functionalized
tethers for stenting applications.
While gold (Au) is not typically used in stenting applications it has been used as a substrate
to demonstrate the potential for dual delivery of PAT and dipyridamole, an anti-platelet
medication, from mixed methyl- and carboxyl-terminated alkylthiol SAMs.78 The drugs were
applied to the surface utilizing a microdrop technique and relied on intermolecular interactions to
provide surface binding properties. Release of the drug was found to extend for up to 28 days, with
elution rates of dipyridamole being far higher than its counterpart across the timeframe.78 This is
likely due to its lower polarity in comparison to PAT, which would account for weaker interactions
with the polar SAM tailgroups.78
SAMs have also been determined to be compatible with the proliferation of human aortic
endothelial cells. Despite being unpopular materials for stent usage, Au and Titanium (Ti) surfaces
have been modified with hydroxyl terminated SAMs and esterified with the drug flufenamic acid
to demonstrate SAM interaction with HUACs.79-80 Proliferation was found to be slower on both
esterified and unesterified SAMs than on plain glass or control Ti substrates. The polygonal shape
of the HAECs which spread on the SAMs indicated favorable endothelialization on these surfaces
and the slowed rate of proliferation implies potential for use inhibiting of NH.79-80 This study also
significant in that it proves that SAMs are biocompatible with endothelial cells.
SAMs on CoCr substrates for stent purposes have been widely explored due to their use as
the material of choice for . Methyl and carboxylic acid terminated phosphonic acid SAMs on CoCr
have been maintained at physiological temperatures for up to 4 weeks in tris-buffered saline and
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for up to 2 weeks in oxidative conditions.81-82 Carboxylic acid terminated SAMs have been shown
to be excellent substrates for immobilization of PAT and have been compared to CoCr surfaces
with PAT directly applied with no prior surface modification.61, 76, 83 In vitro drug release studies
showed that PAT was released from SAM coated Co-Cr surfaces in a biphasic manner (an initial
burst release in first 7 days was followed by a slow release for up to 35 days), while the PAT was
burst released from control-Co-Cr surfaces within 1–3 days confirming the superiority of SAM
use in favor of traditional NPDES.61, 76 A separate study focused on determining the effects of
processing methods on the drug release profiles from CoCr substrates with PAT applied -COOH
SAMs and compared results from room temperature controls, heat treatment, cold treatment, and
quenching. It was found that in vitro drug elution could be sustained for all groups for up to 56
days at which point the study terminated.84

1.4 Thrombosis
Circulating platelets are critical to the maintenance of haemostasis by mitigating blood loss
following tissue injury. When healthy tissue, such as the endothelium inside of blood vessels, is
damaged platelets become activated. These activated platelets spread over the surface of the
exposed wound site and form either a healthy platelet aggregate or a thrombus in the case of
uncontrolled coagulation. Once activated, platelets release further platelet activating granules
which triggers the coagulation cascade, culminating in fibrin deposition on the platelet clot. This
process is regulated to a great degree by adhesion receptors on the platelet surface which recognize
mediators released from the environment or other activated platelets. The most common
environment which exposes platelets to such activators is damaged tissue. Damaged tissue,
particularly within a blood vessel, expresses platelet activators triggering the coagulation cascade.
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Healthy haemostatic activation is mediated by tissue factors expressed by the endothelium,
circulating inhibitors in the blood stream, and the mitigating effect of blood flow at the wound site.
However, when the endothelium is disrupted in a significant fashion the activation of platelets is
vigorous and often overexpressed leading to thrombus formation. This overexpression is often
seen as a result of endothelial disruption during a PCI procedure leading to ST.
When ST was first being reported in the literature, authors did not use a common definition
for the term, resulting in confusion surrounding the definition of thrombosis.85 For the purposes of
this discussion, the intended pathology meant by the use of the term ST will be defined and will
then be categorized into the three traditional diagnostic timeframes. Those being: early ST, late
ST, and very late ST.19, 22, 46 ST can be triggered by a variety of stent-, patient-, and procedurerelated causes but is usually found to occur in the presence of multiple triggering factors.85
Stent thrombosis refers to the partial or complete occlusion of a blood vessel at the site of
an inserted coronary stent, due to thrombotic clot formation at the wound site. This process is
diametrically opposed to the occurrence of NH. NH is a relatively slow process generated over
time by an exuberant wound response.17, 43, 69 By comparison, ST symptoms are due to an impaired
wound healing process and acts in a much shorter time-frame. Therefore, incidence of this
complication is more likely to result in acute coronary syndromes than restenosis caused by vessel
recoil or NH which tends to present as angina.85-87 As ST events occur suddenly with abrupt vessel
obstruction, they are also more likely to cause myocardial infarctions and are correlated with
higher mortality rates.23, 85, 88-89
ST is typically associated with mechanical triggers and the subsequent biological response
most but not all of which may be associated with a clinical diagnostic timeframe. Stent apposition
has been implicated in prompting ST due to the effects of hemostatic stasis and is an example of a
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time-frame independent trigger for thrombotic incidence.88 In this case, the diameter of an inserted
stent is not flush to the cell wall causing valvular sinus stasis to result in hypoxia and increased
hematocrit, in turn constituting a potentially hypercoagulable micro-environment.90-91 Other
factors correlating to an increased risk of ST regardless of diagnostic timeframe are the
presentation of a localized inflammatory response, longer stent length and/or thicker stent struts,
patient predisposition to resisting the effects of DAPT, and increased risk proportional to the
number of implanted stents in a patient.92
Early ST occurs within the first 30 days of a PCI procedure, in some cases even as early as
24 hours. Without DAPT, this is the most commonly encountered form of ST in a clinical setting.93
The simultaneous occurrence of several of the following conditions has been shown to result in
the increased risk of early ST: prolapsed plaque or tissue through the plane of the implanted stent,
impaired flow due to distal obstruction in the blood vessel, incomplete stent apposition, plaque
lesions with necrotic components, incomplete inhibition of platelet activation by DAPT, and
impaired left ventricular function of the patient.28, 93-94 Rates of early ST have been shown not to
be significantly impacted by the use of DES in place of BMS and may be readily treated by the
application of DAPT.93
Late ST occurs within 1 month to a year of stent implantation, which is also the
conventional timeframe for the continuation of a traditional DAPT regimen.10,

57, 95

Clinical

variables reliably associated with late ST after DES implantation include premature
discontinuation of antiplatelet therapy, incomplete stent apposition, brachytherapy post-PCI
procedure and before cessation of DAPT, bifurcation stenting at artery junctions, renal
insufficiency, and in patients with diabetes.46, 90, 92, 96 Late ST is a rare complication which had
been well documented prior to the use of DES in cases where intracoronary irradiation had been
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applied to reduce restenosis.14 The increase in prothrombotic behavior in these cases was attributed
to a delay in vascular healing, resulting in thrombotic occlusion. Re-endothelization of stent
surfaces has been shown to be delayed in clinical trials using both sirolimus and PAT DES when
compared to BMS.43 This delay in healing combined with other factors placing patients at risk of
LST has resulted in recommendations of extending DAPT for timeframes of over a year.43
Very late ST is a rare but critical development occurring more than one year after the
implantation of a stent. This complication usually occurs in patients after the discontinuation of
DAPT, but the mechanisms underlying its occurrence remain poorly defined.46 Recent studies have
implicated combined mechanisms from stent malapposition, neoatherosclerosis, and long-term
failure of the blood vessel to complete re-endothelialization.14
Risk of ST occurrence can be reliably correlated to the acuity of the clinical syndrome
preceding stenting with either the insertion of BMS or DES. Insertion of a vascular stent carries
minimal risk in use during preventative PCI in cases with stable coronary artery disease, and
intermediate risk in cases presenting acute coronary syndromes. In patients with a history of
myocardial infarctions, or in patients who are experiencing a heart attack during the procedure, the
risk of stent insertion is considered to be high.85 This trend holds true for any of the traditional
diagnostic timeframes of ST but is most prevalent in early ST.

93

The acuity of the patients

circumstances are usually not considered a factor in the occurrence of very late ST due to the
elapsed time from the procedure.93

1.4.1 Clinical Significance of Stent Thrombosis
With the current conventional treatments utilizing DES and DAPT the incidence of ST is
estimated to be ≈1%, but can be higher in cases with patients who are already at risk for
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complications due to poor health and pre-existing conditions.23, 97 Regardless of the low rate of
thrombosis occurrence, the increasingly high number of PCI procedures continuing to be
performed results in the absolute quantity of patients experiencing this complication rising each
year.1-2, 95, 98 Clinical results of ST occurring are regularly catastrophic. Reported ST incidents
indicate the quantity of subsequent myocardial infarctions being as high as 60-70% of cases as
well as short-term mortality rates reaching as high as 20-25%.88-89 A study on the economic impact
of ST in 2002 indicated a median direct cost of over $11,000 per ST patient for hospitals, excluding
any additional complications, indirect, or outpatient costs.89 Accounting for the fact that the
number of implanted stents has risen to 1.5-2 million stents implanted each year and given that ST
rates range from 0.4-0.8%, a conservative estimate of the accumulated annual economic burden
would be well over 100 million dollars.14

1.4.2 Pathology of Stent Thrombosis
There are several theories on how thrombosis is initiated in arteries and vasculature. Most
theories agree that a mechanical disturbance to the endothelial lining (such as compression from a
PCI procedure) is likely to trigger the event. The subendothelial lining is highly thrombogenic and
expresses high levels of collagen, Von Willebrand factor (vWF), and other platelet adhesion
proteins.99 When the endothelium is damaged two major changes occur which promote
thrombosis; conformational changes to local platelets and the exposure of tissue factor to the
wound site triggering the coagulation cascade.
After vascular injury, subendothelial vWF acts to promote platelet adhesion by complexing
with platelet surface glycoprotein (GP) Ib-IX-V to mediate adhesion to collagen or at the wound
site. This catalyzes the formation of a platelet plug, also known as the white thrombus, to fill the
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initial wound. As platelets are activated they release α-granules such as P-selectin, vWF, ADP,

Figure 1.2: Depiction of coagulation cascade at a wound site in the endothelium. TIC blocking ADP from interacting
with the P2Y12 receptor of an unactivated platelet is depicted to the right.

and fibrinogen which activate additional platelets in turn. Activation induces platelets to undergo
the so-called ‘flip-flop’ reaction exposing phosphatidylserine on the platelet surface.
Phosphatidylserine prepares the surface for interaction with coagulant enzyme complexes like
ADP and Thromboxane A2 to generate thrombin and enable fibrin deposition. Similarly to
activated platelets, subendothelial cells in the inner lumen of blood vessels express P-selectin and
other platelet activators from their inner granules upon agitation. Activated endothelial cells have
been shown to provide a surface that is as efficient for coagulation an activated platelet surface
which contributes to the overexpression of clotting mechanisms typical of thrombus formation.100
Damage to the blood vessel wall initiates the coagulation cascade by releasing Factor III
(FIII), also known as tissue-factor (TF) from the exposed sub-endothelium (Figure 1.2). FVII,
17

expressed on the inner surface of complete blood vessel walls, interacts spontaneously with TF to
form the complex TF-FVIIa. TF-FVIIa activates the zymogen FX in turn. The activated FX and
its co-factor FV form prothrombinase. Thrombin is then generated from the interaction of
prothrombinase with phosphatidylserine on the surface of nearby activated platelets. GpIIb/IIIa
receptors are activated following the interaction if ADP granules with surface P2Y12 receptors on
platelets. Fibrinogen, also known as FI, interacts with formed thrombin to generate fibrin which is
deposited on the adhered platelets via activated GpIIb/IIIa receptors. The deposition of insoluble
fibrin greatly increases the stability of the platelet plug. When this process is uncontrolled by
natural anti-platelet effects, a ‘red’ thrombus forms from excess fibrin entrapping red blood cells.
Over-expression of either white or red thrombi often results in occlusive clot formations resulting
in blockage of the blood vessel.
Given the considerable number of ST complications each year, a parallel technology to
traditional DES capable of inhibiting thrombosis using localized delivery techniques is highly
desirable. Currently available DES focus on inhibiting NH by delivering anti-proliferative
medication. Despite this focus, the methods of drug delivery utilized and advances in metallic and
non-metallic stent materials remain relevant to this line of research.

1.4.3 Dual-antiplatelet Therapy
Since the 1980s, ST has been recognized as a serious risk when performing angioplasty
procedures due to high mortality rates as a result of the complication. The original solution for
addressing this issue when BMS were introduced was the utilization of warfarin and aspirin to
reduce the risk of thrombotic events. This short-term strategy reduced risk of thrombosis to 3.5%
for early ST events, but failed to address the yet unknown complications of late ST and very late
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ST while also failing to meet current standards for thrombosis inhibition rates. Dual anti-platelet
therapy (DAPT) strategies utilizing thienopyridines and aspirin were introduced to improve ST
rates and lower the chance of bleeding and other complications caused by the aggressive strategy
of its predecessor.
Thienopyridines are a class of anti-platelet drugs, commonly used to combat thrombosis,
irreversibly inhibiting the P2Y12 receptor on the platelet surface, blocking the activating site for
major platelet agonist adenosine diphosphate (ADP).23 Primarily found on the surface of platelets,
the P2Y12 receptor potentiates platelet aggregation, procoagulant activity, and dense granule
secretion in platelets resulting in the triggering of the coagulation cascade.101-103 Thienopyridines
require conversion to their active metabolite, which results in variable responses to set drug
loadings from patient to patient. The permanent deactivation of platelets and variable hepatic
conversion results in poor control over how different loadings will affect individual patients. 12, 39,
104-105

Despite these drawbacks, thienopyridines remain far more effective in clinical settings for

DAPT than aggressive anti-platelet medications such as warfarin resulting in their continued use
into the modern era of DAPT. Ticlopidine, known by the trade name Ticlid, was the first
commonly used thienopyridine and was applied in conjunction with aspirin to provide DAPT to
patients undergoing PCI with BMS. Due to the rare but serious side effects of Ticlopidine such as
neutropenia and thrombotic thrombocytopenic purpura, the development of safer thienopyridines
for DAPT use was pursued. Of these newer generational thienopyridines, clopidogrel has found
the greatest and most widespread use in clinical settings and was utilized in 30-day DAPT for the
duration of the BMS era.
Currently, Ticagrelor (TIC) is the recommended anti-platelet medication for DAPT from the
ACC/AHA and was shown to significantly reduce the rate of death from vascular causes,
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myocardial infarction, or stroke in a phase III PLATelet inhibition and patients Outcomes trial in
comparison to clopidogrel which acts as the current clinical standard.10, 12 TIC is an ADP analog
which acts as a reversible and competitive antagonist of the platelet activating P2Y12 receptor.12,
39, 106

TIC does not require hepatic conversion to become biologically active unlike other

competing classes of anti-platelet medication, such as thienopyridines, increasing surety in
bioavailable dosing and providing a superior medication for DAPT.12, 105, 107
Recent network meta-analyses have indicated that rates of stent thrombosis for current
generation DES are superior to those of their first- and second-generational counterparts,
remaining similar to ST rates in BMS. These results are due to improvements in the thickness of
stent struts, improvements to DAPT design and application, and the use of superior antiproliferative medications. Regardless of the cause of their success, these results have influenced
recent guidelines from the European Society of Cardiology and the American College of
Cardiology and American Heart Association. These guidelines suggest that for patients with stable
coronary artery disease a minimum of 1 month DAPT is required when utilizing BMS while a
minimum of 6 months is required for DES. For patients with unstable coronary artery disease or
at higher risk of bleeding events, the American College of Cardiology and American Heart
Association guidelines indicate a shorter duration of 3 months for DES.

1.5 Conclusion
In summary, thrombosis is a deadly complication of the commonly performed PCI procedure.
Despite low incidence rates, many cases of thrombosis occur each year due to the sheer volume of
PCI procedures performed and there are currently no clinically accepted methods of thrombosis
inhibition that utilize localized drug delivery techniques. Drug delivery techniques to modify both
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SS316L and CoCr stent surfaces have been developed in the past but are only applied in clinical
settings to combat the occurrence of NH. Therefore, the development of a parallel technology for
thrombosis prevention on both SS316L and CoCr surfaces is desirable and is expected to fill a
tangible gap in the current medical approach to combating atherosclerosis.
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Chapter 2 – Self-assembled Monolayers and Methods of Surface Functionalization
2.1 Introduction to Surface Drug Delivery
Medications applied via oral or venous methods often have deleterious side-effects outside
of their intended use due to their systemic delivery to the body of a patient. This often presents
unintended contraindications with other medications or results in poor interactions during future
surgical procedures.1-2 Localized drug-delivery represents a significant advance in the production
of biomedical devices and implant engineering, by limiting the influence of a delivered medication
to the site of the implant or wound.3-4 Localized drug delivery techniques from implant surfaces
have been established as viable alternatives in the literature.5-9 Coatings have been developed
which either release medication in a predictable manner from the surface or immobilize a bioactive
molecule for improved biocompatibility. Drug-eluting stents or antibiotics delivered from
orthopedic implant surfaces represent common examples of drug delivery using this
methodology.10-12 The adsorption and covalent immobilization of pharmaceuticals and bioactive
compounds directly onto implant surfaces is considered a viable alternative for tailoring the
interfacial properties of biomaterials.13

2.1.1 Functionalization of Metal Oxide Surfaces using Self-Assembled Monolayers
One method that has been studied as a way of controlling and influencing the surface
interactions of bulk metals is the deposition of SAMs.6, 14 SAMs have been used to control the
wetting properties of surfaces, provide increased corrosion resistance, and to increase
biocompatibility in medical devices.15-24 In the case of implant materials, SAMs have been
suggested to be effective barriers for the protection of the surface of the substrate via the
hydrophobic/hydrophilic and steric interactions they are capable of providing.
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Self-assembled monolayers (SAMs) are molecular assemblies of organic molecules
composed of a headgroup, long alkyl chain, and a tail-group which is often functionalized to
provide a labile site for reaction or enhanced interfacial properties (Figure 2.1).15,

19, 25

The

headgroups of SAMs are usually hydrophilic moieties such as acids or thiols, although a diverse
amount of head groups with binding capabilities are commercially accessible that enable
monolayer formation on a diverse
range of substrates.18,

20, 22-24

SAM

modified surfaces can be prepared
through either immersion in solution,
vapor deposition, or aerosol spraying of
organic thiols, silanes, or acids.15, 23-25
When exposed to a substrate via one of
these methods the headgroup attaches
the molecule to the surface in a facile
manner beginning the process of selfassembly.19,

25-26

On common metal

Figure 2.1: Depiction of ordered and stabile PHDA SAM. Mono, bi-, and tridentate binding modes are shown for the phosphonic
acid headgroups.

oxide layers, this process is a dehydration reaction between an acidic headgroup and a surface
hydroxyl on the oxide layer of the bulk metal.
Following head-group attachment, the long organic tails of the molecules align in an alltrans conformation providing additional stability to the thin film by exploiting stabilizing
properties generated by van der Waals interactions between alkyl chains.15, 23 This forms a semicrystalline coating that evenly presents tail-groups at the interface for further reaction.19, 22, 25
SAMs have been used to functionalize metal oxide surfaces in the past, providing increased
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corrosion resistance and superior biocompatibility by presenting specific tail-groups at the surface
of the thin film.15-24 It has been shown in the literature that SAMs can be further stabilized by the
presence of hydrogen bonding tail groups.15-19, 24, 27

2.1.2 Covalent Modification of Self-Assembled Monolayers
Self-assembled monolayers have proven to be viable candidates for modifying the interfacial
properties of biomaterials by the covalent attachment of various small molecules.6-7, 28-33 Utilizing
SAMs to introduce bioactive molecules from the surface of an implant preserves the physical
properties of the material while improving biocompatibility in a predictable fashion. This has lead
to the development of monolayers as a more targeted approach to influencing the surface
interactions of implant materials. Bioactive compounds such as perphenazine,7 ibuprofen,34
peptides28, 35, and various antibiotics11, 36 have been immobilized to SAMs using cross-linking
reactions and have been shown to remain bioactive after attachment.
Very few studies which have altered the biocompatibility of medical device surfaces using
SAMs have achieved covalent attachment of an active molecule. Most of these studies have simply
physisorbed active molecules onto a surface with similar polarity, or simply modified interfacial
properties by form.5, 13, 37-40 Physisorption of compounds to the surface has been utilized as a
method of localized drug-delivery from stent surfaces but this has been shown to be unreliable.4144

Without covalent attachment, adsorbed molecules fail to provide continued protection of the

surface due to quick release from the device after implantation. Some studies have modified
surfaces without the delivery of a drug, instead using functional tail-groups to change the
interfacial properties of the surface. While these thin films have been shown to provide longer term
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protection, surfaces shielded by unmodified functional groups remain susceptible to biofouling
despite changes in the surface energetics.45-47
A common biocompatibility issue with implant materials, such as vascular stents, is
thrombus formation on the surface of the biomedical device in vivo.48-52 Despite the commonality
of this complication, research into the use of surface drug delivery techniques for the purposes of
improving biocompatibility of blood-contacting surfaces has remained limited.13, 42, 53-54 Lowering
thrombosis rates on biomaterials presents a significant challenge which has only been explored in
the literature to a limited degree with little success.29, 47, 55-57 Most studies seeking to protect
implant surfaces from thrombus formation have employed polymeric or crystalline coatings which
do not covalently attach the delivered drug and only provide a brief window of anti-platelet
behavior after which DAPT is still required.58-59 DES use polymer coatings which entrap and then
release drugs from the surface, but these coatings have been implicated as having inflammatory
downstream effects in some patients.13, 43, 60 Of the few methodologies which have sought to
deliver medications on SAMs without the use of an entrapping polymer, few have characterized
the effect of the modified surfaces against platelets to demonstrate true in vitro thrombosis
inhibition. None of the studies which have covalently immobilized anti-platelet medications on
stents have tested the efficacy of the modification at inhibiting the actual aggregation of platelets,
demonstrating a clinical need which remains to be filled.29, 53, 57
Very few studies have applied SAMs alongside anti-platelet drugs in the past, however
unmodified monolayers have been previously demonstrated to provide a safe and biocompatible
interface for blood contacting surfaces.47,

55-56

Davaran et al. demonstrated dual delivery of

paclitaxel and the antiplatelet molecule dipyridamole from the surface of methyl- and carboxylicacid terminated SAMs for stent applications.29 While the previously mentioned work lacked a
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covalent approach, the study demonstrated extended release of both compounds from the surface.
The immobilization of the drugs was achieved by exploiting the low solubility of the compounds
in vitro and increasing the polar drugs’ affinity for the surface. The authors utilizing monolayers
with carboxylic tail-groups to increase surface polarity prior to deposition polar molecules on the
surface. This demonstration was sufficient to indicate that SAMs hold the potential for a nextgenerational drug delivery system where compounds of varied solubility may be delivered with
increased control via cross-links to the surface. As such, the study presented herein has considered
the use of various organic cross-linking reactions for the immobilization of anti-platelet
medications to the surface of vascular stents. Phosphonic acid headgroups have been previously
demonstrated in the literature to be effective and reliable moieties for the formation of SAMs.23,
61-62

The monolayers used in this study all employ phosphonic acid headgroups to reliably

functionalize the substrate surface for the covalent cross-linking of anti-platelet medication.

2.1.3 Selection of Anti-platelet Compounds for Immobilization on Self-assembled
Monolayers
Covalent attachment to the surface of an implant greatly improves the longevity of the
protection afforded to the medical device. However, many drugs have been designed under the
assumption that they will circulate freely throughout a patients blood stream and that they may be
delivered in a non-biologically active state prior to being metabolized by a patient. This assumption
results in many existing drugs being unsuitable for covalent attachment to a medical device
surface. To ensure an immobilized anti-platelet molecule will retain bioactivity after
immobilization, several properties must be considered when selecting an ideal compound. Firstly,
the target cannot require hepatic conversion to be metabolized into a biologically active state as it
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will not pass through the liver while immobilized onto the surface of the implant material. Many
drugs depend on the body to metabolize them into an active form making them poor candidates
for covalent surface attachment. The compound must also contain a non-bioactive functional group
for use in cross-linking reactions to achieve the covalent connection without compromising the
functionality of the drug. Most medications are not designed with excess functional groups which
can serve this purpose without changing their behavior in vivo. Lastly, it must inhibit platelet
activation by interacting only with the surface receptors of an incident platelet as it will not be
capable of penetrating the cell membrane to achieve its purpose. If any of these properties are not
met, the immobilized drug would not accomplish its intended effect of inhibiting platelet
aggregation when covalently linked to the SAM formed on the stent surface.
Ticagrelor (TIC) has been selected as the compound of interest for this study. TIC is an
adenosine diphosphate (ADP) analog which acts as a reversible and competitive antagonist of the
platelet activating P2Y12 receptor (Figure 2.2).63-65 Primarily found on the surface of platelets, the
P2Y12 receptor potentiates platelet aggregation, procoagulant activity, and dense granule secretion
resulting in the triggering of the coagulation cascade (Figure 2.2).66-68 TIC is the recommended
anti-platelet medication for DAPT from the
American College of Cardiology and the American
Heart Association and was shown to significantly
reduce the rate of death from vascular causes,
myocardial infarction, or stroke in a phase III
PLATelet inhibition and patients Outcomes
(PLATO) trial.64, 69 TIC does not require hepatic
conversion to become biologically active unlike Figure 2.2: Depiction of TIC blocking the P2Y12 site
on the outside of a platelet, structures of Ticagrelor and
ADP shown side by side
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other competing classes of anti-platelet medication, such as thienopyridines, making it a suitable
target for this study.64, 70-71 In addition, the terminal hydroxyl tail on TIC is not biologically active,
providing a fitting target functional group for cross-linking reactions to the surface.72-74 These
properties makes TIC uniquely suited to provide localized protection from thrombus formation
when immobilized upon a surface.70, 72 As expected from previous literature studies, it has been
shown herein that the covalent attachment of TIC to a SAM formed on the surface of SS316L will
inhibit platelet aggregation on the stent material in a localized manner.7, 11, 75 A variety of different
methods for covalent immobilization of both aspirin and TIC have been explored in this work.
Due to the excessive cost of pure TIC, 2-Phenoxyethanol (2-Phen) was chosen as a model
compound for preliminary attempts at immobilization. This
molecule was chosen due to the hydroxyl terminated alkyl
chain (Figure 2.3), which is identical to the target functional
group on TIC (Figure 2.2). It was expected that the similar
chemical structure of the target functional group would
Figure 2.3: Comparison of TIC and 2Phen tail groups

enable 2-Phen to be used as a viable alternative to the more

expensive pharmaceutical compound.

2.2 Approaches for the Covalent Linkage of Biomolecules to Self-Assembled
Monolayers
Few methodologies have sought to immobilize specific anti-platelet medications on SAMs
without the use of an entrapping polymer, and none of those have characterized their surfaces
against platelet plasma to demonstrate true in vitro thrombosis inhibition.29,

53, 57

To achieve

covalent attachment of TIC for this purpose, both established methods for SAM modification and
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novel uses of non-surface related organic reactions have been explored. Phosphonic acid
headgroups have been previously used in the literature as effective and reliable moieties for the
formation of SAMs on implanted biomaterials.23, 61-62 The monolayers used in this study all employ
phosphonic acid headgroups but have varied functional tail-groups and slight differences in alkyl
chain lengths due to availability constraints.

2.2.1 – Esterification via Reaction of Acyl Chloride and Alcohol
Acyl chlorides are known to be exceptionally versatile compounds for reactions with
nucleophiles and have been used
extensively in the literature to
produce

amides,

esters,

and

anhydrides.76-77 These derivatives of
carboxylic

acids

are

far

more

reactive due to the replacement of the

Scheme 2.1: Reaction progression gas phase esterification between
2-Phen and surface acyl chloride

hydroxyl leaving group with a chloride ion.78 Chloride ions are weak bases and are excellent
leaving groups due to their increased stability in solution.77-78 The stability of a Cl- ion enables
even weak nucleophiles to displace it in a facile manner.78 The reaction of acyl chlorides with
alcohols is a well-known method of esterification and represents a viable route towards the
immobilization of molecules on SAMs.79 Several biomolecules have been immobilized in
precisely this manner including the NSAID flufenamic acid,7 the tobacco mosaic virus,80 alkyl
thiols,76 and both alkyl and aromatic amines.77 Typically in these systems, the acyl chloride is
formed by modification of a carboxylic acid on the molecule to be immobilized followed by
subsequent reaction with a hydroxyl- or amine- terminated SAM.
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7, 77, 80

Herein, the functional

groups are reversed in a novel manner in the attempts to immobilize 2-Phen on a SAM. The
carboxylic acid is present on the surface as the tail-group of the SAM and the alcohol is present on
the molecule to be immobilized. Unfortunately, attachment to the surface utilizing this method was
unsuccessful and other methods of cross-linking were pursued.

2.2.2 – Steglich Esterification and Variations
The use of carbodiimide compounds for cross-linking reactions is one of the most robust and
well-known methods of producing amide or ester bonds from carboxylic acid functional groups.
This strategy has been utilized in the past for various cross-linking reactions on SAMs such as
covalent attachment of anti-bodies,30 ligands,81 antibiotics,32, 36, 81 cell adhesion peptides,35-36 and

Scheme 2.2: Carboxyl-to-alcohol crosslinking utilizing EDC and NHS. a) Direct addition between nucleophile
and O-acylisourea intermediate, b) Hydrolysis of intermediate by water, c) Addition of NHS to form NHS-ester
intermediate improving cross-linking efficiency with the incoming nucleophile (R-OH)
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nitric oxide donors33 among others. The two most utilized carbodiimides for this purpose are 1ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and dicyclohexylcarbodiimide (DCC).30, 36,
81-84

Catalysts such as N-hydroxysuccinimide (NHS) or 4-dimethylaminopyridine (DMAP) are

often utilized alongside carbodiimides to improve efficiency and reduce the likelihood of
undesirable side-reactions.83 The utilization of DCC and DMAP for the conjugation of carboxylic
acids and alcohols is a named reaction known as the Steglich esterification.85
A strength of this methodology is that a direct bond is formed between the targeted conjugate
molecules, with no additional atoms or functionalities remaining from the employed cross-linking
reagents. Cross-linking via carbodiimide moieties proceeds by the activation of -COOH groups
and the subsequent reaction of primary amines or alcohols to produce amides or esters, respectively
(Scheme 2.3). Carbodiimides react with carboxylic acids to form an O-acylisourea intermediate,
which can be considered as a carboxylic acid with a labile leaving group (Scheme 2.3). Due to the
labile nature of this bond, the original carbodiimide molecule is easily displaced by nucleophilic
attack and released as a urea side-product. The lability of the O-acylisourea intermediate opens the
possibility of undesirable hydrolysis, resulting in the regeneration of the carboxylic acid and the
release of an unreactive N-unsubstituted urea.84 The use of NHS or DMAP in conjunction with the
carbodiimide results in an NHS or DMAP ester intermediate which is stable enough to preclude
the possibility of hydrolysis but still allows for efficient nucleophilic displacement.84-85
Unpublished work provided to our group by Michael Danahy, PhD. in the Schwartz research
group at Princeton University indicates that the hydrogen bonding network of surface carboxylic
acid groups provides additional stability to the monolayer. This hydrogen bonding network is so
stable that it prevents terminal -COOH groups from reacting when treated with the esterification
molecules. It has been shown in the literature that -COOH groups do contribute significantly to
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the stability of the SAM by forming a hydrogen bonding network on the surface between functional
groups.19 Because of this, TDPA molecules were used in an attempt to intercalate the methyl
terminated molecules among the PHDA SAM to space apart the carboxylic acid tails to prevent
this hydrogen bonding from occuring.
Both EDC/NHS and DCC/DMAP have been explored as cross-linking agents in this study on
both pure and mixed carboxylic acid terminated monolayers. Both NHS and DMAP monolayer
intermediates were successfully formed in this study. Despite successful intermediate formation,
cross-linking of 2-Phen and TIC both failed to achieve esterification with the surface resulting in
other methods of cross-linking being explored.

2.2.3 - Mitsunobu Reaction
The Mitsunobu reaction is a well-known method for the condensation of alcohols with various
nucleophiles used in organic synthesis due to the mildness of the reaction conditions and variety
of compatible substrates.86-90 The Mitsunobu reaction has been used to form C–O, C–N, C–S, and
C–C bonds, utilizing phosphine and an azo reagents as reducing and oxidizing agents
respectively.86-87, 91 As an extrapolation of this, aza-bis(oxazoline) copper complexes may be
covalently linked to hydroxyl-terminated SAMs via a secondary amine present on the complex
utilizing the Mitsunobu reaction.92 This demonstrates the use of the Mitsunobu as a potential
pathway for the immobilization of Ticagrelor, which contains a primary hydroxyl group similar to
that of a hydroxyl-terminated SAM, to an amine terminated monolayer surface via a secondary
amine cross-link.
The

traditional

Mitsunobu

reaction

utilizes

triphenyl

phosphine

(TPP)

and

diethylazodicarboxylate (DEAD) as reductive and oxidative agents but suffers a major limitation.
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This limitation is referred to as ‘the restriction of pKa’, in which the acidic pronucleophiles utilized
opposite the alcohol must have a pKa <11 for the reaction to favor the generation of the intended
product (Scheme 2.3).90, 93-95 The reaction mechanism must be discussed in order to understand
this notable shortcoming. First, TPP attacks DEAD as a nucleophile generating a zwitterionic
phosphonium as an intermediate. The DEAD intermediate deprotonates the alcohol which binds
to the phosphonium forming an alkoxyphosphonium and a resulting hydrazo anion. It is at this
step reaction requires the nucleophilic hydrogen to have a pKa <11. If the pKa is sufficient then
the nucleophile is deprotonated by the hydrazo anion and proceeds to attack the
alkoxyphosphonium intermediate to form the final product, leaving triphenyl phosphine oxide as
a by-product. Should the nucleophile not have a pKa low enough then the hydrazo anion attacks
the alkoxyphosphonium directly, affording a hydrazine derivative instead of the intended crosslinked product.
Primary amines have a pKa of ~10.7 and are rarely used as nucleophiles in this reaction
due to how closely they come to the pKa limitation.96-97 However, novel P-reagents and
azocompounds have been developed in recent years to overcome the pKa limitation of the
Mitsunobu reaction. Tsunoda et al. developed
several new azo-type reagents to expand the
scope

of

the

reaction.90,

(azodicarbonyl)dipiperidine

93-94

1,1’-

(ADDP)

and

N,N,N’,N’-tetramethylazodicarboxamide
(TMAD) were developed by substituting the
alkoxy OEt moieties in diethyl azodicarboxylate
(DEAD)

with

electron

donating

groups.

Scheme 2.3: The desired and undesired routes of the
Mitsunobu reaction
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Tributyl phosphine (TBP) was employed alongside the modified azocompounds as a more
nucleophilic phosphine to promote the formation of the betaine adduct in the first step of the
reaction. The azocompounds must be added dropwise during the Mitsunobu reaction to minimize
the generation of the undesirable hydrazine side product. The application of the Mitsunobu
reaction is herein demonstrated as a viable route for accomplishing the formation of a stable
secondary amine cross-link between TIC and SAMs formed on stent substrates.

2.3 – Conclusions
To review, currently accepted methods of stent surface modification for the purposes of drug
delivery lack covalent modification resulting in uncontrolled release of the drug and short-term
protection of the implanted device. SAMs offer a biocompatible method for functionalizing metal
oxide surfaces and have been demonstrated to have great potential for applications as a localized
anti-thrombotic methodology. There are few viable compounds available which can be crosslinked to stent surfaces while retaining bioactivity for this purpose but TIC has been identified as
a promising candidate for use. Several organic coupling reactions are available in the literature
which may be applied to accomplish the immobilization of TIC on SAMs formed on SS316L and
CoCr substrates and these will be tested for efficacy using both 2-Phen and TIC to evaluate the
most promising methodology for forming an anti-thrombotic thin film on stent surfaces herein.
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Chapter 3 – The Immobilization of 2-Phenoxyethanol on SS316L
3.1 – Introduction
The compound 2-Phenoxyethanol (2-Phen) was used as a model for TIC. The target
functional group for cross-linking is a 2-oxyethanol tail on TIC, a moiety which is also found on
the far less expensive 2-Phen. Attempts to immobilize 2-Phen via both esterification and amidation
reactions were performed. The different approaches to achieving this immobilization are presented
in this chapter.

Scheme 3.1: Generalized immobilization of 2-Phenoxyethanol on 16-Phosphonohexadecanoic Acid

Carboxylic acid terminated monolayers were exposed to SOCl2 to convert the -COOH tailgroups to acyl chlorides intended for use in facile esterification reactions with 2-Phen. EDC/NHS
reactions were also explored to facilitate esterification, and NHS-ester intermediates were formed
on carboxylic acid terminated monolayers. The NHS modified surface was then exposed to 2-Phen
to immobilize the molecule via an ester cross-link. To form amide bonds which are known to be
more stable than their ester counterparts in vivo, the Mitsunobu reaction was employed to couple
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2-Phen to an amine terminated monolayer. Both SAMs and immobilized molecules were
characterized via DRIFT and contact angle goniometry.
3.2 – Materials
3.2.1 - Experimental Materials
Stainless steel foils (AISI 316L, Fe69/Cr18/Ni10/Mo3) of 0.5 mm thickness were obtained
from Goodfellow Inc. 12-Aminododecylphosphonic acid hydrochloride salt (ADPA), 16Phosphonohexadecanoic

acid

(PHDA),

2-Phenoxyethanol

99%

(2-Phen),

4-

Dimethylaminopyridine (DMAP), 40% diethyl azodicarboxylate (DEAD) by weight in toluene,
N-hydroxysuccinimide

(NHS),

N,N'-Dicyclohexylcarbodiimide

(DCC),

tetramethylazodicarboxamide (TMAD), thionyl chloride (SOCl2), and triphenylphosphine (TPP),
were purchased from Sigma Aldrich. 14-tetradecylphosphonic acid (TDPA), 1-Ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC), and carbonyldiimidazole (CDI) were purchased from
Alfa Aesar. Tetrahydrofuran (THF) was purchased from Macon. Tetrahydrofuran was dried over
sodium and benzophenone and distilled under N2 gas before use. Tri-n-butyl phosphine (95%)
(TBP) was purchased from Acros Organics. Ticagrelor (98%) (TIC) was purchased from Asta
Tech. 2-Propanol was purchased from Thermo-Fischer Scientific.

3.2.2 - Instrumentation
All infrared spectra were collected using a Thermo Nicolet-NEXUS 470 FT-IR equipped with
a Diffuse Reflectance Infrared Fourier Transform (DRIFT) attachment. Contact angles were taken
using a Rame-Hart Model 200-U1 goniometer with distilled H2O.
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3.3 - Methods
3.3.1 – Stainless Steel 316L Substrate Cleaning and Preparation
SS316L foil was sanded using silicon carbide sandpaper of increasing grit (150, 320, 400,
and 600) to provide a fresh and uniform surface oxide layer. Substrates were then cut into 1 cm x
1 cm squares. The resulting coupons were then cleaned by sonication in acetone and immersion in
boiling methanol for 15 minutes each, to remove remaining organic residue and metallic dust.
Substrates were then dried overnight at 120 ⁰C.

Scheme 3.2: Formation of 16-Phosphonohexadecanoic Acid monolayer on SS316L

3.3.2 – Self-assembled Monolayer Formation
3.3.2.1 – 16-Phosphonohexadecanoic Acid monolayers
Monolayers of 16-Phosphonohexadecanoic acid (PHDA) were formed on the native oxide
surface of the substrates using immersion deposition (Scheme 3.2). Samples were submerged in a
1 mM solution of PHDA in THF and were then annealed at 120 ⁰C for 24 hours. Once annealed
the substrates were rinsed and sonicated in THF to remove any physisorbed molecules. After
drying at 120 ⁰C for at least 45 minutes, monolayer formation was confirmed using contact angle
goniometry and DRIFT spectroscopy.
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3.3.2.2 – Mixed 14-Tetradecylphosphonic Acid and 16-Phosphonohexadecanoic Acid
monolayers
As seen in Table 3.1, several methods were attempted in during development of a successful
method for mixed monolayer formation. Mixed monolayers of TDPA and PHDA were formed on
the native oxide surface of the substrates using aerosol deposition (Scheme 3.3). Samples were
sprayed with a 1 mM solution of PHDA and 0.3 mM TDPA in THF and dried for 30 minutes at
120 ⁰C. This was repeated until 3 sprays had been completed and the substrates were then annealed
at 120 ⁰C for 24 hours. Once annealed the substrates were rinsed and sonicated in THF to remove
any physisorbed molecules. After drying at 120 ⁰C for at least 45 minutes, monolayer formation
was confirmed using contact angle goniometry and DRIFT spectroscopy.

Table 3.1: Mixed TDPA/PHDA Monolayer Deposition Conditions
TDPA (mM)

PHDA (mM)

Dry Time (Min)

Dry Temp (⁰C)

Technique

Cycles

Results

1

1

-

120

Immersion

1 Hour

Multi-

1

1

30

120

Spray

x3

Sub-

0.1

1

30

120

Spray

x3

Mono-

0.3

1

30

120

Spray

x3

Multi-

0.3

1

30

120

Spray

x3

Mono-

All solutions were made in THF. Sub- refers to sub-monolayer, mono- refers to monolayer, and multi- refers to
multilayer.
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Scheme 3.3: Formation of Mixed 16-Phosphonohexadecanoic Acid and 14-Tetradecylphosphonic Acid
Monolayer on SS316L

3.3.2.3 - 12-Aminododecylphosphonic Acid monolayers
Many attempts were made to determine the proper conditions for the reproducible formation
of an ADPA monolayer, referenced in Table 3.2. Monolayers of ADPA were formed on the native
oxide surface of the substrates using aerosol deposition (Scheme 3.4). Samples were sprayed with
a 0.5 mM solution of ADPA in EtOH and dried for 30 minutes at 60 ⁰C. This was repeated until 4
sprays had been completed and the substrates were then annealed at 60 ⁰C for 24 hours. Once
annealed the substrates were rinsed and sonicated in EtOH to remove any physisorbed molecules.
After drying at 60 ⁰C for at least 45 minutes, monolayer formation was confirmed using contact
angle goniometry and DRIFT spectroscopy.

Scheme 3.4: Formation of 12-Aminododecylphosphonic Acid monolayers on SS316L

66

Table 3.2: ADPA monolayer Deposition Conditions
Solution

Conc. (mM)

Substrate (⁰C)

Annealing (⁰C)

Result

ADPA

0.5

RT

3

RT

120

Sub-

ADPA

0.5

RT

3

RT

120

Multi-

ADPA

0.5

RT

1

RT

120

Sub-

ADPA/TEAD

0.5

RT

3

RT

120

Sub-

ADPA/TEA

0.5

RT

3

RT

120

Sub-

ADPA/TEA

0.5

RT

1

RT

120

Mono-

ADPA

0.25

10 ⁰C

3

60

120

Sub-

ADPA

0.5

10 ⁰C

3

60

120

No mono

ADPA

0.5

RT

3

10

120

Sub-

ADPA

0.25

RT

3

10

120

Sub-

ADPA

0.75

RT

3

10

120

Mono-

ADPA

0.75

60 ⁰C

3

10

120

Multi-

ADPA

0.25

RT

3

RT

120

Sub-

ADPA

1

RT

3

RT

120

Multi-

ADPA

1

RT

3

10

120

Multi-

ADPA

0.75

RT

3

RT

120

Mono-

ADPA

0.5

RT

4

10

120

Sub-

ADPA

0.5

RT

4

RT

120

Mono-

ADPA

0.5

RT

4

RT

60

Mono-

D

I

I

Soln. Temp. Cycles

All solutions were made with EtOH. Sub- refers to sub-monolayer, mono- refers to monolayer, and multi- refers to
multilayer. All solutions were applied via aerosol sprayer except those marked with D which were dipped in solution
and those marked with I which used a timed immersion

3.3.3 – Immobilization Techniques
3.3.3.1 - Acyl Chloride Immobilization of 2-Phenoxyethanol
Several different reaction conditions were used to develop the procedure for the formation of
acyl chloride terminated monolayers using thionyl chloride and PHDA terminated monolayers
referenced Table 3.3. A generalized procedure is presented here. PHDA substrates were placed
under active vacuum for two hours to ensure full evacuation of the chamber. Following this, the
chamber was cut off from active vacuum and exposed to a connected chamber containing SOCl 2
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under passive vacuum conditions for 60 minutes to expose the surfaces to SOCl2 vapors. The
substrates were then isolated from the SOCl2 and placed under active vacuum again for 15 minutes,
followed again by passive exposure. After three such exposures, the SOCl2 was removed from the
system while the substrates were kept under active vacuum and a chamber of 2-Phen was
introduced in its place. The same active/passive vacuum procedure was followed to initiate
exposure of the newly formed acyl chloride surfaces to 2-Phen. During these exposures, 2-Phen
was heated via heating tape to a temperature of 60oC to promote the vapor phase deposition on the
acyl chloride terminated substrates. The chamber with the exposed coupons was rested on dry ice
in a insulated styrofoam chamber to cool the substrates and promote the condensation of the
incident vapors onto the surface. All depicted reactions were carried out on PHDA/TDPA modified
SS316L coupons.

Scheme 3.5: Transformation of -COOH tail-groups on PHDA to acyl chlorides and subsequent
immobilization of 2-Phen
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Table 3.3: Reaction conditions for Acyl Chloride Immobilization
Active SOCl2

Passive SOCl2

(Min)

(Min)

15 Min

60 Min

1 Hour

Active 2-Phen

Passive 2-Phen

Cycles

Success

(Min)

(Hr)

2

15 Min

1 Hour

2

No

15 Min

3

15 Min

1 Hour

3

No

1 Min

-

2

15 Min

1 Hour

2

No

15 Min

15 Min

1

15 Min

1 Hour

2

No

15 Min

15 Min

2

15 Min

1 Hour

2

No

15 Min

15 Min

3

15 Min

1 Hour

3

No

3.3.3.2

-

2

mM

Cycles

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-

Hydroxysuccinimide Intermediate Formation
PHDA SAM modified substrates were added to a three necked flask with a stir bar. Each neck
was sealed via septum and the flask was purged for 2 hours with N2 gas. A 25 mL solution of EDC
and NHS in 2-Propanol at a concentration of 2 mM each was injected into the flask and stirred for
24 hours. The substrates were then removed from solution and rinsed with anhydrous ethanol.

3.3.3.3

-

20

mM

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/50

mM

N-

Hydroxysuccinimide Intermediate formation
PHDA SAM modified substrates were added to a three necked flask with a stir bar. Each neck
was sealed via septum and the flask was purged for 2 hours with N2 gas. 25 mL of a 20mM EDC
and 50 mM NHS in 2-Propanol was injected into the flask and stirred for 24 hours. The substrates
were then removed from solution and rinsed with anhydrous ethanol.
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3.3.3.4

–

2-Phenoxyethanol

Immobilization

on

N-Hydroxysuccinimide-

Phosphonohexadecanoic Acid Monolayer Intermediate
Once confirmed with DRIFT, NHS-PHDA modified substrates were added to a three necked
flask with a stir bar. Each neck was sealed via septum and the flask was purged for 2 hours with
N2 gas while cooled in an ice bath. 25 mL of a 5 mM solution of 2-Phen in anhydrous THF was
added via syringe and allowed to stir for 24 hours. Substrates were then removed and rinsed with
anhydrous ethanol.

Scheme 3.6: Functionalization of PHDA with NHS to form NHS-PHDA intermediate and subsequent
immobilization of 2-Phen

3.3.3.5 – 2 mM N,N'-Dicyclohexylcarbodiimide/4-Dimethylaminopyridine Intermediate
Formation
SAM modified substrates were added to a three necked flask with a stir bar. Each neck was
sealed via septum and the flask was purged for 2 hours with N2 gas. A 25 mL solution of DCC and
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DMAP in 2-Propanol at a concentration of 2 mM each was injected into the flask and stirred for
24 hours. The substrates were then removed from solution and rinsed with anhydrous ethanol.

3.3.3.6

–

2-Phenoxyethanol

Immobilization

on

4-Dimethylaminopyridine-

Phosphonohexadecanoic Acid Monolayer Intermediate
Once confirmed with DRIFT, DMAP-PHDA modified substrates were added to a three
necked flask with a stir bar. Each neck was sealed via septum and the flask was purged for 2 hours
with N2 gas while cooled in an ice bath. 25 mL of a 5 mM solution of 2-Phen in anhydrous THF
was added via syringe and allowed to stir for 24 hours. Substrates were then removed and rinsed
with anhydrous ethanol.
Table 3.4: Steglich-type Esterification on Carboxylic terminated monolayers
SAM

Time (Hours)

Catalyst (mM)

Carbodiimide (mM)

Temp (⁰C)

Success

16-PHDA

24

NHS (2)

EDC (2)

RT

Fail

16-PHDA

24

NHS (2)

EDC (2)

RT

Fail

TDPA/PHDA

2

NHS (2)

EDC (2)

0⁰C → RT

Fail

TDPA/PHDA

2

NHS (2)

EDC (2)

0⁰C → RT

Fail

TDPA/PHDA

2

NHS (2)

EDC (2)

0⁰C → RT

Fail

16-PHDA

1.5

NHS (5)

EDC (5)

RT

Fail

16-PHDA

30 Min

NHS (50)

EDC (20)

RT

Fail

16-PHDA

1.5

NHS (50)

EDC (20)

RT

Fail

16-PHDA

1.5

NHS (50)

EDC (20)

RT

Fail

16-PHDA

1.5

NHS (50)

EDC (20)

RT

Fail

16-PHDA

24

NHS (2)

DCC (2)

RT

Fail

16-PHDA

24

NHS (2)

DCC (2)

RT

Fail

16-PHDA

24

DMAP (2)

DCC (2)

RT

Fail

TDPA/PHDA

2

DMAP (5)

DCC (5)

RT

Fail
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3.3.3.7 – Mitsunobu Type Reaction (Diethyl azodicarboxylate/Triphenyl phosphine)
ADPA SAM modified substrates, 50 mM (0.03 g) 2-Phen, and a small stir bar were placed in
a 125 mL Erlenmeyer flask, and then evacuated under vacuum followed by purging under an N 2
atmosphere for 5 minutes. 5 mL of dry THF was injected via syringe, followed by 50 mM (0.07
g) of TPP, after which the reaction was placed in an ice bath. 50 mM of DEAD was added dropwise
via syringe over the course of 20 minutes. The reaction was allowed to come to room temperature
and was stirred for 24 hours. Substrates were then removed, sonicated in THF, and dried under
vacuum.

Scheme 3.7: Functionalization of SS316L with ADPA Monolayers followed by immobilization of 2Phen via Mitsunobu reaction

3.3.3.8

–

Mitsunobu

Type

Reaction

(Tetramethylazodicarboxamide/Tributyl

Phosphine)
ADPA SAM modified substrates, 50 mM (0.03 g) 2-Phen, and a small stir bar were placed in
a 125 mL Erlenmeyer flask, and then evacuated under vacuum followed by purging under an N 2
atmosphere for 5 minutes. 5 mL of dry THF was injected via syringe, followed by 50 mM (0.05
g) of TBP, after which the reaction was placed in an ice bath. 50 mM (0.04 g) of TMAD added
dropwise via syringe over the course of 20 minutes. The reaction was allowed to come to room
72

temperature and was stirred for 24 hours. Substrates were then removed, sonicated in THF, and
dried under vacuum.
Table 3.5: Mitsunobu Conditions on SS316L
2-Phen
(mM)

Azo-Reagent (mM) Phosphine (mM) Solvent (mL)

Solvent (mL)

Temp ⁰C Time (Hr) Success

50

40% DEAD (50) TPP Recrys. (50)

THF (5)

-

0⁰C → RT

24

No

50

40% DEAD (50) TPP Recrys. (50)

Benzene (5)

-

0⁰C → RT

24

No

50

40% DEAD (50) TPP Recrys. (50)

DCE (5)

-

0⁰C → RT

24

No

50

TMAD (50)

TBP (50)

Benzene (5)

THF (1)

0⁰C → RT

24

No

50

TMAD (50)

TBP (50)

DCE (5)

THF (1)

0⁰C → RT

24

No

3.4 – Surface Characterization Techniques
3.4.1 – Diffuse reflectance infrared Fourier transform spectroscopy
Diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy was used to confirm the
formation of SAMs and their subsequent modification on SS316L. Measurements were collected
using a Thermo Nicolet-Nexus FT-IR with a diffuse reflectance attachment. The sample
compartment was purged with N2 prior to scan collection to eliminate IR stretches contributed by
atmospheric CO2 and H2O. Spectra were collected using an average of 256 scans (4000-400 cm-1)
at a resolution of 4 cm-1. Bare SS316L that had been cleaned to remove surface contaminants was
used to produce a background spectrum.

3.4.2 – Contact Angle
The wettability of unmodified and modified SS316L and CoCr substrates were examined
using contact angle goniometry. A Rame-Hart goniometer with an integrated 10 μL syringe was
used to place droplets of millipore water (2 μL) on the substrate surfaces. A total of three drops
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each were placed on the surface of three different substrates for each modification step (n=9).
Contact angle values of the modified substrates were then compared to unmodified substrates and
standard deviations were calculated.
Contact angle goniometry is a useful tool for evaluating the wettability of a surface by
studying the hydrophobicity or hydrophilicity of the plane. The stability and completeness of an
organic film and the polarity of the surface influences the level of interaction an incident water
droplet has with a substrate. For hydrophobic surfaces, an incident liquid will not wet the surface
completely and will form a droplet with a measurable angle, θ, between the surface and the tangent
of the droplet edge facing the surface. Water droplets on hydrophilic surfaces will wet a surface
by spreading out across the substrate due to favorable interactions between water and the polar
film or material. Contact angles of ≥90º correspond to a hydrophobic surface, whereas a contact
angle <90º indicates a hydrophilic surface.

3.5 – Results and Discussion
SAMs were formed upon the substrate surfaces using aerosol deposition and evaluated using
contact angle goniometry and DRIFT spectroscopy. Following confirmation of monolayer
ordering and stability, cross-linking reactions were performed to attach 2-Phen to the surface.
DRIFT spectroscopy was used to determine the success of these reactions.
The ordering of the alkyl chain and binding of the head group were determined after rinsing
(15 min) and sonication (15 min) in deposition solvent. Solvent rinses ensure that only covalently
linked SAMs are studied and that unbound or physisorbed molecules have been removed from the
surfaces. Mechanical agitation via sonication is sufficient to desorb unstable monolayers, therefore
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ordered SAMs that remain after this treatment are stable. Once the stability and ordering of the
SAMs has been determined, further modification of the surface may be performed.
The formation of stable and ordered SAMs on SS316L was confirmed through DRIFT
spectroscopy. Peaks attributed to CH2 asymmetric and CH2 symmetric stretching of the alkyl
chains of the monolayer molecules were evaluated to confirm the formation of ordered SAMs.
Wavenumbers of 2917 cm-1 and 2848 cm-1 correspond to the CH2 asymmetric and CH2 symmetric
peaks, respectively.1-2 When these IR peaks are found to be below 2918 cm-1 and 2848 cm-1 with
0.3% to 0.7% transmittance, SAMs are considered ordered in an all-trans semi-crystalline
fashion.3-4 If wavenumbers corresponding to the CH2 asymmetric and CH2 symmetric moieties are
> 2918 cm-1 and 2850 cm-1 the alkyl chains are considered disordered. In this case, the monolayer
is typically unstable and easily removed by sonication.1-2, 5

3.5.1 – Formation of 16-Phosphonohexadecanoic Acid monolayers
3.5.1.1

–

Characterization

of

16-

Phosphonohexadecanoic Acid Monolayers by
Diffuse

Reflectance

Fourier

Transform

Spectroscopy
After rinsing and sonication in THF to
remove

physisorbed

molecules,

PHDA

monolayers formed on SS316L were analyzed
using DRIFT. The resulting spectrum presented
peaks corresponding to the alkyl chain C-H stretch
as ν CH2 asym = 2917 cm-1 and ν CH2 sym = 2849 cm-1
indicating a stable and ordered monolayer (Figure

Figure 3.1: DRIFT spectra of PHDA SAM on
SS316L: ν CH2 asym = 2917 cm-1 and ν CH2 sym = 2849 cm1

3.1). Peak intensity of the CH2 asymmetric peak equaled 0.38% transmittance. The wavenumbers
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for the CH2 asymmetric and symmetric peaks and the peak intensity of the CH2 asymmetric peak
are consistent within the expected range for a semi-crystalline all-trans monolayer without
multilayers or islanding on the surface.1, 3, 6 Therefore, the carboxylic acid tail-groups of the PHDA
monolayers are presented evenly at the surface, prepared to be reacted with EDC/NHS to form the
NHS-PHDA ester intermediate.

3.5.1.2 – Contact Angle Analysis of 16-Phosphonohexadecanoic Acid Monolayer
Contact angle goniometry was used to examine the wettability of the newly formed SAMs
and characterize success of monolayer formation by studying the interfacial properties of the
surface. Bare SS316L was found to have a water contact angle of 72 ± 5°. After deposition of
PHDA monolayers, the contact angle of the surface decreased to 66 ± 4°. Bare SS316L is covered
in an oxide layer which has a slightly hydrophilic character due to the presence of surface hydroxyl
groups. In comparison, a fully formed PHDA SAM is expected to increase the hydrophilic
character of the surface due to the high surface density of the carboxylic acid tail-groups which
enables greater hydrogen bonding interactions with the H2O droplets on the surface. The improved
wettability and low standard deviation imply that the SAMs have formed consistently as
monolayers. This further supports that the SAM has an even presentation of -COOH tail-groups at
the surface which will be capable of serving as a functionalized surface for generation of acyl
chlorides or immobilization using carbodiimide chemistry.
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3.5.2

–

Formation

of

Mixed

14-Tetradecylphosphonic

Acid

and

16-

14-Tetradecylphosphonic

Acid

and

16-

Phosphonohexadecanoic Acid monolayers
3.5.2.1

–

Characterization

of

Phosphonohexadecanoic Acid monolayers by Diffuse Reflectance Infrared Fourier
Transform Spectroscopy
Mixed SAMs of TDPA and PHDA were formed based on unpublished work provided to our
group by Danahy and Schwartz from Princeton
University. This research indicates that hydrogen
bonding interactions between surface carboxylic
acid groups may stabilize the -COOH tail-groups
to such a degree that they are prevented from
reacting with cross-linking reagents. After several
attempts at mixed monolayer formation, a method
for stable and ordered monolayer production was
Figure 3.2: DRIFT spectra of TDPA-PHDA

developed, referenced in the last entry in Table 3.1. SAM on SS316L: ν CH3 = 2963 ν CH2 asym = 2917 cm-1
After rinsing and sonication in THF, the resulting

and ν CH2 sym =2848 cm-1

TDPA-PHDA monolayers presented peaks corresponding to the alkyl chain C-H stretch at ν
asym

CH2

= 2915 cm-1 and ν CH2 sym = 2848 cm-1 respectively (Figure 3.2). Additionally, a small peak at

ν CH3 = 2963 cm-1 can be seen corresponding to the methyl group present on the TDPA inclusions
in the mixed monolayer. The peak intensity of the CH2 asymmetric peak was found to be 0.7%
transmittance. The favorable peak intensity and -CH2 wavenumbers indicate the monolayer has
formed successfully and is stable after sonication.

3.5.2.2 – Contact Angle Analysis of 14-Tetradecylphosphonic Acid and 16Phosphonohexadecanoic Acid monolayers
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Contact angle goniometry was used to examine the wettability of the mixed SAMs and
characterize monolayer formation by studying the wettability of the surface. Bare SS316L was
found to have a water contact angle of 72 ± 5°. After deposition of mixed TDPA/PHDA
monolayers, the surface presented a similar contact angle of 72 ± 11°. The increase in contact angle
in the mixed monolayers in comparison to a pure PHDA SAM is expected due to the inclusion of
the nonpolar tail-groups of TDPA (Scheme 3.3). The higher standard deviation in the contact
angles of the mixed monolayers implies that not all the samples formed consistently with regards
to tail-group presentation. This is within expectations for a mixed monolayer in which the quantity
of TDPA intercalated into the PHDA SAM is expected to be variable. The variation in TDPA and
PHDA concentration on the surface and the difference in the polarity of the presented tail-groups
causes differences in observed interfacial properties in different regions of a given substrate as a
result. A pure PHDA SAM increases the wettability of a surface compared to a bare SS316L
substrate, but a pure TDPA monolayer would be expected to increase hydrophobicity instead due
to the nonpolar character of the methyl tail group. The favorable wavenumbers and CH 2
asymmetric peak intensity from the DRIFT spectrum imply a stable and ordered monolayer has
formed. It can be inferred from the relatively large standard deviation in wettability that the two
molecules are not fully intercalated but instead are forming a stable mixed SAM with some areas
presenting higher concentrations of -COOH tail-groups and others with higher quantities of the CH3 tails of TDPA. These localized differences in tail-group concentration would explain the
variability of the droplet behavior based on the location chosen on the surface of a given substrate.
While the relative concentration of the TDPA and PHDA molecules are variable, they must be
intercalating in different ratios across the surface since the monolayer is never found to be fully
hydrophobic. This implies that the formation of the mixed monolayers is successful and has
78

generated a surface with inhibited potential for hydrogen bonding between -COOH tail-groups.
The mixed PHDA/TDPA monolayers are expected to be more suitable for use in EDC/NHS crosslinking reactions.

3.5.3 – Formation of 12-Aminododecylphosphonic Acid monolayers
3.5.3.1 – Characterization of 12-Aminododecylphosphonic Acid Monolayers via Diffuse
Reflectance Infrared Fourier Transform Spectroscopy
The Mitsunobu reaction is known to proceed between an alcohol and a suitable nucleophile.
One of the known products of the Mitsunobu
reaction is a secondary amine.7-8 This product is
suitable for the immobilization of drugs to
biomedical devices as it is resistant to the
hydrolysis experienced in vivo by ester and ether
groups. To generate secondary amine cross-links,
an amine terminated SAM was employed to act as
the nucleophile in the reaction. ADPA SAMs were
Figure 3.3: DRIFT spectra of ADPA SAM on

successfully formed on SS316L after testing SS316L: ν CH2 asym = 2915 cm-1 and ν CH2 sym =2847 cm1

referenced in Table 3.2. ADPA SAMs formed on SS316L using the previously described reaction
conditions were analyzed using DRIFT. The resulting SAM presented peaks corresponding to a
stable and ordered monolayer with wavenumbers equal to ν

CH2 asym

= 2915 cm-1 and ν

CH2 sym

=

2847 cm-1 (Figure 3.3). The CH2 asymmetric peak demonstrated a peak intensity of 0.7%
transmittance after sonication. The favorable wavenumbers and CH2 asymmetric peak intensity
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correspond to the formation of stable and ordered monolayer which will provide an amine
terminated surface ready for cross-linking via the Mitsunobu reaction.

3.5.3.2 – Contact Angle Analysis of 12-Aminododecylphosphonic Acid monolayers
ADPA monolayers were evaluated using contact angle goniometry after DRIFT spectroscopy
to assess the interfacial properties of the surface after SAM deposition. In comparison to the
contact angle of bare SS316L (72 ± 5°), ADPA was found to have a more hydrophilic character
with a contact angle of 59.7±9.4°. Similar to the PHDA monolayers, this increase in wettability is
expected due to the increased density of functional groups on a SAM in comparison to the native
oxide layer and the hydrogen bonding capabilities of the amine tail-groups. As the collected
contact angles have low standard deviation and are consistent with the predicated interfacial
properties, the ADPA SAMs are found to have consistently formed stable and ordered monolayers
which are appropriate for immobilization of 2-Phen using the Mitsunobu reaction.

3.5.4 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy
Analysis of Pure 2-Phenoxyethanol
Evaluation of pure 2-Phen is a crucial step in preparing to determine the success of
immobilization reactions on the surface. By overlaying the IR spectrum of pure 2-Phen with the
IR spectrum of the modified surface, the success of the immobilization will be established. The
only difference anticipated between the spectrum of a successful immobilization of 2-Phen and
pure liquid 2-Phen is the disappearance of the -OH functional group used in cross-linking, and the
addition of peaks contributed by the monolayer. Additional peaks should also be present which
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Figure 3.4: DRIFT spectra of Pure 2-Phen: ν OH = 3384 cm-1, ν Aro.CH = 3062 and 3039 cm-1, ν CH2 Asym = 2936
cm , ν CH2 Sym = 2873 cm-1, ν Aro.C=C = 1599, 1496, and 1455 cm-1, ν C-O = 1242 and 1172 cm-1, ν C-O-C = 1084 and 1040
cm-1, ν C=C = 916 cm-1, ν CH = 753 cm-1
-1

account for the SAM used in the reaction, but these peaks will be absent from the spectrum of the
unreacted target compound. An example spectrum of non-crystalline 2-Phen was taken using
DRIFT spectroscopy (Figure 3.5) and used to identify representative peaks. These peaks are
expected to appear in both the non-crystalline 2-Phen sample spectrum and in the spectrum of a
successful immobilization reaction with the SAM. Peaks corresponding to the primary alcohol in
the non-crystalline sample can be seen at ν OH = 3384 cm-1 and ν C-O = 1040 cm-1. The alkyl tail is
confirmed by the CH2 peaks at ν

CH2 Asym

= 2936 cm-1 and ν

CH2 Sym

= 2873 cm-1. The alkyl aryl

ether in the tail group is indicated by peaks at ν C-O = 1242 and 1172 cm-1 and ν C-O-C = 1084 cm-1.
The phenyl ring on the molecule can be identified by several peaks including the cyclic alkene
character at ν Aro. C=C = 1599, 1496, and 1455 cm-1 and ν C=C = 916 cm-1 with C-H stretching and
bending peaks at ν Aro. CH = 3062 and 3039 cm-1 and ν CH Bend = 753 cm-1. The most prominent and
indicative peaks expected to be observed in a successfully immobilized 2-Phen sample are the
aromatic CH peaks at ν Aro. CH = 3062 and 3039 cm-1, the double bonds at ν Aro. C=C = 1599, 1496,
and 1455 cm-1, and the alkyl aryl ether peaks found at ν C-O = 1242 and 1172 cm-1 and ν

C-O-C

=
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1084 cm-1. The presence or lack of these peaks will be used to determine the success of a crosslinking reaction involving 2-Phen as the immobilized molecule.

3.5.5 - Acyl Chloride Immobilization
One of the first techniques attempted for the immobilization of 2-Phen on SS316L was an
acyl chloride mediated esterification (Scheme 3.6). Attempts at generating acyl chloride
terminated monolayers are represented in Table 3.3. Since acyl chlorides are reactive to moisture
in the air, attempts at intermediate formation were not analyzed via IR as samples must be exposed
to atmosphere for this purpose. Instead, 2-Phen was directly exposed to carboxylic acid

Figure 3.5: DRIFT spectra of SOCl2 treated PHDA monolayers: No peaks besides that at ν = 1064 cm- 1 could
be quantified demonstrating a loss of monolayer from the surface after exposure to SOCl2

monolayers which had been exposed to SOCl2 solutions under an N2 atmosphere and then results
were analyzed after the SOCl2 solution was quenched post-reaction. A representative spectrum of
the last attempt at acyl chloride mediated immobilization can be found in Scheme 3.6. No
indicative peaks for 2-Phen were found in the IR spectrum of the SAM following immobilization
using this technique. Additionally, peaks corresponding to the SAM are lost after exposure to
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SOCl2. This indicates that the SOCl2 is not reacting with the SAM tail-groups, but is stripping the
SAM from the surface. Even attempts at a gentle vapor phase exposure to SOCl2 were found to be
capable of removing a previously formed PHDA monolayer. This can be seen by drastic reduction
of the CH2 asymmetric and symmetric peaks seen in the PHDA overlay in Figure 3.6. While the
loss of the SAM is not complete as indicated by the appearance of faint CH2 asymmetric and
symmetric peaks, the peaks have been reduced to the point of being unquantifiable. Due to the
repeated failure of the method to immobilize 2-Phen and the repeated stripping of the SAMs, other
methods of immobilization were pursued to immobilize 2-Phen.

3.5.6–

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-Hydroxysuccinimide

Immobilization
3.5.6.1

–

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-Hydroxysuccinimide

Intermediate Formation
Carbodiimide cross-linking is a well-known and specific method of forming covalent linkages
between target molecules containing -OH and -COOH groups (Scheme 3.7). This method was
chosen to be used in experiments to immobilize 2-Phen via esterification. In the attempted
immobilizations of 2-Phenoxyethanol, EDC and NHS have been employed to first generate an
NHS-PHDA ester intermediate on SS316L substrates (Table 3.4). Following successful formation
of NHS-PHDA intermediate, 2-Phen was exposed to the surface to allow the target hydroxyl group
to displace the NHS leaving group and couple the compound to the surface via an ester linkage
(Scheme 3.7). These experiments were unsuccessful for immobilizing 2-Phen despite the
successful generation of intermediates on the SAM surface.
It is known that the concentration of surface functional groups presented by monolayers are
in the nano-molar range on the surface.9 Thus, initial attempts to form the NHS intermediate were
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performed with 2 mM of both EDC and NHS and were expected to provide reagents in excess to
the tail-groups provided by the SAM. These attempts were shown to be successful in forming the
intended intermediate when compared to the PHDA SAM using DRIFT (Figure 3.7). It can be
observed from the retention of the CH2 asymmetric and symmetric peaks at ν CH2 asymm = 2915 cm1

and ν CH2 symm = 2848 cm-1 that the monolayer remains stable post-reaction. The appearance of

indicative C=O peaks at ν C=O = 1736 and 1703 cm-1 as well as the N-O peak at ν N-O = 1655 cm-1
demonstrate the attachment of the NHS leaving group to the -COOH tails (Figure 3.7). The
presence of the NHS-intermediate suggests that this modification will be suitable for exposure to
2-Phen in order to facilitate cross-linking to the surface.
Utilizing higher concentrations of EDC and NHS, at 20 mM and 50 mM respectively, have
yielded positive results in the past.10-13 Thus, EDC and NHS have also been employed at
concentrations matching those previously demonstrated by our group generate the NHS-PHDA
intermediate on the surface. The observation of amide I and II peaks at ν Amide I/II = 1647 and 1554
cm-1 seems to imply a higher surface concentration of the NHS molecule that is not seen in the

Figure 3.6: DRIFT spectra of 2 mM NHS-PHDA Intermediate: ν CH2 Asym = 2915 cm-1, ν CH2 Sym = 2848 cm-1, ν
-1
-1
-1
-1
C=O = 1736 and 1703 cm , ν NO = 1655 cm , ν CH = 1440 cm , ν CO = 1278, 1237, and 1201 cm
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2mM trial. However, this increase in peak intensity and clarity is attributed to the physisorption of
excess NHS onto the surface. Hydroxyl peaks are observed at ν

OH

= 3318 cm-1 and ν OH = 1378

cm-1, in addition to a significant increase in the C-O peak seen at ν CO = 1207 cm-1. The presence
of these peaks indicates that the OH found on the NHS molecule has not reacted with the surface.
Since NHS did not fully react with the surface, physisorption to the surface must have occurred.
Physisorbed NHS will not promote nucleophilic displacement by a nucleophile and therefore will
not achieve the covalent attachment of 2-Phen. Since the lower concentration EDC/NHS reaction
conditions demonstrated the formation of the NHS-intermediate without physisorption, that
method was utilized to form the NHS-PHDA intermediates prior to exposures intended to
immobilize 2-Phen.

Figure 3.7: DRIFT spectra of 50 mM NHS-PHDA Intermediate: ν OH = 3318 cm-1, ν CH = 2977 cm-1, ν CH2 Asym
= 2915 cm-1, ν CH2 Sym = 2848 cm-1, ν C=O = 1779 and 1730 cm-1, ν Amide I/II = 1647 and 1554 cm- 1, ν OH = 1374 cm-1, ν
-1
-1
CO = 1207 cm , ν CO = 1107 cm

3.5.6.2

–

2-Phenoxyethanol

Immobilization

on

N-

Hydroxysuccinimide/Phosphonohexadecanoic Acid Monolayer Intermediate
Following the formation of the EDC/NHS intermediate using the 2 mM technique, the surface
was exposed to a solution of 2-Phen for 24 hours to allow the esterification to occur (Scheme 3.7).
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Figure 3.8: DRIFT spectra of 2 mM NHS-PHDA Intermediate after exposure to 2-Phen: ν CH2 Asym = 2915 cm, ν CH2 Sym = 2848 cm-1, ν C=O = 1710 cm-1, ν CH = 1470 and 1436 cm-1, ν CO = 1316, 1207, 1237, and 1200 cm-1

1

Unfortunately, no significant changes can be seen when comparing the NHS-PHDA intermediate
to the 2-Phen treated substrates using DRIFT. This indicates that while the NHS intermediate has
been successfully formed, the 2-Phen fails to displace the leaving group and covalently link to the
surface as intended. EDC and NHS are most often used in the literature to couple -COOH groups
to amines, which are more nucleophilic than their hydroxyl counterparts.14-15 This decrease in
nucleophilicity may be the reason that the hydroxyl group on 2-Phen does not successfully displace
NHS. For posterity, the experiment was performed using the samples of NHS-PHDA formed using
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higher concentrations but this attempt was also met with failure as expected. The inability of 2Phen to displace the NHS-intermediate suggests that this method is unsuitable for immobilizing 2Phen. Other routes for immobilization were explored following this discovery.

3.5.7 - Dicyclohexylcarbodiimide/4-Dimethylaminopyridine Immobilization
3.5.7.1 – Dicyclohexylcarbodiimide/4-Dimethylaminopyridine Intermediate Formation
A popular alternative to the use of EDC/NHS is the Steglich esterification, which follows a
very similar mechanism but employs DCC and DMAP as the carbodiimide and leaving group,
respectively (Scheme 3.9).14,

16-19

The main difference between the compounds lies in their

differing solubilities, but previous work has indicated that one or the other may provide better
results for a given cross-linking system.12, 20 To test whether the Steglich reagents would perform
in a superior manner when using 2-Phen as the nucleophile, the same conditions that were
successful for the formation of the NHS-PHDA intermediate were used to generate a DMAPPHDA intermediate. Indicative peaks for the C=C character in DMAP are observed in the
intermediate spectrum at ν C=C = 1670 cm-1 as well as peaks corresponding to amide I and II at ν
Amide I/II

= 1624 and 1568 cm-1. The C-N peak seen at ν

CN

= 1316 cm-1 further corroborates the

Scheme 3.8: Functionalization of PHDA with NHS to form NHS-PHDA intermediate and subsequent
immobilization of 2-Phen
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formation of the DMAP-PHDA complex. The formation of the DMAP-intermediate considered to
be as successful and suitable for an attempt to immobilize 2-Phen.

3.5.7.2

–

2-Phenoxyethanol

Immobilization

on

4-Dimethylaminopyridine-

Phosphonohexadecanoic Acid Monolayer Intermediate
After exposing 2-Phen to the DMAP-PHDA intermediate surface, there is a more notable
change to the resultant spectrum than was observed with the NHS-PHDA counterpart (Figure

Figure 3.9: DRIFT spectra of 2 mM DMAP-PHDA Intermediate: ν CH2 Asym = 2915 cm-1, ν CH2 Sym = 2848 cm-1,
ν C=C = 1670 cm-1, ν Amide I/II = 1624 and 1568 cm- 1, ν CH = 1397 cm-1, ν CN = 1316 cm-1, and ν PO = 1006 cm-1

3.10). The amide I and II peaks have disappeared along with the prominent C-H peak at ν

CH

=

1397 cm-1 indicating that DMAP has been displaced. However, the phenyl peaks seen in the
spectrum of non-crystalline 2-Phen (Figure 3.5) at ν Aro. CH = 3062 and 3039 cm-1 are not observed,
and the fingerprint region lacks the distinct ether peak which should be present due to the 2oxyethanol tail-group. The lack of expected peaks suggests that the DMAP-intermediate is easily
removed from the surface but fails to catalyze the esterification of 2-Phen. The failure to covalently
attach 2-Phen by displacement of either the NHS-PHDA or DMAP-PHDA intermediates indicates
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that carbodiimide cross-linking is not suitable for immobilizing 2-Phen. The Mitsunobu reaction
was then pursued as an alternative method to achieve covalent attachment.

3.5.8 – Mitsunobu Type Reactions
3.5.8.1 – Diethyl azodicarboxylate/Triphenyl phosphine
The traditional Mitsunobu reaction utilizes TPP and DEAD for the condensation of alcohols
with various nucleophiles (Scheme 3.8).21-25 In the experiments discussed in this chapter, the
reaction is expected to immobilize 2-Phen on amine terminated monolayers via a secondary amine
bond. Various reaction conditions were attempted, referenced in Table 3.5, but none demonstrated

Figure 3.10: DRIFT spectra of 2 mM DMAP-PHDA Intermediate after exposure to 2-Phen: ν CH2 Asym = 2916
cm-1, ν CH2 Sym = 2849 cm-1, ν C=C = 1670 and 1516 cm-1, and ν CN = 1338 cm-1

attachment of the compound to the surface.
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Initial attempts at the Mitsunobu were carried out under traditional reaction conditions for
the experiment using DEAD and TPP. After the reaction, the resultant substrates were compared
to the ADPA monolayer via DRIFT spectroscopy to observe changes to the surface. Peaks from
the ADPA monolayer are retained showing N-H peaks at ν

NH

= 1621 and 1437 cm-1 and what

appears to be C-N peaks at ν CN = 1259 and 1192 cm-1, which had previously resolved as a single
broad peak in the ADPA spectrum. This implies that there are primary amine tail-groups which
remain unreacted on the surface post-reaction. The spectrum lacks any peaks which could be
attributed to the presence of 2-Phen, including the aromatic CH peaks expected at ν Aro. CH = 3062
and 3039 cm-1 and ν Aro. C=C = 1599 cm-1. Due to the tangible lack of peaks correponding to 2-Phen
and the fact that the monolayer appears completely unchanged post-reaction, it can be inferred that
2-Phen has not bound to the surface. It was hypothesized that this failure is due to the primary
amine of the ADPA monolayer being close to the pKa barrier of the Mitsunobu reaction, and
attempts to overcome this restriction using improved reagents developed by Tsunoda et. al were
attempted next.8, 25

Figure 3.11: DRIFT spectra of SAM after DEAD/TPP Immobilization of 2-Phen: ν CH2 Asym = 2918 cm-1, ν CH2
=
2849
cm-1, ν NH = 1621 and 1437 cm-1, ν CN = 1259 and 1192 cm-1, ν PO = 1119 cm-1
Sym

90

3.5.8.2 – Tetramethylazodicarboxamide/Tributyl phosphine
The traditional Mitsunobu reaction utilizing DEAD and TPP suffers from a major
drawback referred to as ‘the restriction of pKa’, in which the participating nucleophile must have
a pKa <11 for the reaction to generate the intended bond.8, 25-27 Primary amines, such as the tailgroups of ADPA have a pKa of ~10.7 which is very close to the limit for the reaction proceeding
properly.28-29 N,N,N’,N’-tetramethylazodicarboxamide (TMAD) has been employed as an
improved azocompound designed to overcome this restriction. TBP is utilized as a more
nucleophilic phosphine which has been shown in the literature to promote the formation of a more
basic betaine adduct with TMAD. Similarly to DEAD, the azocompound was added dropwise
during the Mitsunobu reaction to minimize the generation of the undesirable hydrazine side
product.
After the reaction, the substrates demonstrate nearly identical results to those found with the
use of traditional Mitsunobu conditions via DRIFT. Peaks from the ADPA monolayer are retained

Figure 3.12: DRIFT spectra of SAM after TMAD/TBP Immobilization of 2-Phen: ν CH2 Asym = 2917 cm-1, ν CH2
-1
-1
-1
-1
-1
Sym = 2849 cm , ν NH = 1655 and 1440 cm , ν CN = 1222 cm , ν PO = 1119 cm , ν POH = 1013 cm
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showing N-H peaks at ν NH = 1655 and 1440 cm-1 and a C-N peak at ν CN = 1222 cm-1. As in the
previous reaction, the absence of other indicative peaks such as the aromatic CH peaks at ν Aro. CH
= 3062 and 3039 cm-1 and the double bond peak at ν Aro. C=C = 1599 cm-1 implies that the reaction
has failed to achieve immobilization. None of the significant peaks for 2-Phen are present and the
monolayer remains unchanged after the reaction showing that 2-Phen has not bound to the surface.
Further experiments utilizing 2-Phen were not performed as successful reactions using TIC were
achieved during experiments with the Mitsunobu reaction. Since 2-Phen was intended to act as a
model for TIC but did not provide a pathway, the use of the compound in experiments was
abandoned.

3.6 – Conclusion
Attempts were made to immobilize 2-Phen to the surface of various SAMs, but the results
herein indicate a failure to achieve attachment via the hydroxyl tail group. SAMs of ADPA, PHDA,
and mixed TDPA/PHDA were formed successfully and characterized using both DRIFT and
contact angle goniometry. Exposure of PHDA SAMs to thionyl chloride in attempts to generate
an acyl chloride surface resulted in the loss of the monolayer. This method of immobilization was
abandoned following these results. Trials conducted to form NHS and DMAP intermediates using
carbodiimide cross-linking techniques were shown to be successful. However, further reactions
with the weakly nucleophilic alcohol on 2-Phen failed to displace the leaving groups and this
prompted the exploration of less conventional cross-linking reactions. The Mitsunobu reaction was
employed both using traditional reaction conditions and improved reactants designed to overcome
the ‘restriction of pKa’. Results from these experiments showed that while monolayers remain
stable after reaction, 2-Phen continues to resist immobilization on substrate surfaces. Many of
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these reactions have been explored in greater detail using TIC on SS316L bulk substrates and
SS316L stents. In several cases, greater successes have been achieved due to the differences in
chemical properties between the molecules, such as the presence of secondary alcohols on TIC
which are more prone to participation in the Mitsunobu reaction. Due to repeated failures using 2Phen and successful results achieved in parallel experiments, this line of research was abandoned
in favor of progressing into the use of TIC on a regular basis in immobilization reactions.
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Chapter 4: Immobilization of Ticagrelor on SS316L and Inhibition of thrombosis
formation
4.1 Introduction
TIC was selected as the compound of interest for the immobilization on SS316L to provide
a localized anti-thrombotic coating to vascular stent materials. The synthetic approaches utilized
to immobilize TIC on SAMs formed on SS316L are presented in this chapter.

Scheme 4.1: Generalized immobilization of Ticagrelor on 12-Aminododecylphosphonic Acid

The immobilization of the anti-platelet drug TIC upon SAM modified substrates and the
inhibition of platelet aggregation on implant material surfaces have been demonstrated. Both
esterification and amidation were explored as potential routes for immobilization. As the purpose
of this research is to address thrombosis, a focus has been placed on discovering viable routes for
amination reactions between a SAM and TIC since amines are stable in vivo. One-pot EDC/NHS
coupling of TIC to SS316L modified with mixed PHDA/TDPA monolayers has been briefly
explored but was not successful. Extensive research into the immobilization of TIC on amine
terminated monolayers utilizing several variations of the Mitsunobu reaction is presented including
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a successful example of an anti-platelet SAM. Both the monolayers and immobilized compounds
have been evaluated with DRIFT spectroscopy, contact angle goniometry, and atomic force
microscopy. It has been found that experiments on SS316L stents are far more reproducible than
those performed on SS316L foil substrates. Both the stent and foil substrates have been studied by
energy-dispersive x-ray spectroscopy (EDS) to determine how the oxide layers of the substrates
differ in their elemental composition.
Following the successful immobilization of TIC on SS316L stents, the efficacy of the
immobilization was investigated by exposing the modified stents to platelet rich plasma (PRP).
Both platelets in solution and on the surface have been studied to ensure that platelets retain the
ability to activate in solution but are not able to adhere to the surface. It is known that platelets
release adenosine diphosphate when activated alongside other alpha granules.1-3 The relative
activation of platelets exposed to different stent samples has been determined indirectly using an
ADP ELISA assay. In samples found to have higher levels of ADP, higher levels of platelet
activation are expected. In a successful experiment, similar levels of ADP will be observed in each
sample set. Flow cytometry has been employed to directly determine the number of activated
platelets in solution following incubation with fluorescence conjugated antibodies CD62P and
CD42a. As with the ADP ELISA, similar levels of activated platelets in each sample set are
desired. Once the level of relative platelet activation is determined in solution, the efficacy of
modifications for inhibiting local platelet aggregation will be evaluated by studying the surface
using SEM. Platelet morphology will be studied to ascertain whether adhered platelets are partially
or fully activated, and stent substrates were compared to demonstrate increased protection from
platelet aggregation on modified substrates. Data supporting TIC immobilized samples provide
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increased resistance to platelet adhesion without influencing platelets non-incident to the surface
is presented and discussed in this chapter.
4.2 – Materials
4.2.1 - Experimental Materials
Stainless steel foils (AISI 316L, Fe69/Cr18/Ni10/Mo3) of 0.5 mm thickness were obtained
from Goodfellow Inc. 12-amino-dodecylphosphonic acid (ADPA) hydrochloride (95%) was
purchased from Alfa Aesar. Hexamethyldisilazane (HMDS), 2% osmium tetroxide in H2O, and
40% diethyl azodicarboxylate (DEAD) by weight in toluene were purchased from Sigma Aldrich.
Tetrahydrofuran (THF) was purchased from Macon. Tetrahydrofuran was dried over sodium and
benzophenone and distilled under N2 gas before use. Tri-n-butyl phosphine (95%) (TBP) was
purchased from Acros Organics. Ticagrelor (98%) (TIC) was purchased from Asta Tech. CD41a
Mouse anti-Human, FITC, Clone: HIP8 from Invitrogen and CD62P Mouse anti-Human, PE,
Clone: AK-4 from BDBiosciences were purchased via Thermo Fischer. Human Adenosine
Diphosphate (ADP) ELISA Kit was purchased from Biotang Inc.
4.2.2 -Instruments
All infrared spectra were recorded using a Thermo Nicolet-NEXUS 470 FT-IR equipped
with a Diffuse Reflectance Infrared Fourier Transform (DRIFT) attachment. Contact angles were
taken using a Rame-Hart Model 200-U1 goniometer. Atomic force microscopy (AFM)
micrographs were generated using an Asylum Instruments MFP-3D Bio AFM. Flow cytometric
measurements were performed using a BD Biosciences Accuri C6 Flow Cytometer. SEM
micrographs were collected using a Hitachi S-3400N Scanning Electron Microscope.
4.3 – Methods
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4.3.1 – Stainless Steel 316L Substrate Cleaning and Preparation
SS316L foil was sanded using silicon carbide sandpaper of increasing grit (150, 320, 400,
and 600) to provide a fresh and uniform surface oxide layer for SAM formation. Substrates were
then cut into 1 cm x 1 cm squares. The resulting coupons were then cleaned by sonication in
acetone and immersion in boiling methanol for 15 minutes each, to remove remaining organic
residue and metallic dust. Samples for AFM were further polished using a Metaserv 2000 Polisher
using 800 grit and 1200 grit sandpaper. Samples were then polished using 1 µm MetaDi
Monocrystalline Diamond Solution supplied by Buehler on a felt pad. Substrates were then
sonicated in acetone and ethanol (EtOH) for 15 minutes each to remove any remaining adhered
wax or diamond dust. Samples were dried and stored under vacuum prior to use.
4.3.2 – Self-assembled Monolayer Formation
4.3.2.1 – Mixed 14-Tetradecylphosphonic Acid and 16-Phosphonohexadecanoic Acid
Monolayers
Several methods were attempted to form mixed monolayers of TDPA and PHDA,
referenced in Table 3.1. Mixed monolayers of TDPA and PHDA were formed on the native oxide

Scheme 4.2: Formation of Mixed 16-Phosphonohexadecanoic Acid and 14-Tetradecylphosphonic Acid
Monolayer on SS316L
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surface of the substrates using aerosol deposition. Samples were sprayed with a 1 mM solution of
PHDA in THF and dried for 30 minutes at 120 ⁰C. This was repeated until 3 sprays had been
completed and the substrates were then annealed at 120 ⁰C for 24 hours. Once annealed the
substrates were rinsed and sonicated in THF to remove any physisorbed molecules. After drying
at 120 ⁰C for at least 45 minutes, monolayer formation was confirmed using contact angle
goniometry and DRIFT spectroscopy.
4.3.2.2 - 12-Aminododecylphosphonic Acid Monolayers
Monolayers of ADPA were formed on the native oxide surface of the substrates using
aerosol deposition. Samples were sprayed with a 0.5 mM solution of ADPA in EtOH using a thin
layer chromatography sprayer, and then dried at 120 ⁰C for 30 minutes. This process was repeated
until the substrates had been sprayed 3 times, at which point they were annealed at 120 ⁰C for 24
hours. Once annealed the substrates were rinsed and sonicated in EtOH to remove any physisorbed
molecules. Monolayer formation was confirmed using contact angle goniometry, DRIFT
spectroscopy, and AFM.

Scheme 4.3: Formation of 12-Aminododecylphosphonic Acid Monolayers on SS316L
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Table 4.1: Carbodiimide Esterification Reaction Conditions
Material

TIC Conc. (mM)

Catalyst (mM)

Carbodiimide (mm)

Temp (⁰C)

Success

SS316L Foil

2

DMAP (2)

DCC (2)

0⁰C → RT

Fail

SS316L Foil

2

NHS (2)

EDC (2)

0⁰C → RT

Fail

SS316L Foil

100

DMAP (100)

DCC (100)

20⁰C

Fail

SS316L Foil

100

NHS (100)

EDC (100)

20⁰C

Fail

SS316L Foil

100

NHS (50)

EDC (20)

0⁰C → RT

Fail

SS316L Foil

100

NHS (50)

EDC (20)

0⁰C → RT

Fail

SS316L Foil

100

NHS (50)

EDC (20)

0⁰C → RT

Fail

SS316L Foil

100

NHS (50)

EDC (20)

0⁰C → RT

Fail

SS316L Foil

100

NHS (50)

EDC (20)

0⁰C → RT

Fail

4.3.3 – Immobilization Techniques
4.3.3.1

–

One-pot

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

and

N-

Hydroxysuccinimide Ticagrelor Immobilization
Mixed TDPA-PHDA SAM modified substrates were added to a 125 mL Erlenmeyer flask
alongside 50 mM NHS, 20 mM EDC, and a stir bar. The flask sealed via septum and the flask was

Scheme 4.4: Immobilization of TIC on Mixed TDPA/PHDA Monolayers on SS316L

purged for 2 hours with N2 gas. 5 mL of anhydrous dichloromethane (DCM) was injected into the
flask. The flask was cooled to 0 oC in an ice bath and allowed to stir for 30 minutes to allow
102

intermediate formation. During this time, a 100 mM solution of TIC in 5 mL of THF was produced.
After the EDC/NHS reaction stirred for 30 minutes, the 100 mM TIC solution in THF was injected
via syringe and the reaction was removed from the ice bath. The reaction was stirred for 3 hours
after which substrates were removed and sonicated in a 1:1 mixture of THF and DCM before being
dried under vacuum.
Table 4.2: Mitsunobu Reaction Conditions utilizing DEAD
Substrate

SAM

Foil

ADPA

Azo-Reagent
(mM)
DEAD (50)

Rate of addition
Dropwise/20 Min

Phosphine (mM)

Solvent

Time (Hrs)

Success

TPP (50)

THF

24

Fail

Foil

ADPA

DEAD (50)

Dropwise/20 Min

RTPP

(50)

THF

24

Fail

Stent

ADPA

DEAD (50)

Dropwise/20 Min

RTPP

(50)

THF

24

Partial

(50)

Benzene

24

Partial

Foil

ADPA

DEAD (50)

Dropwise/20 Min

RTPP

Foil

ADPA

DEAD (50)

Dropwise/20 Min

RTPP

(50)

Benzene

24

Fail

(50)

THF

24

Fail

Foil

DPA/ADPA

DEAD (50)

Dropwise/20 Min

RTPP

Foil

DPA/ADPA

DEAD (50)

Dropwise?20 Min

RTPP

(50)

THF

24

Partial

Foil

DPA/ADPA

DEAD (100)

10µL/min

RTPP

(50)

THF

24

Partial

Foil

DPA/ADPA

DEAD (100)

10µL/min

TBP (50)

THF

24

Fail

Foil

ADPA

DEAD (100)

10µL/min

TBP (50)

THF

48

Fail

Foil

DPA/ADPA

DEAD (100)

10µL/min

TBP (50)

THF

48

Fail

Foil

ADPA

DEAD (100)

10µL/min

TBP (50)

THF

48

Partial

Foil

ADPA

DEAD (100)

10µL/min

TBP (50)

THF

72

Partial

Foil

ADPA

DEAD (100)

10µL/min

TBP (50)

THF

96

Fail

Foil

ADPA

DEAD (100)

10µL/min

TBP (100)

THF

24

Partial

Stent

ADPA

DEAD (100)

10µL/min

TBP (150)

THF

48

Success

All experiments were run using 50 mM of TIC. R Indicates the use of TPP which was recrystallized to remove TPP oxide
impurities. Partial success indicate 1-2 out of 3 substrates were successful in an experiment but these results could not be
reproduced.
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4.3.3.2 – Mitsunobu Type Reaction (Diethylazodicarboxylate/Triphenylphosphine)
ADPA SAM modified substrates, 50 mM TIC, 50 mM TPP, and a small stir bar were
placed in a 125 mL Erlenmeyer flask, and then evacuated under vacuum followed by purging under
an N2 atmosphere for 5 minutes. 5 mL of anhydrous THF was injected via syringe and the reaction
was placed in an ice bath while stirring. 50 mM of DEAD was slowly added via syringe over the
course of 20 minutes. The reaction was stirred for 24 hours and allowed to come to room

Scheme 4.5: Immobilization of TIC on ADPA monolayers on SS316L by the traditional Mitsunobu
reaction

temperature for the duration of the experiment. Substrates were then removed, sonicated in THF,
and dried under vacuum.
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Table 4.3: Mitsunobu Reaction Conditions utilizing TMAD
Substrate

SAM

Foil

ADPA

Foil

ADPA

Stent

ADPA

Foil

DPA/ADPA

Rate of addition
Dropwise/20
Min
Dropwise/20
Min
Dropwise/20
Min
Dropwise/20
Min

Phosphine (mM)

Solvent

Time (Hrs)

Success

TBP (50)

Benzene/THF

24

Partial

TBP (50)

Benzene

24

Partial

TBP (50)

Benzene/THF

24

Partial

TBP (50)

DCE

24

Fail

All experiments utilized 50 mM of TIC and 50 mM of TMAD. Partial results indicate 1-2 out of 3
substrates in an experiment were successful but these results could not be reproduced.

4.3.3.3 – Mitsunobu Type Reaction (Tetramethylazodicarboxamide/Tributyl
phosphine)
ADPA SAM modified substrates, 50 mM TIC, 50 mM TMAD and a small stir bar were
placed in a 125 mL Erlenmeyer flask, and then evacuated under vacuum followed by purging under
an N2 atmosphere for 5 minutes. 5 mL of anhydrous THF was injected via syringe, followed by 50
mM of TBP, after which the reaction was placed in an ice bath. The reaction was stirred for 24
hours and allowed to come to room temperature for the duration of the experiment. Substrates
were then removed, sonicated in THF, and dried under vacuum.
4.3.3.4 – Mitsunobu Type Reaction (Diethyl azodicarboxylate/Tributyl phosphine)
ADPA SAM modified substrates, 50 mM TIC, and a small stir bar were placed in a 125
mL Erlenmeyer flask, and then evacuated under vacuum followed by purging under an N2
atmosphere for 5 minutes. 5 mL of anhydrous THF was injected via syringe, followed by 250 mM
of TBP, after which the reaction was placed in an ice bath. 100 mM of DEAD was slowly added
via syringe pump at 5 µL per minute while stirring. The reaction was stirred for 48 hours and
allowed to come to room temperature for the duration of the experiment. Substrates were then
removed, sonicated in THF, and dried under vacuum.
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Scheme 4.6: Immobilization of TIC on ADPA monolayers on SS316L using optimized Mitsunobu
reaction conditions

4.3.4 – Surface Characterization Techniques
4.3.4.1 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy
A Nexus 470 Fourier Transform Infrared Spectrometer with a diffuse reflectance (DRIFT)
attachment was used to characterize substrates confirming both monolayer formation and TIC
immobilization. Spectra were collected under N2 for 256 scans with a resolution of 4 cm-1 on each
sample and corrected with respect to a background reference spectrum of SS316L.
4.3.4.2 – Contact Angle Goniometry
A Rame-Hart goniometer was used to measure static contact angles of water to determine
the uniformity of the ADPA monolayers. Contact angles were measured using 2 μL drops of
deionized water (Millipore 18Ω) to characterize the hydrophobicity of the surface modifications.
Three measurements were performed on three substrates for a total of 9 measurements per
modification. The average contact angle value and standard deviation (n=9) are reported.
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4.3.4.3 – Atomic Force Microscopy
An AppNano ACL-20 Atomic Force Microscope (AFM) operating in tapping mode was
utilized in ambient conditions. AFM micrographs (5m x 5m area) were collected using silicon
cantilevers with a resonant frequency of 190 kHz and a force constant of 58 N/m. Three substrates
were analyzed for each modification, and three micrographs were collected on each substrate for
a total of 9 micrographs. Root mean square (RMS) roughness are reported as an average plus or
minus the standard deviation (n=9).
4.3.5 - In Vitro Platelet Function Testing
4.3.5.1 – Exposure to Platelet Rich Plasma
Three sets of three substrates were placed in a 24 well-plate with one set of wells left empty
to act as a control. The sample sets are as follows; four empty control wells, four bare SS316L
substrates, four ADPA coated substrates, and four TIC immobilized substrates. 1 mL of platelet
rich plasma (PRP) was gently pipetted into each of the wells and were left for one hour at room
temperature. After the time had elapsed, substrates were removed from their wells and fixed
according to the below procedure in preparation for study by SEM. The remaining PRP was
centrifuged at 3500 rpm for 10 minutes to separate the remaining platelets and the supernatant for
analysis via flow cytometry and ADP ELISA, respectively.
4.3.5.2 - Flow cytometry
Following exposure to substrates, the PRP from each well was spun down at 3500 rpm for
10 minutes. The resultant platelet pellet was resuspended in 100 µL of phosphate buffered saline
(PBS). To each vial of resuspended platelets, 5 µL FITC conjugated CD41a and 20 µL PE
conjugated CD62P anti-human antibodies were added and incubated for 30 minutes at 37 oC.
Following incubation, the platelets were analyzed using flow cytometry. The instrument was set
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to an excitation wavelength of 488 nm. FITC fluorescence was detected using a 533/30 filter and
PE fluorescence was detected with a 585/40 filter. Platelet samples were passed through the laser
beam after setting the flow rate to low and 10,000 activation-independent platelet events were
collected from each sample set at n=9.
4.3.5.3 – Adenosine Diphosphate Enzyme Linked Immunosorbent Assay
The supernatant removed from the platelet pellet post-centrifugation was frozen for up to
7 days before evaluation using ADP ELISA. The ELISA kit was balanced at room temperature for
30 minutes prior to use. Samples corresponding to empty control wells, and wells containing bare,
ADPA, and TIC modified stent substrates were added in 5 μL amounts at an n=6 to the pre-coated
microplate. Standard solutions were then prepared in 8 clean 1.5 ml tubes. 200 μL of 1 X Sample
Buffer was aliquoted into each of the eight tubes separately. 200 μL of the 2000 nmol/L standard
solution was added into the first tube and mixed with a pipette. Following that, 200 μL of the first
solution was aliquoted into the second tube. Mixing and transfer steps were repeated moving from
the third to the seventh tubes, omitting the eighth tube to act as a blank control. 5 μL of each
standard was then added to the remaining wells in duplicate to provide a calibration curve. 100 μL
of substrate solution was added into each well and incubated at 37 ºC for 5 minutes. The
absorbance value for each well was collected at 550 nm using the plate reader to generate an
average baseline optical density (OD1). Following that, 20 μL of enzyme conjugate was added to
each well and incubated at 37 ºC for 15 minutes. The absorbance value for each well was again
collected at 550 nm to generate the sample optical density (OD2). Duplicate readings for each
standard, control, and sample were averaged and OD1 was subtracted from OD2 to determine the
optical density of each well. The concentration of ADP for each control and sample were be
calculated according to standard curve and averaged. The data was subjected to a one-way
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ANOVA to determine if the ADP concentrations in the sample sets were significantly different
from one another.
4.3.5.4 - Platelet Fixation
Following exposure to PRP in well-plates, stent samples were removed and fixed prior to
analysis using SEM. Stent samples were added directly to a 5% glutaraldehyde solution for 7 days.
Following fixation by glutaraldehyde, samples were immersed in 2% osmium tetroxide (OsO 4)
solution for one hour as a secondary fixative. Samples were then dehydrated by immersion in
aqueous ethanol (EtOH) solutions of increasing concentration (25%, 50%, 75%, and 100%) for 20
minutes each. Dehydration of samples was completed by immersion in hexamethyldisilazane
(HMDS) for 10 minutes followed by placement in a desiccator for at least 2 hours prior to use with
the SEM.
4.3.5.5- Scanning Electron Microscopy Analysis
Hitachi S-3400N-II scanning electron microscope (SEM) run in backscatter electron mode
was used to examine the morphology of platelets adhered to the stent surfaces after fixation. SEM
micrographs of stent surfaces were collected between at 500x and 1000x magnification.
Micrographs were collected under vacuum by applying a 2.00 kV accelerating voltage, 80.0-volt
(V) probe current, and a working distance of 10.0 millimeters.
The elemental composition of the surfaces of both SS316L stents and SS316L foil
substrates were examined and compared by using the energy dispersive x-ray spectroscopy (EDS)
on the SEM. Spectra collected from 0-20 eV on a Hitachi S-3400N-II SEM under vacuum using a
Bruker XFlash with ESPIRIT software, under a magnification of 1000x and accelerating voltage
of 15.0 kV.
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4.4 – Results and Discussion
A limited quantity of SS316L stents were available, so bulk SS316L foil was purchased to
provide an adequate number of substrates for experimentation and optimization studies. The
atomic make-up of the oxide layers of both SS316L foil and stent substrates were evaluated using
EDS to ensure that experiments on the foil substrates would be representative of the stents. As
SS316L is composed of various metals, the surface oxide content is an amalgamation of different
metal oxides such as Fe2O3, Cr2O3, and NiO. The ratio of oxides on the surface is not necessarily
the same as the ratio of the metals which make up the bulk of the substrate material due to
enrichment or depletion of elements from the surface caused by treatment processes.4-6 Interfacial
analysis confirmed the presence of the elements Fe, Cr, Ni, Mn, and Mo in all samples examined,
as well as trace amounts of Si, P, and S (Table 4.4). These numbers are in within reasonable
accordance with the standard composition of SS316L, that being; between 16-18% Cr, 10-14%
Ni, and 2-3% Mo with less than 2% Mn, 0.75% Si, 0.045% P, and 0.03% S as trace elements.4, 7-9
There are only minor differences between the stent and foil substrates. Discrepancies between
Table 4.4: Elemental content of SS316L stents and foil substrates
Si

P

S

Cr

Mn

Fe

Ni

Mo

Reported

1

0.045

0.015

16.5-18.5

2

Balance

10-13

2-2.5

Foil

0.61

0.03

0.01

14.75

3.73

68.25

10.61

2.01

Stent

0.56

0.02

0.01

18.03

4.24

61.30

12.79

3.05

reported and experimental compositions may be attributed to the specific enrichment of certain
elements near the surface of the material because of differing passivation and treatment techniques.
Despite the apparent similarity in surface composition between the stents and foil
substrates when studied by EDS, the data does not reflect the surface which is interacting with
incident molecules in solution. When utilizing EDS, an electron beam is directed at the surface
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and the resultant x-rays scattered by the elements present are detected at a depth of 1-2 microns.
However, the thickness of the hydroxyl content on the metal oxide layer of SS316L has been
demonstrated to be as little as 3-5 nm when studied with XPS.4, 10 This means that the composition
detected by the instrument includes the oxide layer and a large quantity of the bulk material beneath
it at once, making it impossible to determine the exact make-up of the surface alone. Since EDS
cannot differentiate between the oxide layers of the substrates and XPS is currently unavailable
for use with this study, it is presently impossible to determine how the SS316L foil and stents
differ in terms of surface chemistry.
While the exact make-up of the oxide layers cannot be ascertained, there are several notable
differences in the treatment of the surfaces of the stent and foil substrates expected to impact the
composition of the surface oxide layers, and subsequently their chemical behavior. The first is the
methods of planarization used to prepare the surfaces of the foil and stent substrates. The foil
substrates are mechanically sanded and then sonicated in acetone and methanol to remove any
organic contaminants or debris. This produces a roughened surface upon which forms a fresh oxide
layer under atmospheric conditions. By comparison, vascular stents are electropolished and then
sterilized using proprietary techniques which cannot be reproduced in the lab.11-13 Electropolishing
is known to leave a passivated and atomically smooth surface produced by the application of
potential to the substrate in a solution of mixed strong acids.14-15 This methodology changes both
the topography and enrichment of metal oxides on the surface, thus altering the concentration of
hydroxyl groups on the exterior of the substrate.11-13 The stent is then subjected to sterilization
techniques which may include exposure to chemicals such as ethylene oxide, or placement in
heated, irradiated, or high pressure environments capable of further modifying the atomic content
of the surface.16-18 As a result of these proprietary treatment methods, differences in the results
111

from stent and foil substrates is expected. The electropolished stents are more difficult to form
SAMs on due to the increased passivation from the electropolishing they undergo. However, the
stents have an atomically smooth surface produced as a byproduct of the electropolishing process
which should not be significantly changed by SAMs since they have been shown to form in
accordance with surface topography.6, 19 In comparison, the foil substrates are mechanically sanded
which produces a much rougher surface with visible polishing lines. This may make stents more
compatible with cross-linking reactions as the decrease in surface defects will enable incident
molecules to interact with the SAM surface more easily.
4.4.1 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy Analysis of
Pure Ticagrelor
Pure TIC was analyzed by DRIFT to determine the expected IR spectrum after successful
modification of the SS316L substrate after cross-linking to a SAM functionalized substrate (Figure
4.4). The resultant spectra may be easily overlayed with attempts at immobilization to compare

Figure 4.4: DRIFT spectra of Ticagrelor: ν Free OH = 3608 cm-1, ν Bound OH = 3515 cm-1, ν NH Stretch = 3292 cm-1, ν
-1
-1
-1
-1
-1
CH = 2909 cm , ν C=N = 1623 cm , ν NH = 1514 cm , ν CH = 1451 cm , ν CN = 1327 cm , ν CO= 1273, 1195, 1098, and
-1
1039 cm
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the peaks in the spectra. When the peaks of the immobilized surface match those found in the
spectra of the pure solid, a successful immobilization is considered to have occurred. Each of the
functional groups present in TIC can be seen in the resultant IR spectrum and only the alcohol
peaks are expected to change in an immobilized sample since they are utilized during cross-linking.
Free OH stretching can be observed at ν Free OH = 3608 cm-1 while hydrogen bonded OH stretching
is present as a broad peak at ν

Bound OH

= 3515 cm-1. NH stretching from the secondary amine in

TIC can be observed at ν NH = 3292 cm-1. CH stretching and bending vibrations typical of organic
compounds is present at ν CH = 2909 cm-1 and ν CH = 1451 cm-1, respectively. A large peak at ν C=N
= 1623 cm-1 corresponds to the center of the TIC molecule, dominated by a (1,2,3)triazolo(4,5)pyrimidine moiety which resembles the adenine character of adenosine diphosphate (Scheme
4.1). The secondary amine adjacent to the (1,2,3)triazolo-(4,5)pyrimidine moiety presents a peak
at ν NH = 1514 cm-1. Both the pyrimidine character and the secondary amine contribute to the peak
at ν CN = 1327 cm-1. TIC contains multiple C-O bonds from the primary and secondary amines, as
well as the alkyl ether in the tail-group. These bonds are expressed in the IR spectrum at ν

CO

=

1274, 1195, 1098, and 1039 cm-1. The peaks at ν = 1623, 1514, 1451, 1327, and 1273 cm-1 were
used to determine successful immobilization based on their correlation with functional groups in
TIC.
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4.4.2 – 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-Hydroxysuccinimide
Immobilization
4.4.2.2

–

Formation

of

Mixed

14-Tetradecylphosphonic

Acid

and

16-

14-Tetradecylphosphonic

Acid

and

16-

Phosphonohexadecanoic Acid Monolayers
4.4.2.2.1

–

Characterization

of

Phosphonohexadecanoic Acid Monolayers by Diffuse Reflectance Infrared Fourier
Transform Spectroscopy
Carboxylic acid terminated SAMs were formed to provide a functionalized surface
appropriate for the formation of NHS intermediates using
carbodiimide cross-linking reactions. Mixed SAMs of
TDPA and PHDA were formed after several attempts at
mixed monolayer formation referenced in Table 3.1.
Findings from unpublished work provided to our group by
Danahy and Schwartz from Princeton University indicates
Figure 4.2: DRIFT spectra of TDPAPHDA SAM on SS316L: ν CH3 = 2963, ν CH2
-1
-1
asym = 2915 cm , and ν CH2 sym =2848 cm

that hydrogen bonding interactions between carboxylic
acid tail-groups have sufficient stability to inhibit cross-

linking reactions. To improve the reactivity of the surfaces functionalized with carboxylic acid tail
groups, mixed monolayers were employed. The hydrogen bonding of the surface carboxyl groups
is expected to be disrupted by incorporating methyl-terminated SAM molecules which will
intercalate into the monolayer and space the COOH-tail groups apart. After deposition and
sonication in THF, the resulting TDPA-PHDA monolayers presented peaks corresponding to the
alkyl chain C-H stretch at ν CH2 asym = 2915 cm-1 and ν CH2 sym = 2848 cm-1 respectively (Figure 3).
Additionally, a small peak at ν CH3 = 2963 cm-1 can be seen which corresponds to the methyl group
present on the TDPA inclusions implying that the spacing molecules have successfully intercalated
into the formed SAM. The wavenumbers corresponding to -CH2 asymmetric and symmetric
114

stretching coupled with the -CH2 asymmetric peak intensity of 0.7 indicate a successfully formed
monolayer which is ready for use in EDC/NHS coupling reactions with TIC.
4.4.2.2.2 – Contact Angle Analysis of 14-Tetradecylphosphonic Acid and 16Phosphonohexadecanoic Acid Monolayers
To confirm monolayer formation and functional tail-group presentation, contact angle
goniometry was used to examine the change in surface wettability between bare SS316L and
substrates modified with the mixed SAMs. The contact angle of the surface after deposition of
mixed TDPA/PHDA monolayers was found to be 66.2 ± 3.2⁰ which is only slightly lower than
that of bare SS316L at 72.8 ± 4.8⁰. In a pure PHDA monolayer this would be cause for concern as
the hydrogen bonding capacity of the carboxylic tails should demonstrate greater wettability than
that of the bare metal oxide surface. In the case of a mixed TDPA/PHDA monolayer however this
contact angle makes sense, given that the non-polar methyl- tails of the intercalated molecule
would prevent a decrease in the number of hydrogen bonding sites. Additionally, the small
standard deviation among samples indicates that the intercalation is uniform throughout the SAM

Figure 4.3: Contact angles on SS316L measured by static sessile drop method. Bare SS316L = 72.8 ± 4.8⁰, ADPA SAMs =
53.0 ± 2.8⁰, Mixed TDPA/PHDA = 66.2 ± 3.2⁰ and TIC Immobilized surfaces = 55.8 ± 2.9⁰
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and the intended decrease in hydrogen bonding capacity is not localized on the substrates. Coupled
with the positive results from the IR spectrum, the mixed monolayer is demonstrated to be stable,
ordered, evenly presents tail-groups, and should be sufficiently reactive for EDC/NHS crosslinking due to the spacer molecules.
4.4.2.3

–

Immobilization

of

2-Phenoxyethnol

by

1-Ethyl-3-(3-

dimethylaminopropyl)carbodiimide and N-Hydroxysuccinimide
Attempts made to immobilize TIC on mixed PHDA/TDPA monolayers utilizing EDC and
NHS as cross-linking reagents were met with limited success (Figure 4.5). Monolayers remain
stable and ordered as evidenced by peaks at CH2asym ≤ 2915 cm-1 and CH2sym ≤ 2847 cm-1. Many
indicative peaks for the presence of TIC on the surface are missing from the EDC/NHS treated
substrates including the alcohol peaks at ν Free OH = 3608 cm-1 and ν Bound OH = 3515 cm-1 as well as
peaks attributed to the (1,2,3)triazolo-(4,5)pyrimidine moiety at ν Aromatic = 1514 cm-1 and ν C-N =
1327 cm-1. While the peaks that are present seem to line up well with the spectrum of TIC when
overlayed in Figure 4.5, it is more likely that they should be attributed to the similar functional

Figure 4.4: DRIFT spectra of TIC immobilized via EDC/NHS overlayed with TIC: ν CH2 Asym = 2915 cm-1, ν CH2
-1
-1
-1
-1
-1
-1
Asym = 2847 cm , ν C=O = 1724 cm , ν CN = 1619 cm , ν CH = 1466 cm , ν CO = 1238, 1113 cm and 1001 cm
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groups on the NHS intermediate that forms during carbodiimide cross-linking. The C-N peak at ν
N-O

= 1619 cm-1 and the small C=O peak at ν

C=O

= 1724 cm-1, which is not present in TIC,

corresponds to characteristics found in NHS. Surface methyl- groups from TDPA and C-H
stretching from the cyclic moiety in NHS explain the presence of the peak at ν C-H = 1466 cm-1.
NHS contains several oxygen atoms accounting for the C-O peaks at ν C-O = 1238, 1113, and 1001
cm-1 which lack the splitting demonstrated by TIC in Figure 4.4, which contains a greater variety
of C-O functional groups. Primary amines are typically used as the nucleophile of choice when
employing carbodiimide cross-linking techniques. The NHS group is quickly displaced in the
presence of amines acting as nucleophiles, resulting in an amide cross-link. The use of hydroxyl
groups to displace NHS-ester intermediates is possible but is much less efficient due to the
decreased nucleophilicity of alcohols in comparison to amines. Since the NHS intermediate is
observed in the spectrum of the modified substrate, it can be assumed that the alcohol groups of
TIC are not sufficiently nucleophilic to successfully cross-link to the surface. Even in the case of
a successful displacement of NHS by an alcohol, an unstable ester bond would formed which is
susceptible to hydrolysis in the presence of water. Since the TIC modified surfaces to be produced
in this study are intended for in vivo usage, further attempts to immobilize TIC utilizing this
methodology were not pursued in favor of more stable and successful cross-linking reactions.

4.4.3 – Mitsunobu Type Reactions
4.4.3.1 – Formation of 12-Aminododecylphosphonic Acid Monolayers
4.4.3.1.1 – Characterization of 12-Aminododecylphosphonic Acid Monolayers by
Diffuse Reflectance Infrared Fourier Transform Spectroscopy
SAMs were formed from ADPA to provide a functionalized amine surface to be used in
cross-linking Mitsunobu reactions. A 0.5 mM solution of ADPA in EtOH was sprayed on the oxide
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layer of SS316L substrates. Substrates were
sonicated in EtOH to remove any physisorbed
molecules

or

multilayers

and

were

then

characterized by DRIFT spectroscopy, AFM, and
contact angle goniometry. Stable and ordered
monolayers are known to have alkyl chains in an
all trans conformation, indicated by IR absorptions
at CH2asym ≤ 2918 cm-1 and CH2sym ≤ 2848 cm-1.9,
20-21

Figure 4.5: DRIFT spectra of ADPA SAM on

Peaks were observed at CH2asym = 2915 cm-1 SS316L: ν CH2 asym = 2915 cm-1, ν CH2 sym =2847 cm-1,
-1

and NH3+ = 2937 cm-1

and CH2sym = 2847 cm indicating the formation of a stable and ordered SAM.6, 19, 22 An additional
peak is observed at NH3+ = 2937 cm-1 which corresponds to the presence of a primary amine salt
tail-group on ADPA, which is expected since the molecule was provided commercially as a
hydrochloride salt prior to use in the experiment. The data reveals that the alkyl chains in the SAM
remain ordered after sonication. This implies that the SAM is mechanically stable and will present
amine tail-groups in a uniform manner at the surface appropriate for use in the Mitsunobu reaction
between TIC and the ADPA monolayer.

4.4.3.1.2 – Contact Angle Analysis of 12-Aminododecylphosphonic Acid Monolayers
To ensure that ADPA monolayers were complete and presented amine tail-groups as
intended, substrates were evaluated using a contact angle goniometer via the static sessile drop
method (Figure 4.2). In comparison to the contact angle of bare SS316L (72.8 ± 4.8°), ADPA was
found to have a more hydrophilic character with a contact angle of 53.0 ± 2.8°. This increase in
wettability is expected due to the hydrogen bonding capabilities of the amine tail-groups. The
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surface behaves as expected due to the successful formation of a hydrophilic thin film and the data
presents a low standard deviation indicating that the SAM is complete and has little to no defects.
If the monolayer was disordered, the hydrophobic alkyl chains would be exposed and increase the
contact angle. This is not the case, demonstrated by the decrease in contact angle after SAM
formation. The ADPA SAMs presented here are stable, ordered, and complete according to the
data shown in both the IR spectrum and the resulting contact angles of the modified surface. Since
the substrate has been successfully functionalized with amine tail-groups evenly presented at the
surface, the Mitsunobu reaction can be performed using monolayers generated with this method.

4.4.3.2 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy Analysis of
Diethylazodicarboxylate/Triphenylphosphine
The Mitsunobu reaction was chosen for the condensation of the target alcohol on TIC with
an amine monolayer to produce a stable cross-link to the substrate.23-27 Initial attempts at
immobilization of TIC using traditional Mitsunobu conditions was met with some success. Diethyl

Figure 4.6: DRIFT spectra of TIC immobilized using the Mitsunobu reaction overlayed with TIC:  CH2asym ≤
2914 cm-1, CH2sym ≤ 2847 cm-1, ν C=N = 1623 cm-1, ν NH = 1514 cm-1, ν CN = 1327 cm-1, ν Asym C-O = 1219 cm1
, and ν Sym C-O = 1063 cm-1
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azodicarboxylate (DEAD) and tributyl phosphine (TPP) were employed to form a secondary amine
cross-link between the functionalized surface and the primary hydroxyl on TIC.25-29 DRIFT spectra
of pure TIC and TIC immobilized on SS316L were collected and overlaid to demonstrate the
immobilization of TIC to the surface by covalent attachment to the SAM. The monolayer remains
ordered and stable after the cross-linking reaction has been performed as indicated by retained
peaks at CH2asym ≤ 2914 cm-1 and CH2sym ≤ 2847 cm-1. The (1,2,3)triazolo-(4,5)pyrimidine
character of TIC is represented by the large peak at ν C=N = 1623 cm-1. Both the pyrimidine and
amine moieties contribute to peaks at ν NH = 1514 cm-1 and ν CN = 1327 cm-1. The multiple C-O
bonds in TIC are also present including the asymmetric and symmetric C-O ether stretching at ν
Asym C-O =

1219 cm-1 and ν Sym C-O = 1063 cm-1, as well as the secondary alcohols at ν C-OH = 1117

cm-1. CH stretching and bending vibrations typical of organic compounds is present at and ν CH =
1451 cm-1. The presence of TIC on the surface of the substrates is clear and is stable after sonication
indicating successful covalent linkage to the surface. Further optimization of this methodology
was pursued due to reproducibility issues encountered during further trials of this reaction.
Reproduction of results on SS316L stent substrates was possible but difficult, and the use of
SS316L foil substrates was met with complete failure. To improve the reproducibility of these
results, reagents designed to expand the scope of viable nucleophiles used in the Mitsunobu
reaction from the literature were employed alongside optimization studies to improve reaction
conditions.

4.4.3.3 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy Analysis of
Tetramethylazodicarboxamide/Tributyl phosphine
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To improve the reproducibility of the reaction, experiments were performed to address a
limitation of the Mitsunobu reaction known as ‘the restriction of pKa’. The participating
nucleophile, in this case the amine tail-group of ADPA, must have a pKa <11 for the to occur as
intended and generate a cross-link between the surface and TIC.27-30 Primary amines, such as those
found in the tail groups of ADPA, have a pKa of ~10.7 which is why they are very rarely used as
a nucleophile in this methodology. Additionally, the nucleophile is anchored to the surface in the
experiments performed as part of this study, whereas the Mitsunobu reaction is typically performed
in solution. This situation is expected to further decrease the nucleophilicity of the amine due to
the added steric hindrance. The unfavorable pKa of the primary amine tail-groups coupled with
the significant steric barrier of the substrate surface has lead to the idea that this ‘pKa barrier’ could
be a potential limiting factor in the reproducibility of TIC cross-linking.31-32 Tsunoda et al.

Figure 4.7: DRIFT spectra of TIC immobilized using the updated Mitsunobu reaction overlayed with TIC: 
2916 cm-1,  CH2 sym ≤ 2848 cm-1, ν P=O = 1194 cm-1, ν PO = 1118 cm-1, ν NH = 3260 cm-1, and ν CN = 1369 cm-

CH2 asym ≤
1

developed several new azo-type reagents, 1,1’- (azodicarbonyl)dipiperidine (ADDP) and
N,N,N’,N’- tetramethylazodicarboxamide (TMAD), modified with electron donating groups to

overcome the barrier of pKa to expand the scope of viable nucleophiles.27-29 Tributyl phosphine
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(TBP) was also employed as a more nucleophilic phosphine to promote the formation of the initial
betaine adduct in the first step of the reaction. These new reagents were employed in attempts to
improve the reproducibility of the cross-linking reaction but were discovered to be less efficient
than DEAD when attempting to link TIC to an amine at the SAM interface (Figure 4.7). The
resultant spectrum after reaction lacks indicative peaks for TIC as can be seen in the overlay in
Figure 4.7. A stable and ordered monolayer remains, presenting alkyl chain peaks at CH2asym ≤
2916 cm-1 and CH2sym ≤ 2848 cm-1 and head-group peaks at ν P=O = 1194 cm-1 and ν PO = 1118 cm1

. The only other additional peaks observed correspond to amines at ν

NH

= 3260 cm-1 and ν CN =

1369 cm-1 which are attributed to the tail-group of ADPA. Despite the failure of the new azo-type
reagents to cross-link, it was discovered that the use of the more nucleophilic phosphine reagent
TBP alongside DEAD improved the reproducibility of the reaction on both stent and foil
substrates. This discovery was utilized in further optimization studies in which a more robust
procedure was developed.

4.4.3.4 – Further optimizations to the Mitsunobu reaction
Using DEAD and TBP, optimization studies were performed to maximize the
reproducibility of TIC cross-linking to SS316L stent and foil substrate surfaces functionalized with
ADPA. The use of mixed monolayers of decyl phosphonic acid (DPA) and ADPA was attempted
but no meaningful change in results was observed. Therefore, the use of mixed monolayers was
abandoned. Various solvents were also utilized based on literature studies which indicated that
certain solvents such as benzene, toluene, or DCM produced superior results in the Mitsunobu
reaction.27, 30, 33 Unfortunately, the solubility of TIC in these solvents was very poor making these
solvents unsuitable for use with the drug.
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Using TBP as a stronger nucleophile than TPP has resulted in a notable improvement to
reproducibility due to the promotion of betaine adduct in the first step of the reaction.28-29, 34 The
addition of DEAD and other azo-reagents to the reaction mixture is known to be exothermic and
leads to the thermal degradation of the reagent upon rapid addition.23-24 To prevent this, the
protocol for the traditional Mitsunobu reaction requires that the solution be cooled to 0 ⁰C prior to
the dropwise addition of the utilized azo-reagent, minimizing the exothermic effect of the addition.
For this project, a syringe pump was implemented to exert greater control over the addition of the
azo-reagent. Slowing the rate of addition to 1 µL/minute was found to improve reaction
reproducibility on SS316L stents.24, 30
A further improvement to the reaction conditions was achieved by extending the time for
In the literature, participating nucleophiles are typically free in solution, however, in this system
the nucleophile is provided by the SAM. It was hypothesized that the steric hindrance of anchoring
the amine nucleophile to the surface was decreasing the rate of reaction, so extended run-times of
48, 72, and 96 hours were attempted utilizing reaction conditions found in Table 4.2. It was found
that reproducibility was significantly improved when allowing for reaction times of up to 48 hours.
Trials which allowed the reaction to run longer than 48 hours were found to give similar results to
the 48-hour time trial with no significant improvement. Therefore, 48 hours is considered the
optimal length of time for the reaction to run. The fully optimized reaction conditions are as found
in Table 4.2. The aforementioned results were generated using SS316L stents. Enough samples
were generated on foil SS316L substrates to perform contact angle and AFM analysis. However,
reproducible results on foil SS316L substrates remained unattainable due to reasons previously
discussed in Section 4.5.1. Namely, the differences in surface topography between the foil and
stent substrates is assumed to impact the success of cross-linking reactions. The proprietary pre123

treatments on stents appears to generate a more favorable surface for immobilization reactions via
the Mitsunobu-type reaction.

4.4.3.5 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy Analysis of
Optimized Mitsunobu Reaction (Diethyl azodicarboxylate/Tributyl phosphine)
Following the implementation of these improvements, DRIFT spectra were collected
demonstrating the superior results of the optimized Mitsunobu reaction utilized to cross-link TIC
to the surface Peaks for the monolayer are retained after immobilization at CH2asym ≤ 2913 cm-1
and CH2sym ≤ 2847 cm-1. The (1,2,3)triazolo-(4,5)pyrimidine and amine character of TIC is present
at ν C=N = 1603 cm-1, ν NH = 1522 cm-1 and ν CN = 1323 cm-1. The multiple C-O bonds in TIC are
identified at ν Asym C-O = 1220 cm-1, ν C-OH = 1115 cm-1, and ν Sym C-O = 1052 cm-1. CH bending
vibrations are seen at ν CH = 1464 cm-1. The success of the reaction is clear since the peaks from
TIC and the immobilized spectrum line up exactly as anticipated. Following the development of
the optimized conditions, immobilization was further confirmed using contact angle goniometry
and AFM.
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Figure 4.8: DRIFT spectra of immobilized using the optimized Mitsunobu reaction overlayed with TIC: ν CH3
= 2956 cm-1, ν CH2 sym = 2913 cm-1, ν CH2 asym = 2847 cm-1, ν C=O = 1724 cm-1, ν C=N = 1603 cm-1, ν NH = 1522 cm-1, ν CH
= 1464 cm-1, ν CN= 1323, ν CO = 1220, 1115, and 1052 cm-1

4.4.3.6 - Contact Angle Analysis of Diethyl azodicarboxylate/Tributyl phosphine

Following immobilization of TIC on SS316L contact angles were determined using a
Rame-Hart goniometer via the static sessile drop method to assess changes in the wettability of
the surface. Nine measurements for an n=9. Prior to reporting, the data was averaged, and the
standard deviation was calculated. Due to failure to immobilize TIC upon mixed TDPA/PHDA
monolayers, the average contact angle of immobilized TIC will be compared to that of ADPA
SAMs to observe the change in interfacial properties. There was only a minor change in the contact
angle of the surface after TIC was immobilized with the contact angle increasing from that of 53.0
± 2.8° on the ADPA SAM to 55.8 ± 2.9°. This is consistent with expectations from the
immobilization of a polar molecule. The structure of TIC is dominated by a polar (1,2,3)triazolo(4,5)pyrimidine moiety which contains many C-N bonds. This character coupled with the presence
of hydrogen bonding groups in its structure such as the secondary amine and secondary alcohols
explains why the contact angle does not significantly change from that of the polar ADPA
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monolayer. Additionally, the standard deviation of the measurements is quite small indicating that
TIC has been immobilized evenly across the surface. This data supports the conclusion that TIC
has been covalently linked to the SAM and provides evidence that the immobilization will provide
comprehensive protection from thrombotic effects across the surface.

4.4.3.7 – Atomic Force Microscopy Analysis of Diethyl azodicarboxylate/Tributyl
phosphine
a)

b)

c)

Figure 4.9: AFM Micrographs. a) Bare SS316L, b) APDA monolayer on SS316L, c) TIC immobilized on
SS316L To confirm the change in surface topography expected from the immobilization of a large

biomolecule such as TIC, AFM micrographs were taken of mechanically polished SS316L
substrates, after the formation of the ADPA monolayer, as well as after TIC immobilization to
confirm both the uniformity of the monolayer on the surface and the coverage of the covalently
attached anti-platelet molecule. The RMS roughness values and representative micrographs of the
bare SS316L, ADPA monolayer, and TIC immobilized samples are compared in Figure 4.9.
Successfully formed monolayers have been shown to follow the contours of the surface in the
literature and accordingly present comparable RMS roughness. Polishing lines are apparent in both
the bare SS316L and modified substrates as expected, and the bare and APDA coated surfaces
demonstrate similar RMS roughness values at 4.3 ± 2.0 and 11.3 ± 7.2 respectively.35-36 In the case
of multilayers or islanding forming in place of a stable and ordered monolayer, the RMS roughness
126

would deviate significantly from that of the bare substrate, however that is not the case. The ADPA
monolayer does have a notable standard deviation. This is attributed to the intermittent multilayer
islanding on the surface, which have been observed in all ADPA samples. Despite these structures
forming on the surface, the film behaves as would be expected from a successful SAM. After TIC
is cross-linked to the substrates, the polishing lines were fully obscured demonstrating a notable
change to the surface post-immobilization. The patterning on the TIC immobilized samples is
consistent with prior results in the literature in which large bioactive molecules have been linked
to substrate surfaces.37 The TIC modified samples exhibit a RMS roughness of 6.7 ± 1.0 which
represents a very uniform attachment despite the visible change to the surface post-Mitsunobu
reaction. These results are consistent with those observed via both DRIFT and contact angle
goniometry, confirming successful coverage of covalently linked TIC to the surface. These
surfaces are considered to have complete coverage and were then analyzed for efficacy against
platelet deposition using in vitro analytical techniques.

4.4.4 In Vitro Platelet Behavior Study
a)
b)

c)

Figure 4.10: Depictions of interactions of platelets with exposed surfaces. a) Systemic deactivation, b) Complete
activation, c) Selective deactivation limited to interactions with the surface

Once TIC immobilized samples had been produced, an in vitro platelet challenge was
performed to test the efficacy of immobilized TIC on SS316L against thrombosis formation by
incident platelets. Bare, ADPA coated, and TIC immobilized SS316L stents were exposed to PRP
for one hour, with two additional TIC immobilized sample sets being tested for 24 and 48 hours
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each. Platelets were allowed to interact with the surface of the sample substrates in a static setting
before the stents, platelets in solution, and supernatant were removed for analysis. The desired
outcome of this experiment is to confirm that platelets retain the ability to activate but do not
adhere and clot on protected surfaces. Platelets were expected to activate in all cases, including
control samples, as the polystyrene material of the well-plates used as a vessel for the experiment
is a well-known platelet activator. There are three potential outcomes for this experiment. In the
unlikely case that platelets are not observed to be activated on the surface or in solution, an
excessive amount of TIC would be presumed to have desorbed from the surface of a modified stent
and caused systemic deactivation in solution. If it is instead observed that platelets have activated
both on the surface and in solution, the modification will have failed to affect their behavior. The
last possible event is that platelets activate in solution but do not to adhere to the surface, indicating
successful localized protection provided by immobilized TIC. To characterize the behavior of the
platelets exposed to each sample set, platelets were evaluated after exposure in solution by flow
cytometry and an ADP ELISA assay and on the surface of stent substrates by SEM.

4.4.4.1 – Scanning Electron Microscopy Analysis of Substrates Surfaces and Adhered
Platelet Morphology

Figure 4.11: Bare and modified SS316L stents exposed to PRP for one hour. a) BMS b) ADPA coated stents
c) TIC coated stents
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SEM micrographs were collected from the surface of each substrate to identify changes in
platelet morphology and the extent of platelet inhibition by modified surfaces (Figure 4.11).
Platelets are known to maintain a globular conformation prior to activation. Once activated,
platelets adhere to the surface of the substrate and flatten, extending dendritic tendrils outwards to
form a network with other activated platelets.38-39 To evaluate the protection afforded to the surface
against thrombosis and the effect of surface modification on platelet behavior, the relative extent
of platelet aggregation and the morphology of adhered platelets has been studied. Bare stent
substrates are utilized as a control and are expected to demonstrate higher levels of platelet
aggregation and activated platelet morphologies.
SEM micrographs of the bare SS316L surface display large aggregates of platelets. These
platelets demonstrate a fully activated morphology. They are difficult to distinguish from one
another due to having fully flattened and cross-linked, forming a thrombotic network on the metal
surface. Once aggregated in this manner, platelets become very difficult to distinguish individually
as they extend tendrils into one another and become fixed in place by deposited fibrin. Platelets
are adsorbed in far smaller quantities to ADPA coated substrates and appear to be only partially
activated. Many of the platelets which are present on the surface retain a spherical morphology
and have failed to adhere to one another once attached to the surface. This indicates that the process
of thrombosis formation has been slowed but not fully inhibited. Given time the few aggregates
which have formed are anticipated to grow into clots similar to those seen on bare samples. By
comparison, the TIC immobilized surface has exceptionally low platelet density and the platelets
which remain appear to be fully deactivated despite their presence on the surface. The few platelets
which remain on the TIC samples are believed to have simply failed to have been rinsed off after
settling in place during the static conditions during PRP exposure. The behavior of the platelets on
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Figure 4.11: Bare and modified SS316L stents exposed to PRP for one hour. a) BMS b) ADPA coated stents
c) TIC coated stents

the TIC substrate supports this idea, as they fail to adhere to one another and remain fully globular
indicating a complete lack of activation despite their direct contact with the stent. This indicates a
successful protection of the surface against thrombosis formation by TIC immobilization.

4.4.4.2 Flow Cytometry Analysis of Platelets
To determine how platelet behavior in solution differs from that of the platelets on the
surface, the platelets remaining in solution were seperated from the supernatant by centrifugation
and subjected to flow cytometry. The platelets remaining from each sample set were resuspended
in phosphate buffered saline (PBS) and incubated with anti-human CD62P and CD42a antibodies
prior to analysis by detection of fluorescence conjugated monoclonal antibodies. It was anticipated
that each of the platelet samples would demonstrate similar levels of activation. TIC delivered via
SAMs is covalently linked to the surface and should not systematically deactivate platelets in
solution. This is an intended a feature of this methodology to localize the influence of the delivered
medication when utilized in vivo. Similar levels of activation in each sample set would indicate
promising results.
The first antibody selected for analysis is CD62P (commonly known as P-selectin) which
is a G protein expressed on the plasma membrane of platelets after release from α-granules upon
platelet activation.40-41 The ligand of P-selectin, glycoprotein ligand-1, is the primary facilitator of
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platelet binding and cross-linking interactions, such as platelet-leukocyte aggregate formation and
adhesion to the endothelium.42 To target P-selectin as a reliable expression of platelet activation,
an anti-human CD62P monoclonal antibody conjugated to the fluorophore phycoerythrin (PE) was
utilized. Isolated from red algae, PE is a bright phycobiliprotein which exhibits a fluorescence
emission peak at 578 nm as a red-orange color making it a common and useful fluorophore for
detection of antibodies via conjugation.43-44
The second activation dependent protein in this experiment is CD42a (Glycoprotein IX), a
small membrane glycoprotein.45 This G protein complexes with glycoprotein Ib (GP Ib) on
activated platelet surfaces to form the Glycoprotein Ib-IX-V Receptor Complex (GPIb-V-IX
complex) which functions as a receptor for von Willebrand factor (vWF).46 The GPIb-V-IX
complex is responsible for mediating vWF-dependent platelet adhesion to endothelial cells at
wound sites, making it a suitable target for evaluating platelet activation in thrombosis
experiments. An anti-human CD42a monoclonal antibody conjugated to the fluorophore
fluorescein isothiocyanate (FITC) was utilized alongside the anti-human CD62P-PE antibody to
determine platelet activation by flow cytometry. FITC is a fluorescein derivative and is the one of
the most used fluorophores for biological applications.43, 47 Known to fluoresce when excited by a
blue 488 nm laser, FITC exhibits a fluorescence emission peak at 525 nm, which falls in the
green spectrum. 47-48
After incubation with the CD62P and CD42a anti-bodies, platelets in solution were studied
by flow cytometry and to determine the level of platelet activation in each sample set. After
selection of the appropriate fluorescence channels for the excitation of the conjugated
fluorophores, the platelet samples were investigated for activation. A quadrant gate was
implemented to analyze the resultant density plots of the activated platelets. The lower left hand
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quadrant of these plots corresponds to a double negative, while the upper right hand quadrant
corresponds to double positive events expressing both PE and FITC fluorescence. The control and
BMS samples appear to have lower levels of activation (4.3% and 4.6%) in the double positive
region than their ADPA and TIC coated counterparts (13.4% and 17.9%). Because activated
platelets adhere to foreign bodies whenever possible, it is assumed that this discrepancy is due to
most of the platelets adhering to the surface of the empty well in the control or to the BMS. In the
BMS sample set, most of the activated platelets were no longer present during centrifugation,
having formed thrombi and subsequently being removed along with the substrates. With less
activated platelets to bind to, it follows that those samples would show less total binding by either
of the fluorescence conjugated antibodies. In the case of the control samples, decreased levels of
activation is expected as no foreign material is present to promote activation. Conversely, the
ADPA and TIC coated stents activate platelets in solution but exhibit greater levels of surface
protection resulting in higher quantities of fully activated platelets being left in solution. In the
SEM micrographs shown later in this work it can be seen that the TIC immobilized samples had
greater levels of protection from adherence than the SAM coated samples, consistent with the
inverse relation found in the flow cytometry data sets. Thus, greater the protection afforded to the
surface results in greater quantities of activated platelets remaining in solution.

4.4.4.3 - Adenosine Diphosphate Enzyme-linked Immunosorbent Assay
To indirectly determine the relative amount of activation in PRP from each sample set, an
ADP ELISA was used. Activated platelets release ADP and other platelet activating granules as
part of the coagulation cascade.1-3 As ADP is a major platelet agonist released from activated
platelets, an ADP ELISA was performed on the supernatant of each sample set following
132

centrifugation to determine relative levels of activation independent of platelet behavior. An
increase in ADP concentration would indicates a greater level of activation in a sample set, while
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Figure 4.12: Average ADP Concentration in supernatant of PRP exposed to bare and modified substrates

statistically equivalent levels of ADP would indicate equal amounts of activation. Results from the
assay, shown in Figure 4.12, indicate that there is an equivalent amount of ADP released in each
sample set and the results are shown to be significant after analysis with one-way ANOVA. This
indicates that after centrifugation all sample sets have demonstrated complete activation regardless
of the surface. These results are consistent with those of the other analyses, indicating that the
surface of the substrates is protected from platelet aggregation, but does not inhibit the activation
of platelets in solution. Platelets are notoriously susceptible to activation having been shown to
activate upon contact with foreign materials including both polymer surfaces and fixation solvents,
or even simple shear forces experienced during pipetting or centrifugation. While it is difficult to
identify exactly what caused platelet activation in each of the samples, it is safe to say that the
surface TIC immobilized substrates are protected from aggregation.
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4.5 – Conclusions
Thrombosis formation is a widespread problem for blood contacting alloy biomaterials due
to the susceptibility of the native oxide layer to platelet aggregation. The formation of SAMs
followed by the immobilization of TIC on SS316L improved the biocompatibility of vascular
stents by reducing the amount of platelet aggregation on the stent surface. The formation of SAMs
followed by the immobilization of TIC on blood contacting surfaces inhibited the aggregation of
platelets for up to one hour. DRIFT spectroscopy was used to confirm the presence of TIC on the
surface of the substrates. This modification resulted in an increase to the wettability of the surface,
as well as visible coverage of the surface with TIC in AFM micrographs. Results from flow
cytometry and ADP ELISA show activation of platelets in solution, while the SEM micrographs
of modified and unmodified samples demonstrated successful protection of the surface from
thrombosis formation. This implies that the thin film provides protection to the surface from
platelet aggregation but does not inhibit the function of platelets in solution. However, many
additional challenges remain on the path towards creating a fully biocompatible vascular stent,
including the promotion of non-occlusive neointimal growth and improvements to the longevity
of protection.
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Chapter 5: Immobilization of Ticagrelor on CoCr and Inhibition of Thrombosis
5.1 Introduction
Prior to 2016 SS316L was the most common material for stent production.1-4 However,
cobalt alloys have been discovered to present superior mechanical qualities to SS316L for stent
applications, allowing for stents to be manufactured with much thinner struts which greatly
improves stent biocompatibility.5 This has lead to a major shift in industrial stent production, and
now CoCr L605 has become the most commonly used stent production material on the market. 6
To compensate for this shift in stent production, similar methodology to the successful
immobilization of the anti-platelet drug upon SAM modified SS316L via the Mitsunobu reaction
was used to maintain the relevance of this research. Both the monolayers and immobilized
compounds have been evaluated with DRIFT, contact angle goniometry, and atomic force
microscopy. As with SS316L, it has been found that experimental results are far more reproducible
on stent substrates than on bulk CoCr. Stent and bulk substrates have both been studied by EDS to
confirm material similarities between the proprietary stents and CoCr purchased in bulk from
Goodfellow.
Once TIC had been successfully immobilized on CoCr, the efficacy of the methodology
was reproduced on the CoCr samples by exposure to platelet rich plasma. Platelets are shown to
behave similarly in solution across sample sets and again modified surfaces are shown to be
protected from thrombosis formation. Flow cytometry, ADP ELISA, and SEM have been
employed to study both platelets in solution and on the surfaces of exposed substrates. Following
the demonstration of successful surface modification and thrombosis inhibition, an in vivo rabbit
study was performed by collaborators demonstrating the successful inhibition of thrombosis and
the biocompatibility of the modified stent surface in an endothelial environment.
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5.2 – Materials
5.2.1 - Experimental Materials
Stainless steel foils (AISI 316L, Fe69/Cr18/Ni10/Mo3) of 0.5 mm thickness were obtained
from Goodfellow Inc. 12-amino-dodecylphosphonic acid (ADPA) hydrochloride (95%) was
purchased from Alfa Aesar. Hexamethyldisilazane (HMDS), 2% osmium tetroxide in H2O, and
40% diethyl azodicarboxylate (DEAD) by weight in toluene were purchased from Sigma Aldrich.
Tetrahydrofuran (THF) was purchased from Macon. Tetrahydrofuran was dried over sodium and
benzophenone and distilled under N2 gas before use. Tri-n-butyl phosphine (95%) (TBP) was
purchased from Acros Organics. Ticagrelor (98%) (TIC) was purchased from Asta Tech. CD41a
Mouse anti-Human, FITC, Clone: HIP8 from Invitrogen and CD62P Mouse anti-Human, PE,
Clone: AK-4 from BDBiosciences were purchased via Thermo Fischer. Human Adenosine
Diphosphate (ADP) ELISA Kit was purchased from Biotang Inc.
5.2.2 - Instrumentation
All infrared spectra were recorded using a Thermo Nicolet-NEXUS 470 FT-IR equipped
with a Diffuse Reflectance Infrared Fourier Transform (DRIFT) attachment. Contact angles were
taken using a Rame-Hart Model 200-U1 goniometer. Atomic force microscopy (AFM)
micrographs were generated using an Asylum Instruments MFP-3D Bio AFM. Flow cytometric
measurements were performed using a BD Biosciences Accuri C6 Flow Cytometer. SEM
micrographs were collected using a Hitachi S-3400N Scanning Electron Microscope.
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5.3 – Methods
5.3.1 – Stainless Steel 316L Substrate Cleaning and Preparation
CoCr foil was sanded using silicon carbide sandpaper of increasing grit (150, 320, 400, and
600) to provide a fresh and uniform surface oxide layer. Substrates were then cut into 1 cm x 1 cm
squares. The resulting coupons were then cleaned by sonication in acetone and immersion in
boiling methanol for 15 minutes each, to remove remaining organic residue and metallic dust.
Samples for AFM were further polished using a Metaserv 2000 Polisher using 800 grit and 1200
grit sandpaper. Samples were then polished using 1 µm MetaDi Monocrystalline Diamond
Solution supplied by Buehler on a felt pad. Substrates were then sonicated in acetone and ethanol
(EtOH) for 15 minutes each to remove any remaining adhered wax or diamond dust. Samples were
dried and stored under vacuum prior to use.
5.3.2 - 12-Aminododecylphosphonic Acid Monolayer Formation

Scheme 5.1: Formation of 12-Aminododecylphosphonic Acid Monolayers on CoCr

Monolayers of ADPA were formed on the native oxide surface of the substrates using
aerosol deposition. Samples were sprayed with a 0.5 mM solution of ADPA in EtOH using a thin
layer chromatography sprayer, and then dried at 60 ⁰C for 30 minutes. This process was repeated
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until the substrates had been sprayed 3 times, at which point they were annealed at 60 ⁰C for 24
hours. Once annealed the substrates were rinsed and sonicated in EtOH to remove any physisorbed
molecules. Monolayer formation was confirmed using contact angle goniometry and DRIFT
spectroscopy.
Table 5.1: ADPA Monolayer Formation Conditions on CoCr
Substrate

ADPA Conc. (mM)

CoCr Temp. (⁰C)

Sprays

Drying Temp. (⁰C)

Result

Foil

0.5

10

3

120

Sub-

Foil

0.25

10

3

120

Sub-

Foil

0.25

RT

3

120

Sub-

Foil

0.5

RT

3

120

Sub-

Foil

0.5

RT

4

120

Sub-

Foil

0.5

RT

4

120

Sub-

Foil

0.75

RT

3

120

Sub-

Foil

0.75

RT

3

120

Multi-

Foil

1

RT

3

120

Sub-

Foil

1

RT

3

120

Sub-

Foil

0.75

RT

3

120

Multi-

Foil

0.75

RT

3

60

Fail

Foil

0.75

RT

3

60

Fail

Foil

0.75

RT

3

120

Multi-

Foil

0.75

10

3

120

Sub-

Foil

1

RT

4

120

Mono-

Stent

1

RT

4

120

Mono-
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Scheme 5.2: Immobilization of TIC on ADPA monolayers on CoCr using optimized Mitsunobu
reaction conditions

5.3.3 – Mitsunobu Type Reaction (Diethyl azodicarboxylate/Tributyl phosphine)
ADPA SAM modified substrates, 50 mM TIC, and a small stir bar were placed in a 125
mL Erlenmeyer flask, and then evacuated under vacuum followed by purging under an N2
atmosphere for 5 minutes. 5 mL of anhydrous THF was injected via syringe, followed by 120 mM
of TBP, after which the reaction was placed in an ice bath. 200 mM of DEAD was slowly added
via syringe pump at 5 µL per minute while stirring. The reaction was stirred for 72 hours and
allowed to come to room temperature for the duration of the experiment. Substrates were then
removed, sonicated in THF, and dried under vacuum.
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Table 5.2: Mitsunobu Reaction Conditions utilizing DEAD
Time

Substrate

Azo-reagent (mM)

Rate of Addition

Phosphine (mM)

Solvent

Foil

ADDP (50)

Dropwise/20 Min

TPPR (50)

DCE

24

Fail

Foil

TMAD (50)

Dropwise/20 Min

TPPR (50)

DCE

24

Fail

Foil

TMAD (50)

Dropwise/20 Min

TPPR (50)

DCE

24

Fail

Foil

TMAD (50)

Dropwise/20 Min

TPPR (50)

DCE

24

Fail

Stents

TMAD (50)

Dropwise/20 Min

TPPR (50)

DCE/THF

24

Fail

Foil

TMAD (50)

Dropwise/20 Min

TPPR (50)

DCE/THF

24

No

Stents

TMAD (50)

Dropwise/20 Min

TPPR (50)

THF

24

Partial

Foil

CMBP (120)

Dropwise/20 Min

-

Benzene

24

Fail

Foil

40% DEAD (50)

Dropwise/20 Min

TPPR (50)

Benzene

24

Fail

Stents

40% DEAD (50)

Dropwise/20 Min

TPPR (50)

Benzene/THF

24

Fail

Foil

40% DEAD (50)

Dropwise/20 Min

TPPR (50)

Benzene/THF

24

Fail

Stents

40% DEAD (50)

10 µL/min

TPPR (50)

THF

24

Partial

Foil

40% DEAD (50)

10 µL/min

TBP (50)

THF

24

Partial

Foil

40% DEAD (100)

10 µL/min

TBP (150)

THF

48

Partial

Foil

40% DEAD (250)

10 µL/min

TBP (120)

THF

72

Partial

Foil

40% DEAD (100)

5 µL/min

TBP (150)

THF

72

Partial

Foil

40% DEAD (250)

5 µL/min

TBP (120)

THF

72

Partial

Stents

40% DEAD (250)

5 µL/min

TBP (120)

THF

72

Success

R

(Hrs)

Success

Indicates the use of TPP which was recrystallized to remove TPP oxide impurities. Partial results indicate 1-2 out

of three substrates were successful but these results could not consistently be reproduced.
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5.4 – Surface Characterization Techniques
5.4.1 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy
A Nexus 470 Fourier Transform Infrared Spectrometer with a diffuse reflectance (DRIFT)
attachment was used to characterize substrates confirming both monolayer formation and TIC
immobilization. Spectra were collected under N2 for 256 scans with a resolution of 4 cm-1 on each
sample and corrected with respect to a background reference spectrum of CoCr.

5.4.2 – Contact Angle Goniometry
A Rame-Hart goniometer was used to measure static contact angles of water to determine
the uniformity of the ADPA monolayers. Contact angles were measured using 2 μL drops of
deionized water (Millipore 18Ω) to characterize the hydrophobicity of the surface modifications.
Three measurements were performed on three substrates for a total of 9 measurements per
modification. The average contact angle value and standard deviation (n=9) are reported.

5.5 - In Vitro Platelet Function Testing
5.5.1 – Exposure to Platelet Rich Plasma
Three sets of three substrates were placed in a 24 well-plate with one set of wells left empty
to act as a control. The sample sets are as follows; four empty control wells, four bare CoCr
substrates, four ADPA coated substrates, and four TIC immobilized substrates. 1 mL of platelet
rich plasma (PRP) was gently pipetted into each of the wells and were left for one hour at room
temperature. After the time had elapsed, substrates were removed from their wells and fixed
according to the below procedure in preparation for study by SEM. The remaining PRP was
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centrifuged at 3500 rpm for 10 minutes to separate the remaining platelets and the supernatant for
analysis via flow cytometry and ADP ELISA, respectively.

5.5.2 - Flow cytometry
Following exposure to substrates, the PRP from each well was spun down at 3500 rpm for
10 minutes. The resultant platelet pellet was resuspended in 100 µL of phosphate buffered saline
(PBS). 5 µL FITC conjugated CD41a and 20 µL PE conjugated CD62P anti-human antibodies
were added to each vial of resuspended platelets and incubated for 30 minutes at 37 oC. Following
incubation, the platelets were analyzed using flow cytometry. The instrument was operated at an
excitation wavelength of 488 nm. FITC fluorescence was detected using a 533/30 filter and PE
fluorescence was detected with a 585/40 filter. Platelet samples were passed through the laser
beam after setting the flow rate to low and 10,000 activation-independent platelet events were
collected from each sample set at n=9.

5.5.3 – Adenosine Diphosphate Enzyme Linked Immunosorbent Assay
The supernatant removed from the platelet pellet post-centrifugation was frozen for up to
7 days before evaluation using ADP ELISA. The ELISA kit was balanced at room temperature for
30 minutes prior to use. Samples corresponding to empty control wells, and wells containing bare,
ADPA, and TIC modified stent substrates were added in 5 μL amounts at an n=6 to the pre-coated
microplate. Standard solutions were then prepared in 8 clean 1.5 ml tubes. 200 μL of 1 X Sample
Buffer was aliquoted into each of the eight tubes separately. 200 μL of the 2000 nmol/L standard
solution was added into the first tube and mixed with a pipette. Following that, 200 μL of the first
solution was aliquoted into the second tube. Mixing and transfer steps were repeated moving from
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the third to the seventh tubes, omitting the eighth tube to act as a blank control. 5 μL of each
standard was then added to the remaining wells in duplicate to provide a calibration curve. 100 μL
of substrate solution was added into each well and incubated at 37 ºC for 5 minutes. The
absorbance value for each well was collected at 550 nm using the plate reader to generate an
average baseline optical density (OD1). Following that, 20 μL of enzyme conjugate was added to
each well and incubated at 37 ºC for 15 minutes. The absorbance value for each well was again
collected at 550 nm to generate the sample optical density (OD2). Duplicate readings for each
standard, control, and sample were averaged and OD1 was subtracted from OD2 to determine the
optical density of each well. The concentration of ADP for each control and sample were be
calculated according to standard curve and averaged. The data was subjected to a one-way
ANOVA to determine if the ADP concentrations in the sample sets were significantly different
from one another.

5.5.4 - Platelet Fixation
Following exposure to PRP in well-plates, stent samples were removed and fixed prior to
analysis using SEM. Stent samples were added directly to a 5% glutaraldehyde solution for 7 days.
Following fixation by glutaraldehyde, samples were immersed in 2% osmium tetroxide (OsO4)
solution for one hour as a secondary fixative. Samples were then dehydrated by immersion in
aqueous ethanol (EtOH) solutions of increasing concentration (25%, 50%, 75%, and 100%) for 20
minutes each. Dehydration of samples was completed by immersion in hexamethyldisilazane
(HMDS) for 10 minutes followed by placement in a desiccator for at least 2 hours prior to use with
the SEM.
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5.5.5 – Scanning Electron Microscopy Analysis
Hitachi S-3400N-II scanning electron microscope (SEM) run in backscatter electron mode
was used to examine the morphology of platelets adhered to the stent surfaces after fixation. SEM
micrographs of stent surfaces were collected between at 500x and 1000x magnification.
Micrographs were collected under vacuum by applying a 2.00 kV accelerating voltage, 80.0-volt
(V) probe current, and a working distance of 10.0 millimeters.
The elemental composition of the surfaces of both CoCr stents and CoCr foil substrates
were examined and compared by using the energy dispersive x-ray spectroscopy (EDS) on the
scanning electron microscope. Spectra collected from 0-20 eV on a Hitachi S-3400N-II SEM under
vacuum using a Bruker XFlash with ESPIRIT software, under a magnification of 1000x and
accelerating voltage of 15.0 kV.

5.6 – Results and Discussion
5.6.1 - Energy Dispersive X-Ray Spectroscopy of Substrate Materials
The elemental make-up of the oxide layers of CoCr foil and stent substrates were evaluated
using EDS. The oxide layer of CoCr has been shown to be dominated by a protective passive film
Table 5.3: Elemental content of CoCr stent and foil substrates
Co

Cr

W

Ni

Mn

S

P

Si

Fe

Reported

Balance

19-21

14-16

9-11

1-2

>0.03

>0.04

>0.04

>3

Foil

49.48

19.78

15.24

11.18

1.97

0.01

0.02

0.02

2.35

Stent

50.11

18.82

15.89

10.83

2.10

0.01

0.01

0.02

1.85

of Cr2O3 with trace amounts of other metal oxides present on the surface.7-9 Interfacial analysis
confirmed the presence of the elements Co, Cr, W, Ni, and Mn in all samples examined, as well
as trace amounts of Fe, Si, P, and S (Table 5.3). These numbers are in accordance with the reported
composition of CoCr.7-8, 10 Little to no discrepancy is observed between reported and experimental
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components, and both foil and stent substrates are compositionally identical with less than <1%
difference for any constituent elements.
As with SS316L, the data does not reflect the oxide layers at the surface of the substrates.
It is known that the oxide layer of CoCr is dominated by enrichment of Cr2O3, but the data collected
via EDS corresponds accurately with the bulk composition of the alloy in both foil and stent
samples. Assuming the oxide layer of CoCr is similar in thickness to that of SS316L, the thickness
of the interfacial surface will be within a nm range.11-12 The electron beam of the SEM penetrates
to a depth of 1-2 microns, over an order of magnitude deeper than the oxide layer is thick. It has
been confirmed that the elemental composition of both substrates is almost identical. While EDS
penetrates through the oxide layer making comparison of the surface oxide content difficult, it can
be assumed that the oxide layers will only differ if enrichment of a particular element occurred
due to differences in pre-treatment techniques.
The treatment of the surfaces of the CoCr stent and foil substrates differ similarly to those
of their SS316L counterparts. CoCr foils are planarized mechanically in our lab prior to being
cleaned with organic solvents to remove debris and contaminants from the surface. All metallic
vascular stents are electropolished regardless of composition and sterilized using proprietary
techniques which cannot be reproduced in the lab.7-8, 13 The specific conditions of the applied
electropolishing and the sterilization techniques used are both unknown to us and may vary
depending on the stent manufacturer. However, it is commonly known that electropolishing
changes the surface composition and topography of substrates after treatment.7-8, 13-15 Additional
sterilization techniques such as exposure to chemicals such as ethylene oxide, or placement in
heated, irradiated, or high pressure environments may also modify the surface of the stent.16-18 As
expected, the CoCr stents and substrates function differently from each other. CoCr is harder to
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form SAMs on due to the passive Cr oxide layer it forms, and the increased passivation from the
electropolishing makes CoCr stents even less reactive. However, both CoCr and SS316L stents
are more easily modified with TIC after SAMs have been successfully formed. It can be inferred
that the reason for cross-linking being more facile on stents is due to surface topography, not
chemical make-up. A fully formed SAM covers the surface of the substrate and presents a
functional group evenly at the surface, which should make both SS316L and CoCr substrate
chemically equivalent after thin film deposition when the same molecule is used for the monolayer.
Additionally, the reactivity of the stent substrates was increased compared to the foil substrates
regardless of substrate composition. As such, it is believed that the atomically smooth surface
generated by the electropolishing of the stents makes these substrates more capable of crosslinking via the Mitsunobu reaction.19-20

5.6.2 – Formation of 12-Aminododecylphosphonic Acid Monolayers on Cobalt
Chromium Alloy L605
5.6.2.1 – Characterization of 12-Aminododecylphosphonic Acid by Diffuse
Reflectance Infrared Fourier Transform Spectroscopy
ADPA monolayers are formed on CoCr substrates to provide a functionalized surface for
immobilization of TIC using the Mitsunobu reaction. After deposition of ADPA on CoCr by
aerosol spray, sonicated substrates characterized by DRIFT spectroscopy and contact angle.
Retention of IR peaks after sonication at CH2asym ≤ 2914 cm-1 and CH2sym ≤ 2846 cm-1 indicate that
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the ADPA SAM is alkyl chain ordered.21-23 The peak observed at NH3+ = 2934 cm-1 corresponds
to the presence of a primary amine salt, which is
seen in the spectra of successfully formed ADPA
SAMs on SS316L as well as here on CoCr. Due to
the CH2 asymmetric and symmetric peaks falling
below 2918 and 2848 cm-1 respectively, it is
inferred that the SAM remains ordered after
sonication. The presence of the SAM postsonication indicates mechanical stability. Based on
the IR data, the monolayer presents amine tail-

Figure 5.1: DRIFT spectra of ADPA SAM on CoCr:
ν CH2 asym = 2914 cm-1, ν CH2 sym =2846 cm-1, and NH3+
= 2934 cm-1

groups in a uniform manner at the surface appropriate for crosslinking via the Mitsunobu reaction
between TIC and the functionalized surface.

5.6.3– Diffuse Reflectance Infrared Fourier Transform Spectroscopy Analysis of
Diethyl azodicarboxylate/Triphenyl phosphine
Due to the similarity in the substrate surfaces after the formation of ADPA monolayers,
reaction conditions similar to those found to be optimal on SS316L were utilized for CoCr samples.
Advances to the procedure such as the use of TBP and the addition of DEAD via syringe pump at
5 µl/min were retained in the successful immobilization conditions on CoCr. However, some
changes were made when transitioning to the new substrate material. The runtime was increased
to 72 hours in the optimized conditions on CoCr, and concentrations of both DEAD and TBP were
increased to provide an excess of reactants to the reaction over the longer time period.
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Figure 5.2: DRIFT spectra of immobilized using the optimized Mitsunobu reaction overlayed with TIC on CoCr: ν
-1
-1
-1
-1
-1
-1
CH3 = 2957 cm , ν CH2 sym = 2930 cm , ν CH2 asym = 2869 cm , ν C=O = 1721 cm , ν C=N = 1615 cm , ν NH = 1520 cm ,
-1
-1
ν CH = 1464 and 1379 cm , ν CN= 1323, ν CO = 1216, 1141, and 1061 cm

Figure 5.3 represents a successful immobilization on CoCr stents. Reproducibility on CoCr

foil was much more difficult to achieve. The monolayer is stable after cross-linking as
demonstrated by peaks at CH2asym ≤ 2930 cm-1 and CH2sym ≤ 2869 cm-1. These peaks are above the
expected peaks for an ordered monolayer, however the wavenumbers are considered to have
shifted due to the contribution of CH stretching from immobilized TIC. Both the (1,2,3)triazolo(4,5)pyrimidine and amine moieties of TIC is contribute to significant peaks ν C=N = 1615 cm-1, ν
NH

= 1514 cm-1, and ν CN = 1327 cm-1. The multiple C-O bonds in TIC are also present including

the asymmetric and symmetric C-O ether stretching at ν Asym C-O = 1216 cm-1 and ν Sym C-O = 1061
cm-1, as well as the secondary alcohols at ν C-OH = 1141 cm-1. CH stretching and bending vibrations
typical of organic compounds is present at and ν CH = 1464 and 1379 cm-1. The presence of residual
DEAD on the surface is indicated by the appearance of a peak at ν Sym C=O = 1721 cm-1. The high
correlation between the spectra of pure TIC and the immobilized samples clearly demonstrates the
presence of TIC on the surface post-cross-linking reaction.
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5.6.4 – Contact Angle Analysis of 12-Aminododecylphosphonic Acid Monolayers
To evaluate the completeness of the SAM and to ensure consistent presentation of amine
functional groups at the surface, the contact angles of ADPA on CoCr were evaluated using a
goniometer via the static sessile drop method (Figure 5.2). CoCr was found to have a contact angle
of 80.8 ± 6.3°, indicating a slightly hydrophilic surface. After deposition of ADPA, the surface
was significantly more hydrophilic with a contact angle of 51.7 ± 7.2°. This is an expected result
since a fully formed ADPA SAM presents an even layer of hydrophilic amine tail-groups at the
surface. The data supports the conclusions drawn from the IR results, that the monolayer is stable
and ordered. The low standard deviation implies a fully covered surface with little to no defects in
the monolayer. The ADPA SAMs presented here are stable, ordered, and complete according to
the data shown in both the IR spectrum and the resulting contact angles of the modified surface.
Since the substrate has been successfully functionalized with amine tail-groups evenly presented
at the surface, cross-linking reactions of TIC can be performed using monolayers generated with
this method.
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Figure 5.3: Contact angles on CoCr measured by static sessile drop method. Bare CoCr = 80.8 ± 6.3⁰, ADPA SAMs = 51.7 ± 7.2⁰,
and TIC Immobilized surfaces = 64.8 ± 3.3⁰
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5.6.5 - Contact Angle Analysis of Diethyl azodicarboxylate/Tributyl phosphine on
CoCr
To determine if TIC is evenly distributed across the surface post-immobilization, contact
angles were determined on nine substrates for an n=9 using the static sessile drop method to assess
changes in interfacial properties following immobilization of TIC on CoCr. Prior to reporting, the
data was averaged, and the standard deviation was calculated. The contact angle increased from
the ADPA SAM (51.7 ± 7.2°) to 64.8 ± 3.3° on the TIC immobilized substrates. This indicates an
increase in hydrophobicity, which is not unexpected given that TIC has some non-polar character.
The polar (1,2,3)triazolo-(4,5)pyrimidine, secondary amine, and secondary alcohols present on
TIC result in the contact angle of CoCr being much lower than that of the bare CoCr surface. A
small standard deviation indicates that the immobilization of TIC is consistent across samples.
This data supports the conclusion that TIC has been covalently linked to the SAM and provides
evidence that the immobilization will provide comprehensive protection from thrombotic effects
across the surface.

5.7 In Vitro Platelet Behavior Study
To confirm the efficacy of thrombosis inhibition via the immobilization of TIC on CoCr,
an in vitro platelet challenge was performed. As with the SS316L samples, the behavior of platelets
exposed to TIC immobilized on CoCr stents was compared to platelets exposed to bare CoCr and
ADPA coated CoCr. While there is overall less platelet activation observed to occur in the CoCr
platelets experiments, similar trends were observed to the SS316L experiment. SEM micrographs
show that platelet aggregation occurs in the greatest quantities on bare CoCr stents and the TIC
immobilized stents have the least quantity of adhered platelets. Flow cytometric analysis of the
platelets left in solution demonstrates an extremely limited amount of activated platelets in any of
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the sample sets. As seen with the SS316L experiment, the ADP ELISA demonstrates equivalent
amounts of ADP in each samples set. Both the flow cytometry and ADP ELISA results indicate
that platelets are behaving similarly in solution regardless of the stent. These results are consistent
with what is expected from a successful experiment, demonstrating that TIC immobilized samples
are protected from platelet aggregation and modifications to the surface do not significantly change
the behavior of platelets in solution.

5.7.1 - Scanning Electron Microscopy Analysis of Substrates Surfaces and Platelet
Morphology
SEM micrographs were collected of each sets of CoCr stent surfaces to allow for the
identification of platelet morphology and to observe the extent of platelet aggregation (Figure 5.4).
The micrographs of bare CoCr display large quantities of adhered platelets which have aggregated
into clots on the surface. The deposition of platelets on the bare CoCr stents is uniform, with the
entirety of the stent surface demonstrating vulnerability to platelet adhesion. The extent of platelet
aggregation on bare CoCr is less than what was observed on the SS316L counterpart in a one hour
period of exposure, but the uniform aggregation of platelets on the surface indicates that the
entirety of the stent would be covered in a network of activated platelets in a larger timeframe.
There are fewer regions of platelet deposition on the ADPA coated CoCr stents when compared to
the bare samples. Large areas of the ADPA samples do not have significant platelet adhesion,

Figure 5.4: Bare and modified CoCr stents exposed to PRP for one hour. a) BMS b) ADPA coated stents c) TIC
coated stents
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however the ADPA samples do demonstrate sites where platelets have fully activated and adhered.
The areas where activated platelets have can be seen to act as nucleation points where large
quantities of platelets accumulate and form significant thrombotic clots. This behavior is not
observed on TIC immobilized samples. The TIC modified stents have no aggregates on the surface
and the few adhered platelets maintain a globular morphology indicating a lack of activation. The
phenomena of platelets settling on the surface but failing to activate and aggregate on TIC modified
samples was also observed in the SS316L experiment and is assumed to be a result of the platelets
being exposed to the stents in a static setting prior to fixation. The experiment is considered
successful, as the quantity of adhered platelets decreases with each successive modification, and
the TIC modified samples demonstrate the ability to completely inhibit activation even when
platelets are in direct contact with the substrate.

5.7.2 Flow Cytometry Analysis of Platelets
Platelets remaining in solution were incubated with anti-human CD62P and CD42a
antibodies fluorescence conjugated antibodies and then studied via flow cytometry to determine
the extent of activation in each sample set. CD62P was conjugated to the fluorophore
phycoerythrin (PE) and CD42a was conjugated to the fluorophore fluorescein isothiocyanate
(FITC). To determine the proper gating for the sample sets, control samples with no substrates
were incubated with either CD42a or CD62P alone. Initially, a FSC/SSC plot (not shown) was
gated to segregate data points representing platelets from other debris, platelet aggregates, and red
blood cells present in solution. Following this, the platelets in the single antibody control sample
sets were graphed as side scatter plots vs. the fluorescence of the conjugated antibody present. The
gates were then drawn to capture the platelets which exhibit single positive fluorescence in the
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CD42a – FITC-A

Figure 5.5: Flow cytometric analysis of platelets in solution after exposure to CoCr substrates. PE alone and
FITC alone are control samples with only CD42a or CD62p added. These dot-plots are graphed as side scatter vs.
fluorescence. Both control, Bare, ADPA, and TIC are control and substrate samples which contain both CD42a
and CD62p antibodies. These dot-plots are graphed as the fluorescence of FITC (BL1-A) against the fluorescence
of PE (BL2-A)

absence of the other fluorophore. The gating limits for each antibody determined in this way were
overlayed with dot-plots of samples with both CD42a-FITC and CD62P-PE to determine double
positive platelets in each sample set.
When the gates are applied to each sample set to evaluate double positive platelet activation,
no platelets appear to be activated in any sample set. As a result, not useful conclusions can be
drawn from this experiment. It is hypothesized that the reason for these results is that the platelets
used for the CoCr platelet behavior assay were received late from the manufacturer. It was
observed that platelet aggregates had formed in the bag, but the PRP was utilized in the experiment
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anyway since PRP could be removed while leaving the formed platelet aggregates behind. The
platelets which were left in solution may have failed to bind to the conjugated antibodies due to
the late reception and the activation observed prior to use in the experiment. How the stents
influenced the behavior of these platelets cannot be determined from these results. However,
protection of the surface from the preactivated platelets was still observed on the surface of TIC
immobilized stents, implying that the thrombosis protection afforded is functional regardless of
whether platelets are activated prior to exposure to the stent or not.

5.7.3 - Adenosine Diphosphate Enzyme-linked Immunosorbent Assay
As with the SS316L experiment, an ADP ELISA was performed to determine relative
levels of activation in each sample set by comparing the concentration of the platelet granule ADP.
The concentrations determined via the ELISA assay are shown in Figure 5.6. The ADP levels in
each sample set are identical and there is no significant difference between any of the samples after
evaluation of the data with one-way ANOVA. This finding corresponds to the data found by flow
cytometry. Since the PRP used in the experiment is assumed to have fully activated prior to
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Figure 5.6: Average ADP Concentration in the supernatant of PRP exposed to bare and modified CoCr substrates
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exposure to the substrates, all the platelets would have released their ADP granules before the
experiment was performed. As such, the level of ADP was equivalent in all samples upon removal
of the PRP from the source and did not change after exposures were performed. Again, this
prevents the observation of how the stents would influence the platelet behavior since the platelets
had activated before surface exposure.

5.8 – In Vivo Rabbit Study
An in vivo study was performed in which TIC modified stents were inserted into the right
iliac artery of rabbits for 28-days before removal and fixation. The iliac artery of the rabbit was
removed after the 28-days had elapsed and was dissected so the proximal, mid, and distal regions
could be studied for signs of thrombosis. The stent was well-expanded and well-apposed after
insertion as evidenced in Figure 5.7. This means there were no gaps between the stent struts and
the endothilum of the blood vessel, lowering the possibility of infection or restenosis. Stent struts
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Figure 5.7: Images of the proximal, mid, and distal regions of a stented right iliac artery from a rabbit. Low
magnification images (top) display a well-expanded and well-apposed stent. Images stained with Movat
pentachrome (mid and bottom) demonstrate fully endothelialized stent struts with only mild inflammation as
highlighted by the black arrows.

can be identified as white spaces in Figure 5.7, which do not absorb the Movat pentachrome stain
and therefore do not produce an image under the microscope. Healthy endothilial coverage is
observed to have occurred around the stent struts, and endothilial cells have covered the struts
without excessive inflamation. This indicates that the TIC coating is not cytotoxic and is fully
biocompatible since the endothilial lining has covered the implant material and no throbosis is
observed to have occurred. This in vivo trial demonstrates a successful percutaneous coronary
insertion of a vascular stent with no complications and healthy re-endothilization. Further rabbit
studies are underway to confirm the reproducibility of these promising results.

5.9 – Conclusion
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The use of the optimized Mitsunobu reaction successfully immobilizes TIC on CoCr L605
stents and substrates. Reproducibility is difficult on foil, as with the SS316L counterparts, but
stents are reliable substrates for immobilization. Foil and stent substrates appear identical when
studied using EDS, and surface topography remains the assumed cause for the difference in
substrate behavior since both substrates should present chemically equivilant surfaces after
monolayer formation. The success of TIC immobilization on CoCr has been demonstrated with
both DRIFT spectroscopy and contact angle goniometry. The immobilization of TIC has been
demonstrated to be effective at inhibiting platelet adherence to substrate surfaces by SEM.
Furthermore, the surface modifications have been shown to have no effect on platelets in solution
using both flow cytometry and ADP ELISA. This is considered a success since the intended
function of the developed technique is to prevent thrombosis formation on stent surfaces while
avoiding the systemic deactivation of platelets throughout a patients body exhibited by DAPT.
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Chapter 6 – Corrosion and biofouling inhibition by novel layered polymer thin films on
Stainless Steel 316L for Marine Applications.
6.1 - Introduction
SS316L is commonly used in marine applications as a structural material in pipelines, ships,
and drilling platforms. While the use of SS316L in marine environments is widespread, the
material is known to be highly susceptible to corrosion and biofouling when subjected to prolonged
exposure to seawater. Of the forms of corrosion that impact the function of SS316L, pitting
corrosion is one of the most destructive. Pitting often causes load bearing materials to fail, resulting
in accidents or structural failure.1-4 Pitting corrosion is particularly insidious when compared to
other forms of corrosion due to the underestimation of the damage caused prior to a failure event
occurring.4-5 Pits form as constituent elements in the alloy are selectively dissolved, often leading
to pits with significant depth and impact on structural properties. However, these pits are difficult
to detect as semi-permeable corrosion products cover the mouth of the defect while allowing
corrosion to continue to cause damage into the material itself. The direct costs of corrosion damage
in marine settings is roughly 3.1% of the global GDP, and in 2019 the cost of this damage was
over $654 billion dollars in the US alone.6-7

6.1.2 – Pitting Corrosion of Stainless Steel 316L
A significant quantity of research has been performed to identify the mechanism of pitting
corrosion.8-14 It is commonly accepted that doping iron alloys with chromium provides corrosion
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resistance by forming an oxide layer enriched with chromium oxides. This layer of chromium
oxides is passivated against aggressive ion attack, which causes significant corrosion. These ions
are typically conjugate bases of strong acids, such as Cl-, and are found in marine environments in
significant concentrations.15-16 Defects in the passivated surface of the material at joints, grain
boundaries, stress fractures, or at other sites of mechanical damage expose the bulk material
creating sites susceptible to aggressive anions which initiate corrosion processes.9-10, 12-14

Figure 6.1: Example of pitting corrosion at the site of a defect in passivated SS316L

The mechanism of pitting corrosion is a chemical reaction involves the oxidation and
reduction of metals in the stainless steel (Figure 6.1). This results in constituent atoms ionizing
and diffusing out of the material.2, 4 The cathodic half-reaction begins the process as dissolved O2
and water react at the oxide surface.12 This reaction draws electrons from Fe at the surface causing
the metal to dissolve as soluble Fe(II).

9, 11, 14

As the Fe is selectively dissolved from the alloy, a

pit is generated and an ionic gradient forms. Oxidative reactions continue to occur resulting in
positive metal ions diffusing out of the pit against the potential gradient. Aggressive Cl - acts as a
counter ion to the positive metal ions and flows into the pit increasing local acidity.17 10-11, 18 In the
pit, Fe(II) is further oxidized to Fe(III) generating H+ which lowers the pH in the pit and accelerates
the corrosion process.8-11 Trace amounts of other alloyed metals such as Cr and Ni are also released
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as corrosion progresses.19 Dissolved Fe(III) becomes insoluble in the acidic environment at the
mouth of the pit and deposits as Fe(OH)3, forming a semi-permeable membrane at the entrance to
the pit. This limits diffusion and covers the opening but allows ions to continue to migrate in and
out of the pit.7, 9, 15, 17 These processes result in the pit becoming a locally acidic environment
resulting in the corrosion process becoming autocatalytic and Fe is continually dissolved from the
bulk of the metal weakening the overall structure.4, 14, 17

6.1.3 – Biofouling on Stainless Steel 316L
Biofouling refers to the pollution of a surface with undesirable buildup of proteins and cellular
growth (Figure 6.2) which often results in the formation of biofilms, or adhesion by lifeforms such
as barnacles or mollusks.20-22 Corrosion and biofouling are two significant maintanence costs for
the marine industry, with barnacle and mollusk biofouling accelerating corrosion processes and
producing drag on ships.22 During the process of biofouling proteins adhere onto materials creating
favorable surfaces for biofilms and barnacles to attach to.20-21 Protection from biofilms has been
achieved by immobilizing antibacterial or biocidal compounds to material surfaces in the past.
However, these modifications lose their efficacy over time and fail to prevent initial protein
adsorption.23-27 The formation of certain polymer films such as poly(ethylene glycol) have been
shown in the past to be functional alternatives to biomolecule immobilization by preventing protein

Figure 6.2: Example of biofouling as a result of protein adhesion on bare SS316L
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adsorption and subsequent adherence of biofilms or mollusks.28-30 These polymers will be
incorporated into the novel coatings generated on SS316L in this study and are demonstrated to
prevent cell adhesion on the metal oxide surface.

6.1.4 – Functionalization of Surfaces Using Polymers
SAMs have been used extensively in the past as a method for the functionalization of surfaces
to improve interfacial properties for biomedical, industrial, and sensing applications. Monolayers
have been used to facilitate the absorption or covalent attachment of organic molecules which can
improve material properties to inhibit corrosion31-33 and biofouling,22,

34-36

or improve

biocompatibility.25-26, 37-38 In previous chapters the immobilization of biomolecules on SAMs was
demonstrated to be an effective route for providing increased biocompatibility to implant
materials. In the work presented in this chapter, SAMs provide molecular anchors for the growth
of polymer brushes designed to offer enhanced resistance to corrosion and biofouling in a marine
setting utilizing a “grafting from” approach. Surface initiated polymer growth using a “grafting
from” grows a polymer chain starting from a surface bound polymerization initiator (Scheme
6.1_.39-41 Monomers polymerize from this initiator resulting in the growth of long polymer chains

Scheme 6.1: Reaction progression for the formation of novel layered polymers using SI-ATRP
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anchored to the surface. The chains of the resultant polymer brushes are densely packed and can
act as a protective film for the material on which they are formed.39-41
Surface-initiated atom transfer radical polymerization (SI-ATRP) is a method of controlled
radical polymerization which is especially attractive for “grafting from” approaches to surface
modification. SI-ATRP may be performed under the mild reaction conditions, demonstrates high
functional group tolerance, and generates polymer chains with uniform dispersity resulting in even
coverage across a surface.42
To facilitate SI-ATRP on SAMs, a bromoisobutyrate ester is formed on the tail-group of a
hydroxyl-terminated monolayers using vapor phase deposition of bromoisobutyryl bromide
(BiBB) (Scheme 6.1).30, 43-46 Once the initiator is in place, copper catalysts and monomers may be
introduced to the system initiating the SI-ATRP reaction on the halogen modified surface. During
the copper-catalyzed SI-ATRP, a copper (I) activator undergoes a one-electron oxidation with the
surface bound alkyl halide (Cl or Br) generating a copper (II) deactivator and a radical.47-52 This
radical undergoes an addition reaction with the alkene of a monomer molecule from solution. In a
deactivation step, the radical abstracts a halogen from the copper (II) deactivator and caps the chain
with either Cl or Br.

47-52

This process repeats, adding a new monomer and recapping the alkyl

chain repeatedly as the chain grows.53 In order to simultaneously combat corrosion and biofouling,
polymer films consisting of styrene, a known corrosion inhibitor, andethylene glycol, a known
anti-fouling agent were grown. Specifically, films of poly(styrene) (Sty), poly (styrene-co-(oligo
ethylene glycol) methyl ether methacrylate (Sty-PEG) and poly (styrene-co-([oligo ethylene
glycol] methyl ether methacrylate)-co-styrene (Sty-PEG-Sty) will be formed using SI- ATRP
(Scheme 6.1). The resulting polymer films were characterized by DRIFT spectroscopy, contact
angle goniometry, and SEM to confirm successful film formation. An electrochemical pitting
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study, cyclic voltammetry, and a fibroblast LIVE/DEAD assay were utilized to assess the
corrosion-inhibition and biofouling properties of the polymer films.

6.2 – Materials
6.2.1 – Experimental Materials
Stainless steel foils (AISI 316L, Fe69/Cr18/Ni10/Mo3) of 0.5 mm thickness were obtained
from Goodfellow Inc. 11-Hydroxyundecyl phosphonic acid (>95%), tin (II) ethylhexanoate (95%),
oligo(ethylene glycol)methyl ether methacrylate (PEG, 95%) and dimethylformamide (DMF)
were purchased from Sigma Aldrich. BiBB (97%, BIBB) and styrene (99%) were purchased from
Alfa Aesar. Tetrahydrofuran, (THF) was purchased from Macron. All reagents were used without
further purification unless otherwise stated. Styrene, was passed through silica column prior to
polymerization, to remove inhibitors. Oligo(ethylene glycol)methyl ether methacrylate were
passed through a silica column. THF was dried over sodium and benzophenone and distilled under
N2 gas before use. Tris(2-pyridylmethyl)amine (TPMA) was prepared according to literature
procedures.54 Following the synthesis of TPMA, it was recrystallized once from ethyl acetate then
again from hexanes yielding a yellow/brown solid. Catalyst solution (0.01M [Cu(TPMA)Br][Br])
was prepared by dissolving equal molar amounts of TPMA and copper(II) bromide in DMF and
stirring for 30 minutes prior to use. Dulbecco's modified Eagle medium (DBEM), 10K/10K
penicillin-streptomycin mixture, fetal bovine serum (FBS), trypsin/EDTA, and trypsin neutralizing
solution (TNS) were obtained from Lonza Walkersville Inc. Phospate buffered saline (Sterile
filtered, PBS) was obtained from Sigma Aldrich and stored at 4C between uses. Invitrogen™
LIVE/DEAD™ Viability/Cytotoxicity Kit, for mammalian cells was purchases from Fisher
Scientific and stored at 0C.
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6.2.2 - Instrumentation
All infrared spectra were recorded using a Thermo Nicolet-NEXUS 470 FT-IR equipped with
a Diffuse Reflectance Infrared Fourier Transform (DRIFT) attachment. Spectra were collected at
256 scans with a resolution of 4 cm-1. Contact angles were taken using a Rame-Hart Model 200U1 goniometer. All electrochemical measurements were recorded using a NuVant System EZstatpro potentiostat and EZware-pro software. A three-electrode system was comprised of a platinum
wire as a counter electrode, an Ag/AgCl(aq) as the reference electrode and bare or modified
SS316L substrates as the working electrode. A MelodySusie ultraviolet Lamp (36W) centered at
365nm was use as a source of ultraviolet radiation for photo catalyzed polymerization. An
incubator was maintained at 37°C and 5% carbon dioxide. SEM micrographs were collected using
a Hitachi S-3400N Scanning Electron Microscope. Cells were imaged using a Zeiss Axioskop 2
materials microscope under 10x magnification using fluorescence filters and AxioVision software.

6.3 – Methods
6.3.1 – Stainless Steel 316L Substrate Cleaning and Preparation
SS316L foil was sanded using silicon carbide sandpaper of increasing grit (150, 320, 400,
and 600) to provide a fresh and uniform surface oxide layer for SAM formation. Substrates were
then cut into 1 cm x 1 cm squares or 1 cm x 3 cm rectangular electrodes. The resulting coupons
and electrodes were then cleaned by sonication in acetone and immersion in boiling methanol for
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15 minutes each, to remove remaining organic residue and metallic dust. Samples were dried and
stored under vacuum prior to use.

6.3.2 – 11-Hydroxyundecylphosphonic Acid Monolayers
Monolayers of HUPA were formed on the native oxide surface of the substrates using
aerosol deposition. Samples were sprayed with a 0.5 mM solution of HUPA in THF using a thin
layer chromatography sprayer, and then dried at 120 ⁰C for 30 minutes. This process was repeated
until the substrates had been sprayed 3 times, at which point they were annealed at 120 ⁰C for 24
hours. Once annealed the substrates were rinsed and sonicated in THF to remove any physisorbed
molecules. Monolayer formation was confirmed using contact angle goniometry and
DRIFT spectroscopy.

Scheme 6.2: Formation of 11-Hydroxyundecyphosphonic Acid Monolayers on SS316L

6.3.3 – Gas-phase Immobilization of Bromoisobutyryl Bromide on Hydroxyl
Terminated Monolayerss Under Passive Vacuum
Substrates with HUPA SAMs were placed into a vacuum deposition chamber under active
vacuum on a Schlenck line for 30 minutes and the finger trap was cooled using liquid N2 to prevent
vapors from escaping the system. A flask of BiBB was attached to the vacuum chamber containing
the coupons. The chamber was placed under active vacuum and the coupons were exposed to
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vapors of BiBB for 30 minutes. Following exposure to BiBB, coupons were returned to active
vacuum for 30 minutes. This process was repeated until the coupons had been exposed to BiBB
under passive vacuum 3 times. The coupons were stored under vacuum until ready for analysis
using DRIFT spectroscopy or use in SI-ATRP reactions.

6.3.4 – Surface-initiated polymerization of styrene
Three coupons modified with BIBB-immobilized HUPA SAMs were placed in a 50 ml
Erlenmeyer flask with a stir bar and was sealed with a septum. The flask was evacuated and purged
with N2 gas three times. Reactants were injected into the flask in the quantity and order that
follows: 6mL of styrene, 3ml of DMF, methyl bromoisobutyrate 3.6µL, and 100 µL of tin(II) 2ethylhexanoate. Nitrogen was bubbled through the monomer solution for 20 minutes to degas the
mixture. After degassing, 568µL of [Cu(TPMA)Br][Br] 0.01M catalyst solution was added and
the solution was purged with N2 gas for 15 minutes. The flask was then placed in an oil bath
thermostated at 80°C for 18 hours. Coupons where rinsed and sonicated with ethyl acetate to
remove any physically adhered polymer chains. Samples were dried under vacuum for at least six
hours under vacuum (~0.1 torr) before further use.

6.3.5

–

Surface-initiated

block

polymerization

of

styrene-co-oligo(ethylene

glycol)methacrylate
Three coupons modified with SI-polystyrene were chain extended by placed them in an a 50
ml Erlenmeyer flask with a stir bar and sealed with a septum. The flask was evacuated and refilled
with dry nitrogen gas three times. Reactants were injected into the flask in the quantity and order
that follows; 6mL of oligo(ethylene glycol)methacrylate (mmol), 3ml of DMF, and 100 µL of
tin(II) 2-ethylhexanoate. Nitrogen was bubbled through the monomer solution for 20 minutes to
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degas the mixture. After degassing, 568µL of [Cu(TPMA)Br][Br] 0.01M catalyst solution was
added and the solution was purged with N2 gas for 15 minutes. The flask was then placed on a stir
plate and stirred at 300 RPM and an ultraviolet Lamp (36W) centered at 365nm was placed overtop
of the flask as a source of ultraviolet radiation to photo catalyze the polymerization for 5 hours.
Coupons where rinsed and sonicated with ethyl acetate to remove any physically adhered polymer
chains. Samples were dried under vacuum for at least six hours under vacuum (~0.1 torr) before
further use.

6.3.6

–

Surface-initiated

block

polymerization

of

styrene-co-oligo(ethylene

glycol)methacrylate-co-styrene
Three coupons with modified with SI-block polymerization styrene-co-oligo(ethylene
glycol)methacrylate were chain extended by placed them in an a 50 ml Erlenmeyer flask with a
stir bar and sealed with a septum. The flask was evacuated and purged with N2 gas three times.
Reactants were injected into the flask in the quantity and order that follows; 6mL of styrene, 3ml
of DMF, methyl bromoisobutyrate 3.6µL, and 100 µL of tin(II) 2-ethylhexanoate. Nitrogen was
bubbled through the monomer solution for 20 minutes to degas the mixture. After degassing,
568µL of [Cu(TPMA)Br][Br] 0.01M catalyst solution was added and the solution was purged with
N2 gas for 15 minutes. The flask was then placed in an oil bath at 80°C for 18 hours. Coupons
where rinsed and sonicated with ethyl acetate to remove any physically adhered polymer chains.
Samples were dried under vacuum for at least six hours under vacuum (~0.1 torr) before further
use.

6.3.7 – Diffuse Reflectance Infrared Fourier Transform Spectroscopy
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A Nexus 470 Fourier Transform Infrared Spectrometer with a diffuse reflectance (DRIFT)
attachment was used to characterize substrates confirming both monolayer and polymer formation.
Spectra were collected under N2 for 256 scans with a resolution of 4 cm-1 on each sample and
corrected with respect to a background reference spectrum of SS316L.

6.3.8 – Contact Angle Goniometry
A Rame-Hart goniometer was used to measure static contact angles of water to determine
the uniformity of the ADPA monolayers. Contact angles were measured using 2 μL drops of
deionized water (Millipore 18Ω) to characterize the hydrophobicity of the surface modifications.
Three measurements were performed on three substrates for a total of 9 measurements per
modification. The average contact angle value and standard deviation (n=9) are reported.

6.3.9 - Scanning Electron Microscopy
Hitachi S-3400N-II scanning electron microscope (SEM) was utilized in backscatter
electron mode was used to examine the surface of the substrates after polymer formation. SEM
micrographs of substrate surfaces were collected between at 500x and 1000x magnification.
Micrographs were collected under vacuum by applying a 2.00 kV accelerating voltage, 80.0-volt
(V) probe current, and a working distance of 10.0 millimeters.

6.3.10 – Electrochemical Characterization
Cyclic voltammogram measurements were recorded on a NuVant potentiostat using 3.5%
NaCl (aq) as supporting electrolyte. Voltammograms were collected using a standard 3 electrode
system with a bare or modified SS316L coupon coated on one side with epoxy as the working
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electrode, and a platinum wire as the counter electrode. An Ag/AgCl(aq) electrode was used as the
reference electrode. Cyclic voltammograms were collected from +0.3 V to -1.2 V vs. Ag/AgCl at
a rate of 50 mV/sec. The surface area of each electrode was measured using ImageJ software.
Measurements were normalized to the surface area of each electrode.

6.3.11 – Pitting Corrosion Study
Hitachi S-3400N-II scanning electron microscope (SEM) in backscatter electron mode was
used to collect SEM micrographs of substrate surfaces were collected between at 500x and 1000x
magnification. Micrographs were collected under vacuum by applying a 2.00 kV accelerating
voltage, 80.0-volt (V) probe current, and a working distance of 10.0 millimeters. Substrates were
then subjected to an electrochemically accelerated corrosion study using a standard 3-electrode
system in 3.5% NaCl (aq.) as the supporting electrolyte. A bare or modified SS316L coupon coated
on one side with epoxy was used as the working electrode with a platinum wire as the counter
electrode and an Ag/AgCl (aq.) electrode as the reference electrode. The system was subjected to
25 cycles of sweeping potential from +0.3 V to -1.2 V vs. Ag/AgCl at a rate of 50 mV/sec. SEM
micrographs of the substrates were once again collected to compare the extent of pitting after
corrosion after the electrochemical conditions.

6.3.12 - Antifouling Studies
NIH 3T3 cells were grown to 80% confluency in T75 tissue culture flasks using Dulbecco’s
modified Eagle medium (DMEM) supplemented with both fetal bovine serum and
penicillin/streptomycin added. Cells were then harvested by addition of trypsin for 5 minutes,
followed by rinsing from the flaks into centrifuge tubes using trypsin neutralizing DMEM media.
179

Cells were pelletized by centrifugation at 2.1G for 5 minutes. Cells were then resuspended in
DMEM and diluted to a concentration of 10,000 live cells per mL. Modified coupons were placed
into a 24 well plate and 1 mL of cell suspension was added to each well. Coupons were cultured
with NIH 3T3 mouse fibroblast cells for one-, three-, and five-days intervals and media was
changed every 48 hours. Before imaging, the media was aspirated from each well and rinsed with
1 mL of phosphate buffered saline (PBS) twice. Coupons were then incubated for 5 minutes with
Calcein AM and ethidium bromide in PBS using a Live/Dead kit. Coupons were then imaged using
a Zeiss Axioskop 2 microscope under 10x magnification using fluorescence filters and AxioVision
software to count cells. Cell counts and percent viability were determined and normalized to
unmodified surfaces. One-way analysis of variance (ANOVA) with a Tukey posthoc analysis was
used to determine the statistical difference of averages at a p>0.05 unless otherwise stated, Grubbs
Tests for outliers was used to remove data points when applicable.

6.4 – Results and Discussion
6.4.1 – Formation of 11-Hydroxyundecylphosphonic Acid Monolayers on Stainless
Steel 316L
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Hydroxyl-terminated SAMs were formed
on SS316L to provide a functionalized surface for
the immobilization of BiBB, which was designed
to act as an initiator for surface-initiated
polymerization reactions. Stable and ordered
SAMs of HUPA were formed on the oxide layer of
SS316L. Stable and ordered monolayers are known
to have alkyl chains in an all trans conformation,
Figure 6.3: DRIFT spectrum of HUPA SAM on

indicated by IR absorptions at CH2asym ≤ 2918 cm- SS316L: ν CH2 asym = 2917 cm-1, ν CH2 sym =2850 cm-1,
and OH = 3934 cm-1

1

and CH2sym ≤ 2850 cm-1.38, 55-56 After sonication in THF the DRIFT spectrum of the monolayer

contained peaks at CH2asym ≤ 2917 cm-1 and CH2sym ≤ 2848 cm-1, respectively (Figure 3.6 a). An
additional peak is observed at OH = 3934 cm-1 which corresponds to the presence of the primary
hydroxyl tail-group on HUPA. The data reveals that the SAM remains alkyl chain ordered and is
mechanically stable after sonication. This indicates that the monolayer will present hydroxyl tailgroups in a uniform manner at the surface appropriate for modification by vapor phase deposition
of BiBB and subsequent polymerization via SI-ATRP.

6.4.2

-

Gas-phase

Immobilization

of

Bromoisobutyryl

Bromide

on

11-

Hydroxyundecylphosphonic Acid Monolayers
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Substrates modified with HUPA were exposed to BiBB using vapor phase deposition to
generate a surface bound initiator for deposition. After immobilization, a DRIFT spectrum of the
modified surface was collected and overlayed with that of the HUPA monolayer to ensure
successful initiator formation. The hydroxyl peak of HUPA at ν

OH

= 3934 cm-1 has disappeared

Figure 6.4: DRIFT spectrum of Immobilized BiBB overlayed with HUPA SAMs: ν OH = 3934 cm-1, CH2asym ≤ 2915
cm-1, CH2sym ≤ 2847 cm-1, C=O ≤ 1735 cm-1, C=O--HO ≤ 1576 cm-1, Gem CH3 ≤ 1465 and 1410 cm-1CO ≤ 1277 and 1165
cm-,1P-O ≤ 1108 cm-1, and P-OH ≤ 1108 cm-1

indicating the utilization of the functional group in the immobilization of BiBB. Peaks at CH2asym
≤ 2924 cm-1 and CH2sym ≤ 2852 cm-1 indicate that the monolayer remains stable after exposure to
BiBB. Increases to the wavenumbers corresponding the asymmetric and symmetric CH2 stretches
can be attributed to the contribution of CH stretching present on the bromoisobutyrate moiety. The
head group peaks at P-O ≤ 1108 cm-1 and P-OH ≤ 1108 cm-1 further support the assessment that
the monolayer remains stable and bound to the surface. The peak in the ester stretching region
corresponds to carbonyl of the monolayerbound initiator at C=O ≤ 1735 cm-1. The geminal
dimethyl groups of the initiator are seen at Gem CH3 ≤ 1465 and 1410 cm-1. Hydrogen-bonding
interactions between the carbonyl group and unreacted HUPA hydroxyl groups is responsible for
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the appearance of the band at C=O--HO ≤ 1576 cm-1. Formation of the ester linkage is demonstrated
by the ester C-O stretching bands at CO ≤ 1277 and 1165 cm-1, which are not present in the
spectrum of the HUPA monolayer. The appearance of indicative peaks for immobilized BiBB and

Figure 6.5: DRIFT spectra of Styrene Film: CH Aro ≤ 3080 cm-1, CH Aro ≤ 3023 cm-1CH2asym ≤ 2919 cm-1, CH2sym ≤
2847, C=C ≤ 1600, 1492, and 1451 cm-1

the disappearance of the -OH peak from HUPA indicates a successful immobilization of the
initiator, available for further reaction or polymerizations using SI-ATRP techniques.
6.4.3 - Surface Initiated Atom Transfer Radical Polymerization of Styrene films
SI-ATRP was performed according to the procedure outlined in Section 6.3.4. Substrates
were rinsed and sonicated in ethyl acetate to remove physisorbed polymer chains and dried under
vacuum prior to the collection of a DRIFT spectrum of the surface. The spectrum of styrenemodified substrates presents reflectances between CH Aro ≤ 3080 cm-1 and CH Aro ≤ 3023 cm-1,
indicative of aromatic stretching vibrations. In addition, the reflectances at C=C ≤ 1600, 1492, and
1451 cm-1 are attributed to the skeletal C=C stretching in the phenyl rings. The obvious presence
of peaks correlating to the phenyl rings of the styrene polymer indicate a successful polymerization
of styrene on the surface. The retention of CH2 asymmetric and symmetric peaks at CH2asym ≤ 2919
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cm-1 and CH2sym ≤ 2847 show that the monolayer is preserved as an anchor to the surface of
SS316L. These polymer films are expected to offer corrosion resistance for the surface but will
undergo chain extension polymerizations with PEG to inhibit biofouling. By forming a block
copolymer of both Sty and PEG on the surface, a robust protective polymer film will be generated
for use in marine environments.

6.4.4 - Surface Initiated Atom Transfer Radical Polymerization of Styrene-co-(oligo
ethylene glycol) methyl ether methacrylate films
Styrene films were chain extended with PEG using photo-initiated ATRP (photo-ATRP)
to generate a polymer film with properties expected to inhibit protein adhesion. After photo-ATRP,
excess polymer was sonicated from the surface using ethyl acetate and DRIFT spectroscopy was
used to assess the success of the reaction by overlaying spectrum of the chain extension with that
of the original styrene film. It can be seen in the DRIFT spectrum of the Sty-PEG polymer film
that the aromatic CH peaks between CH Aro ≤ 3080 cm-1 and CH Aro ≤ 3023 cm-1 are diminished
but retained after the chain extension. This implies that the styrene film is still present but has been
partially covered by the PEG extension, whose peaks are more prominent in the spectra. There is
an increase to the CH2 asymmetric and symmetric peaks at CH2 Asym ≤ 2920 cm-1 and CH2 Sym ≤
2850 cm-1, which is expected from the added alkyl character from the PEG side chains and the
polymer backbone. The appearance of peaks at C=O ≤ 1718 cm-1 and at C-O ≤ 1294, 1246, and
1108 cm-1 correspond to the addition of the C=O stretching in the carbonyl and the C-O of the
ester and ether stretching, respectively. The geminal dimethyl groups from the initiator chain end
of the polymer film are suggested by the peaks present at C=C/C-H ≤ 1451 cm-1 and C-H ≤ 1350 cm1

. Additionally, the phenyl ring is retained at C=C ≤ 1492 cm-1 and C=C/C-H ≤ 1451. The peak at
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C=C/C-H ≤ 1451 demonstrates increased reflectance in comparison to the C=C ≤ 1492 cm-1
counterpart peak due to contributions from both the C-H geminal dimethyl group and C=C phenyl
character. Due to the presence of new peaks correlating to the ester and the ether functionalities in
the PEG chain and the diminished reflectances of the styrene film, it can be assumed that the chain
extension was successful. The success of the chain extension is further confirmed by contact angle
analysis and is demonstrated to successfully confer cell adhesion resistance to the film later in this
chapter.

6.4.5 - Surface Initiated Atom Transfer Radical Polymerization of Styrene-co-([oligo
ethylene glycol] methyl ether methacrylate)-co-styrene films
A second chain extension was performed on the Sty-PEG films to form a sandwiched StyPEG-Sty co-block polymer using the same SI-ATRP technique used to form the initial styrene
film. The resulting DRIFT spectrum (overlayed with Sty) exhibits peaks from both the styrene and
Sty-PEG films but increases to reflectance attributed to the styrene implies a successful chain
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extension. The stepped reflectance between CH Aro ≤ 3080 cm-1 and CH Aro ≤ 3023 cm-1 indicative
of aromatic stretching from the phenyl ring are increased from those observed in the first chain
extension. In addition, the reflectance at C=C ≤ 1600, 1492, and 1451 cm-1 are all far more
prominent in the new spectrum indicating a larger amount of phenyl character on the surface. The
peak at C=O ≤ 1718 cm-1 remains prominent but C-O character is diminished between C-O ≤ 1294
and 1108 cm-1. This is expected due to the PEG layer being covered by the chain extension of
styrene. The expected changes in relative reflectance after the chain extension indicate a successful
chain surface reaction, which is confirmed using contact angle goniometry in the next section.

6.4.6 – Contact Angle Analysis of Hydroxyl-terminated Monolayers and Polymer
films on SS316L

Figure 6.7: Contact angles on SS316L measured by static sessile drop method. Bare SS316L = 72.8 ± 4.5⁰, HUPA SAMs = 58.8
± 5.5⁰, Styrene = 103.4 ± 7.7⁰, Sty-PEG = 44.6 ± 5.1⁰, Sty-PEG-Sty = 97.8 ± 1.7⁰
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To confirm the successful modification of SS316L with HUPA SAMs and the subsequent
formation of polymer films using SI-ATRP, contact angle goniometry was used to evaluate
changes to the interfacial properties of the substrates. Following the functionalization of SS316L
with HUPA, the contact angles of the surface decreased from 72.8 ± 4.5° to 58.8 ± 5.5°. This
indicates that the hydrophilicity of the surface increased as expected from a SAM terminated with
a polar head-group capable of hydrogen bonding with incident water such as the hydroxyl group
of HUPA. Once the substrates were polymerized with styrene the contact angle increased
dramatically to 103.4 ± 7.7°, indicating that the formerly hydrophilic surface had become
hydrophobic. Since styrene is an entirely non-polar molecule, this drastic change in contact angle
is expected and confirms the DRIFT results, indicating successful formation of surface bound
styrene polymers. After the chain end extension of the styrene modified surface with PEG, the
surface reversed polarity again, demonstrating a very hydrophilic surface with a contact angle of
44.6 ± 5.1°. This behavior is attributed to the polar character of the ethylene glycol side chains and
indicates a successful chain extension. After further chain extension with styrene the contact angles
are observed to increase again to 97.8 ± 1.7°. The standard deviation is small for each of the contact
angles implying consistent formation of polymer layers across the surface. Each of the
polymerizations generates an expected, and significantly different, contact angle from the surface
preceding it. This implies that each successive modification is successful and that the monolayer
and polymer layers are forming as intended. Both the initial styrene modification and the Sty-PEGSty chain extension have similar contact angles of 103.4 ± 7.7 and 97.8 ± 1.7°, respectively. Since
these two modifications are designed to generate a surface presenting the same moiety at the
surface, this data shows the achievement of the intended result. Having confirmed the attainment
of the intended surface modifications using both DRIFT and contact angle goniometry, the ability
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of the polymers to confer corrosion resistance to the surface will be analyzed using cyclic
voltammetry and SEM.

6.4.7 - Electrochemical Characterization
Cyclic voltammetry has been employed to determine the amount of corrosion inhibition
provided by the surface modifications. Electrochemical reactions occurring at the surface are
studied by measuring the flow of electrons from the surface when a potential is applied to the
substrates. Corrosion is a process of redox reactive process and is directly related to the flow of
current through the substrate used as the working electrode. Functionalized substrates were placed
in a three-electrode system as the working electrode to be studied, with the backside of the
substrate coated in epoxy to prevent electron flow from the nonmodified side form interfering with
results. Substrates were immersed in a 3.5% sodium chloride electrolyte solution to mimic the
saline content of marine environments. The electrochemical data for the native oxide and the
HUPA monolayer is provided alongside the data collected for functionalized coupons for
comparative analysis. Fractional coverage of the surface has been calculated using Equation 6.1,
where imod is the magnitude of the current through the modified substrates, and iBare is the current
through an unmodified SS316L electrode, under the assumption that diffusion from the surface of
the working electrode is planar. Fractional coverages are presented in Table 6.1 and example cyclic
voltammograms are shown for each substrate surface in the overlayed voltammograms in Figure
6.9. Following the assessment of the corrosion resistance of the films by cyclic voltammetry, a
pitting study was performed to evaluate surface protection visually. SEM micrographs were taken
of the substrates surfaces before and after modification. Surfaces were then subjected to 25
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repeated cycles of cyclic potential application to simulate accelerated corrosion. The surfaces were
then once again studied by SEM to determine the extent of pitting after corrosion conditions.
Table 6.1: Fractional Coverage of Substrate Surfaces
Modification

θ

Bare SS316L

---

HUPA

0.12

Poly(styrene)

0.86

Poly(styrene-co-PEG

0.83

Poly(styrene-co-PEG-co-styrene)

0.82

𝑖𝑚𝑜𝑑
Equation 6.1: 𝜃 = 1 − (
)
𝑖𝐵𝑎𝑟𝑒
6.4.7.1 – Cyclic Voltammetry
Cyclic voltammograms were collected from 0.3V to -1.2V vs. Ag/AgCl reference

Figure 6.9: Overlay of Cyclic Voltammograms of Bare SS316L (Black), HUPA (Red), Styrene (Blue), Sty-PEG
(Green), and Sty-PEG-Sty (Yellow) films on SS316L

electrode. In the cyclic voltammogram of the bare substrate, the oxidation/reduction of iron (II)
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oxides to the corresponding iron (III) species occurs at 0.67 V (Figure 6.9).9-10, 13-14 A reduction in
the current is visualized in the voltammogram as a decrease in space between the anodic and
cathodic traces. The upper trace is the anodic trace and corresponds to the oxidation of the surface.
When the applied current is reversed, the cathodic trace is generated from the corresponding
reductive reactions. Current is directly related to the number of redox reactions taking place on the
surface, therefore, less current flow is equivalent to a greater amount of corrosion resistance
provided by the surface coating.11, 14, 16-18 After the bare surfaces were functionalized with HUPA,
there is only a slight increase to the cathodic trace resulting in a low fractional coverage of 0.12
(Figure 6.9). When polymer films are formed on the surface, fractional coverage increases
dramatically, and the current is significantly reduced. The formation of the polymer films on the
surface increased to an average of 0.86, 0.83, and 0.82 for styrene, Sty-PEG, and Sty-PEG-Sty
respectively. While the current passing through the substrates is significantly decreased by the
addition of the polymer films, there is still some corrosion occurring at the surface. It does not
appear that chain extensions performed on the initial styrene film improve the corrosion resistance
of the substrates further.

6.4.7.2 – Pitting Study
To confirm the electrochemical stability of the polymer films, SEM micrographs of the
substrates were collected for comparison after exposure to accelerated corrosion conditions. After
micrographs were collected, the substrates were immersed in 3.5% NaCl and subjected to 25 cycles
of sweeping potential from 0.3V to -1.2V vs. Ag/AgCl reference electrode. The substrates were
then rinsed with deionized H2O to remove salt crystals and were again imaged using SEM.
Comparison of the bare SS316L substrates reveals extensive pitting after accelerated corrosion
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conditions. On pre-corroded bare samples, there is little marring of the surface beyond the clear
and distinct polishing lines from the initial cleaning of the surface when substrates are prepared.
Post-corrosion conditions, much of the polishing lines have been lost and irregular pits can be seen
to have formed on the surface. This is consistent with expected results from an unprotected SS316L
surface. Comparison of HUPA samples reveals a very similar trend. Polishing lines are slightly
more difficult to discern on pre-corroded samples, but they are present and the surface lacks any
notable marring. Following corrosion the surface of the HUPA samples demonstrates extensive
pitting, with sporadic formation of dark pits across the surface where deterioration of the metal has
occurred. When studying the polymer films the micrographs display much different surface
topography. Styrene prior generates an irregular surface which completely covers any of the
previously visible polishing lines. The surface has mounds in the polymer layer which may indicate
some delamination from the surface. Despite these potential defects, the polymer layer remains
continuous with no obvious breakages exposing the metal beneath. After exposure to corrosion
conditions, the styrene layer appears to be intact but has pock markers across the surface. These
pock marks appear to be the mounds where delamination had previously occurred and have now
been punctured, forming single pores on the deflated bubble. Since the polymer surface looks fully
intact besides these defects, it is likely that these deflated areas are responsible for the imperfect
fractional coverage of styrene (0.86) calculated in Section 6.4.5.1. The morphology of the surface
appears to change after chain extension has occurred. As with the styrene layer, the Sty-PEG and
Sty-PEG-Sty layers are unchanged visibly by exposure to corrosion conditions. The chain
extended polymer films appear complete when first observed but have actually formed a layer of
tiny vesicles across the surface, roughly 1-3 microns in diameter each. The ‘pores’ are most likely
formed by polymer chains collapsing into circular structures as solvent from the chain extension
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reaction dries off. The films have likely collapsed into circular structures on the surface as a result
of interactions between the non-polar styrene and the polar-PEG halves of the block co-polymers.
Despite the odd structures forming on the surface after chain extension, the polymer films provide

Figure 6.9: Comparative SEM Micrographs of Bare, HUPA, Styrene, Sty-PEG, and Sty-PEG-Sty substrates before
and after exposure to 25 cycles in a three-electrode system with potential swept from 0.3V to -1.2V vs. Ag/AgCl
reference electrode in 3.5% NaCl. Pits can be observed in the post-corrosion micrographs of both bare and HUPA
SS316L.

visible protection from pitting when compared to the bare and HUPA surfaces. No identifiable
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change to the polymers is observed indicating that the increased corrosion protection is stable in
saline solution equivalent in concentration to marine conditions.
6.4.8 – Cytotoxicity Assay
As a preliminary evaluation of the cytotoxicity of the polymer thin films, and the inhibition
of cell adhesion anticipated from the inclusion of the PEGylated polymer chains, a Live/DEAD
study was conducted. NIH 3T3 mouse fibroblasts for were cultured on bare, HUPA, styrene, Sty-

Figure 6.10: LIVE/DEAD fluorescence microscopy images of substrate surface exposed to fibroblasts. Green =
Live cells, Red = Dead cells.

PEG, and Sty-PEG-Sty substrates for one, three, and five days. Substrates were incubated with the
cells and then rinsed with phosphate-buffered saline prior to staining with both calcein AM and
ethidium bromide homodimer. Calcein AM causes live cells to fluoresce green and the ethidium
bromide homodimer dead cells to fluoresce red, allowing for the evaluation of the extent of cell
attachment, spreading, and death. For each coating and the control, three coupons incubated with
fibroblasts were imaged in five different areas using a fluorescence microscope to evaluate 15
images per sample set. One-way analysis of variance (ANOVA) with a Tukey’s HSD analysis was
used to determine the statistical difference of the averages of the normalized cell counts for each
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day at a p>0.05. Grubbs’ Test for outliers was used to remove data points when applicable.
Statistically analyzed data is presented as mean ± standard error (SE).
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Figure 6.11: Normalized live cell counts of NIH 3T3 mouse fibroblasts on unmodified and modified SS316L
substrates. Bare = unmodified substrates, HUPA = 11-hydroxyundecylphosphonic acid monolayer, Styrene =
poly(styrene), Sty-PEG = Poly(styrene-co-oligo (ethylene glycol) (meth)acrylate), Sty-PEG-Sty = Poly(styreneco-oligo(ethylene glycol) (meth)acrylate-co-styrene). Error bars represent the standard error in each measurement
with n=15. “*” indicates the statistical difference between control (Bare surface) and the modified surface with p<
0.05.

After one day, there was no statistical difference observed in the number of cells on bare
or HUPA substrates, having 100 ± 10 and 115 ± 7 cells respectvely. Substrates modified with
styrene, Sty-PEG, and Sty-PEG-Sty demonstrated 45 ± 6 cells, 13 ± 3 cells, and 24 ± 6 cells per
image and were each statistically lower than the bare or HUPA substrates. It can be seen that initial
cell attachment is lower on the substrates modified with polymer samples.
After 3 days, 100 ± 12 cells, 101 ± 21 cells, 87 ± 19 cells, and 53 ± 14 cells per image were
counted on bare, HUPA, styrene, and Sty-PEG-Sty samples while only 3 ± 1 cells were counted
on the Sty-PEG samples. Cells have proliferated enough on all samples that there is no statistical
difference between the unmodified, HUPA, or styrene surfaces. Both Sty-PEG and Sty-PEG-Sty
surfaces are found to be significantly different from the bare substrates. As surfaces modified with
ethylene glycol are known to be an cell repellant, the extremely low cell count on Sty-PEG
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substrates is expected. The Sty-PEG-Sty cell samples are both statistically different than the
unmodified samples on Day 3, and they are statistically lower than the styrene samples on both
the first and third days. This implies that while both surfaces present styrene as their outermost
layer in theory, the coverage of styrene on the Sty-PEG-Sty layers is incomplete and the exposed
ethylene glycol is acting to reduce cell adhesion in these samples.
On day 5, 100 ± 4 cells, 89 ± 4 cells, 96 ± 2 cells, and 76 ± 10 cells were counted on the bare,
HUPA, styrene, and Sty-PEG-Sty surfaces. Sty-PEG samples demonstrate significant resistance
to cell attachment on the final day with an average of zero cells counted per surface with a standard
error of only 0.07% on the final day. Both the Sty-PEG and Sty-PEG-Sty samples are statistically
lower than the unmodified surface by the final day of the trial due to the presence of the ethylene
glycol polymer layer. Almost no cells are observed across all of the Sty-PEG samples on the fifth
days, highlighting the efficacy of this modification at retarding biofouling. Both HUPA and styrene
modified samples remain statistically equivilant to the unmodified surface, showing that neither
of those thin films afford any degree of protection from biofouling after cell proliferation has taken
place.
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟔. 𝟐: 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

𝐿𝑖𝑣𝑒 𝐶𝑒𝑙𝑙𝑠
𝐿𝑖𝑣𝑒 𝐶𝑒𝑙𝑙𝑠 + 𝐷𝑒𝑎𝑑 𝐶𝑒𝑙𝑙𝑠
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Figure 6.12: Normalized cell viability on unmodified and modified SS316L substrates. Error bars represent the
standard error in each measurement with n=15. “*” indicates the statistical difference between control (Bare
surface) and the modified surface with p< 0.05. Several data points are omitted from Sty-PEG sample sets due to
no live or dead cells being present making viability calculations impossible.

There is very little deviation in the normalized viability of the fibroblasts across all five days
regardless of the surface modification used. None of the surface modification components; HUPA,
styrene, or oligo(ethylene glycol) (meth)acrylate, are anticipated to be cytotoxic and this appears
to be supported by experimental data. On the first and third days, none of the samples sets have
significantly different cell viability than the unmodified substrates. The only sample set on the fifth
day to be significantly different than unmodified substrates is the Sty-PEG polymer film.
It is likely that the increase in dead cells in these samples on the fifth day, which causes the
lowered viability, is due to the failure of these cells to adhere and proliferate due to the cell
repellant nature of the surface. If the decrease in cell viability on the fifth day indicated true
cytotoxicity, the viability in Sty-PEG samples from days one and three would be similarly lowered.
It can be assumed that a higher number of dead cells had settled onto these substrates from solution
after 5 days had elapsed and the commesurate number of live cells seen in other samples has
remained in solution after a failure to attach.
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6.5 - Conclusion
Polymer films of Styrene, Sty-PEG, and Sty-PEG-Sty were formed on HUPA modified
SS316L surfaces using surface initiated polymerization to provide resistance to corrosion and
biofouling in marine settings. The formation of these layered block co-polymers has not been
demonstrated in the literature, nor have their properties been characterized. Successful
modification of substrates was demonstrated using DRIFT spectroscopy and contact angle
goniometry. Contact angles corresponding to each polymer film have been demonstrated. The new
copolymer films have been shown to inhibit corrosion using cyclic voltammetry and pitting has
been significantly reduced as observed by SEM after accelerated corrosion testing. Some flow of
current is still observed after deposition of the polymer layers, due to polymer permeability and
intermittent pores observed on the surface after corrosion conditions. The polymers have been
shown to provide an antifouling functionality due to the inclusion of a PEGylated methacrylate
polymer layer and the films have been shown to successfully inhibit fibroblast adhesion without
cytotoxic effects. These films could be further utilized in marine environments where pitting
corrosion and fouling (caused by algae and barnacles) occurs. Further study of these films using
electrochemical impedance spectroscopy could be performed to elucidate protection efficiency and
charge transfer resistance. Additionally, future electrochemical studies could be performed in
simulated brine to improve the relevance of the results. A more complete anti-fouling study should
be completed using Bivalve Mollusc (Anadara granosa) to evaluate resistance to adhesion and
cytotoxicity.
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Chapter 7: Summary
7.1 - Conclusions
The use of self-assembled monolayers (SAMs) formed on metal oxide layers presents a
method of functionalization that can be used for reactions capable of improving biocompatibility
of medical devices or enhancing corrosion and biofouling resistance in structural materials used in
marine settings. In this work, the anti-platelet medication Ticagrelor (TIC) has been immobilized
via cross-linking to vascular stent materials, Stainless Steel 316L (SS316L) and Cobalt Chromium
L605 (CoCr), which have been functionalized with amine-terminated monolayers. Formation of
SAMs and subsequent immobilizations were confirmed using DRIFT spectroscopy, AFM, and
contact angle goniometry. This study provides a novel parallel technology capable of inhibiting
thrombosis in vivo in a localized manner. These coatings are a direct improvement to the dual antiplatelet therapy regimens used to combat thrombosis as they have been shown to inhibit platelet
adhesion to the stent surfaces, while not influencing the behavior of platelets in solution. The
efficacy of thrombosis inhibition has been demonstrated using SEM and the influence on platelet
behavior has been studied using flow cytometry and an ADP ELISA assay.
In the second project presented in this work, novel layered polymer thin films have been
generated on SS316L functionalized with SAMs for use in marine settings. These polymer layers
include styrene which improves corrosion resistance and poly(oligo ethylene glycol) methyl ether
methacrylate (PEG) layers which have been shown to greatly reduce biofouling when utilized as
the outer-most polymer layer. These two works demonstrate the ability of SAMs to provide a
foundation for the generation of advanced surface coatings on metal oxides.
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7.2 – Immobilization of Ticagrelor onto Stainless Steel 316L and Cobalt Chromium
L605
To inhibit thrombosis formation on blood contacting vascular stents, TIC was immobilized
on both SS316L and CoCr functionalized with amine-terminated SAMs. These modifications are
intended to prevent platelet adhesion to modified surfaces, while not impacting the behavior of the
platelets in solution. Several methods of immobilization onto vascular stent materials were
explored, and a novel strategy utilizing the Mitsunobu reaction for the immobilization of TIC was
devised after other methods failed to achieve immobilization of the drug onto the surface.
Monolayers of 12-aminododecylphospnonic acid (ADPA) were formed on SS316L and CoCr,

Scheme 7.1: Reaction progression of the immobilization of Ticagrelor on 12-Aminododecylphosphonic
Acid Monolayers formed on CoCr L605

followed by the immobilization of TIC on SS316L via an optimized Mitsunobu reaction.
Reproducibility is difficult on bulk foil, but stents made of either SS316L or CoCr are found to be
reliable substrates for immobilization. Foil and stent substrates appear compositionally identical
when studied using energy dispersive x-ray spectroscopy, therefore surface topography remains
the assumed cause for the difference in substrate behavior since both substrates should present
chemically equivilant surfaces after monolayer formation. DRIFT spectroscopy was used to
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confirm the presence of TIC on the surface of the substrates by comparing collected spectra of the
immobilized drug with the spectrum of the drug in crystalline form. The modifications were also
confirmed using contact angle goniometry, which revealed an increase to the wettability of the
surface after immobilization had occurred. Atomic force micrographs of modified SS316L
surfaces reveals that immobilized TIC forms a continuous protective layer across the monolayer
surface. Once the immobilization of TIC was achieved, the efficacy of the modification was tested
to ensure inhibition of platelet deposition and no effect on platelets in solution.
Both modified and unmodified stents were exposed to platelet rich plasma to observe the
behavior of incident platelets on the substrate surfaces, as well as the influence of the modifications
on platelets in solution. Examination of adhered platelets on the stent surfaces using scanning
electron microscopy reveals large quantities of platelets adhered to bare stents, while modified
surfaces are protected from platelet adhesion regardless of the stent material. Study of the behavior
of platelets in solution using flow cytometry and adenosine diphosphate enzyme linked
immunosorbent assay demonstrates similar levels of activation in all SS316L samples, indicating
that the surface modifications have little influence on platelets which are not in direct contact with
the stent itself. Flow cytometry and ADP ELISA results were inconclusive on CoCr but this is due
to an error in the age of the platelets used in the experiment. These results imply that the
immobilized TIC operates as intended, providing protection to the surface from platelet
aggregation but does not inhibit the function of platelets in solution. An in vivo rabbit study is
currently being performed using TIC immobilized stents manufactured with the presented
methodology. Preliminary results have shown no thrombosis formation in the implanted animals
and healthy endothilial growth over the stent surfaces has been observed after 28 days in vivo. This
experiment is considered a success since the intended function of the modifiation has been
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demonstrated and the stents are performing well in biological settings with no adverse affect to the
patient animal.

7.3 - Antifouling and Corrosion Resistant Surface Modifications
Surface-initiated atom transfer radical polymerization (SI-ATRP) has been used to generate
polymer films of films of poly(styrene) (Sty), poly (styrene-co-(oligo ethylene glycol) methyl ether
methacrylate (Sty-PEG) and poly (styrene-co-([oligo ethylene glycol] methyl ether methacrylate)co-styrene (Sty-PEG-Sty) on SS316L surfaces functionalized with 11-hydroxyundecylphosphonic
acid (HUPA) monolayers. A vapor phase technique for the immobilization of a bromoisobutyryl
bromide (BIBB) initiator onto HUPA SAMs has been demonstrated. Once initiator was
immobilized onto the surface, a monomer, copper catalyst, and sacrificial reducing agent were
introduced to generate polymer brushes on the surface. Layered block co-polymer films were
generated using SI-ATRP techniques capable of inhibiting corrosion and improving resistance to
biofouling.

Scheme 7.2: Reaction progression of the surface initiated polymerization of Sty-PEG-Sty films on 11Hydroxyundecylphosphonic Acid Monolayers

DRIFT spectroscopy and contact angle goniometry have been employed to confirm the
polymerization of the polymer films on the surface. Both techniques successfully demonstrate
successful modifications, with distinct changes in both the IR spectra and in the observed
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hydrophobicity/hydrophilicity of the surface after each modification. Cyclic voltammetry was
employed to characterize the corrosion resistance of the polymer films and was performed in a
3.5% NaCl solution, representative of the saline content in marine settings. A large decrease in the
current flowing through SS316L modified with the polymer films has been observed in comparison
to the bare metal oxide layer. Polymer films of Sty, Sty-PEG, and Sty-PEG,Sty exhibited fractional
coverages of 0.86, 0.83, and 0.82. These decreases in current density indicate the polymer films
provide a substantial increase to corrosion resistant properties. However, the reduction of current
is not perfect and chain extensions to the original polymer film do not provide increased corrosion
resistance. Substrates were subjected to 25 cycles of accelerated electrochemical corrosion using
the same three-electrode system as the cyclic voltammetry measurements. Comparison of the bare
and modified substrate surfaces imaged using SEM reveals extensive pitting corrosion on bare and
HUPA SS316L. Corrosion of the polymer layers themselves is not observed, but in the styrene
samples bubbling of the polymer layer appears to compromise the corrosion protection. The
bubbles are compromised and pucker, with visible corrosion products forming at the opening of
the deflated bubbles. This is assumed to account for the imperfect corrosion protection of the
polymer layers. Chain-extensions to the polymer are found to form vesicles upon the surface with
appear porous and allow solution access to the puckers which results in no further corrosion
resistance. The reason for the delamination which causes the bubbling effect on styrene may be
the method used to dry the polymer layer after polymerization. Substrates are removed from
solution, excess polymer is sonicated from the surface, and then samples are placed into a vacuum
chamber to drive off solvent. The rapid decrease in pressure causes solvent trapped in the polymer
film to vaporize rapidly. Delamination occurs in regions where solvent solvent trapped in the
polymer film expands as it evaporates and forces the film from the surface. A future improvement
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to the procedure may be to dry the polymer films at room temperature following sonication to
prevent this from occurring.
Initial styrene polymer films were chain extended with oligo [ethylene glycol] methyl ether
methacrylate to provide resistance to biofouling as an added functionality to the novel polymer
films. As a first level cytotoxicity and biofouling inhibition test, NIH 3T3 fibroblasts were grown
on the bare and modified surfaces and then evaluated at 1, 3, and 5 days with a LIVE/DEAD assay.
Since the intended use for this technology is in marine environments, confirmation that the
polymer films are not cytotoxic is important to ensure that no toxic substances are introduced to
the natural setting. Cell viability was not found to be negatively impacted by any of the surface
modifications ruling out cytotoxic effects from the developed polymer films.
The practical application of the inclusion of this polymer layer is to prevent biofouling by
inhibiting protein adhesion to the metal surfaces. Cells adhere to immobilized proteins, so
preventing protein adhesion prevents biofouling as well. Cells proliferated rapidly on bare, HUPA,
and Sty surfaces but cell adhesion was eliminated on Sty-PEG surfaces. This is expected due to
the known protein repulsive effects of ethylene glycol. Sty-PEG-Sty surfaces exhibit a statistically
significant decrease in cell proliferation when compared to the native oxide layer, but cells do
continue to adhere and proliferate to this surface since styrene is the outermost layer in the polymer
film. To provide maximized reduction of biofouling, it is clear that PEG should be the outermost
polymer as the success of the PEG layer in inhibiting cell adhesion is exceptional.

7.4 - Impact of Projects
The covalent immobilization of TIC on SS316L and CoCr is a novel methodology which has
not been reported in the literature. TIC has never been immobilized on vascular stent materials
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before, and the use of the Mitsunobu reaction to achieve a covalent for thrombosis inhibition has
no published precedent. Additionally, the efficacy of immobilized TIC has been demonstrated with
human platelets in an in vitro setting and modified stents are currently being used in a live animal
rabbit study to provide data on their effectiveness in vivo. TIC modified stents have no activated
platelets present on the surface in the demonstrated static experiment. The time which platelets
will be capable of interacting with the surface of a stent in vivo is much reduced from the one hour
time frame presented in this research due to platelet mobility in blood flow. This technology has
the potential to make the use of dual-antiplatelet therapy after percutaneous coronary interventions
(PCI) obsolete. These stents may be applied in the future in the biomedical industry as a parallel
technology to DES which could provide the foundation for a new generation of stents which can
inhibit both NH and thrombosis locally at once.
Novel layered polymer films of Sty-PEG-Sty have been formed on SS316L. The
electrochemical characterization and cytotoxic effects of these polymer films on SS316L have
never been reported to date. Few surface initiated linear poly(ether) films have been demonstrated
in the literature, and none have been formed on the surface of metal oxide layers for use in marine
settings. These polymer films have the potential to provide a corrosion and biofouling resistant
coating simultaneously for use in marine environments. The only major weakness to the current
corrosion protection of the polymer layers lies in the delaminated areas of the initial styrene layers
generating intermittent pores at which corrosion processes may occur. Improvements to the
procedure for the initial styrene layer have the potential to eliminate the observed delamination
and provide superior corrosion protection capable of completely inhibiting pitting. Additionally,
the success demonstrated by the Sty-PEG samples at preventing biofouling of fibroblasts has
demonstrated a pathway for the successful inhibition of biofouling alongside the corrosion
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protection afforded by styrene. Future work exploiting these results may provide a polymer film
with even more corrosion and biofouling resistance.

7.5 - Future Work
Many additional challenges remain on the path towards creating a fully biocompatible
vascular stent. Neointimal hyperplasia and thrombosis are both complications to PCI procedures
which must be addressed simultaneously. The ideal localized delivery system for vascular stents
would deliver both anti-proliferative and anti-platelet medications to inhibit both complications at
once. The development of a similar methodology for immobilizing an anti-proliferative medication
to prevent neointimal hyperplasia would be the first step towards a self-assembled monolayer
based system to inhibit neointimal hyperplasia and thrombosis using immobilized molecular at
once. Once immobilizations for both TIC and an anti-proliferative medication have been
demonstrated, the application of a mixed monolayer could be used to provide a dual
functionalization of the surface. A mixed monolayer with two different functional groups
presented at the surface followed by two separate cross-linking techniques to immobilize both antiproliferative and anti-platelet medications would provide a new generation of dual-modified stents.
At present, a live animal study using rabbits is currently underway and is anticipated to
demonstrate the efficacy of the presented modification in vivo. If the results from this study are
positive, a larger animal study may be performed to evaluate whether the modification of CoCr
stents with TIC has potential to be patented for clinical use.
Improvements to the formation of styrene polymer films in desirable to further improve the
corrosion protection of the films presented herein. A modification to the current procedure to
achieve this would be to allow the polymers to dry slowly at room temperature to eliminate the
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observed delamination of styrene which compromises the completeness of the surface coverage.
The polymer films presented within provide good corrosion resistance and have been demonstrated
to decrease cell adhesion when PEG is the outermost layer on the film. The most efficient polymer
layer presented here is the Sty-PEG layer, as it demonstrates superior biofouling resistance to StyPEG-Sty and equivalent corrosion protection to both styrene and Sty-PEG-Sty polymer films.
Additional data should be collected on a PEG polymer films alone to evaluate the corrosion and
biofouling protection afforded by PEG without a styrene co-polymer. It may be beneficial to
generate a PEG-Sty-Peg polymer film instead of a Sty-PEG film. When such a film is utilized, the
outermost PEG layer would provide the exceptional biofouling protection demonstrated by StyPEG. If the outer layer of PEG degrades or is compromised, the foundational PEG layer would
provide continued biofouling resistance while corrosion is inhibited by the middle styrene layer.
Another useful permutation of this study would be to form a PEG-Sty-PEG polymer to evaluate if
similar levels of corrosion protection may be achieved while leaving a PEG co-polymer block as
the outermost layer to enhance biofouling resistance to the greatest possible degree.
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